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Abstract 
 
 
The hippocampus is an archicortical region involved in functions including memorisation and 
spatial navigation.  These operations depend on complex synaptic interactions involving both 
excitatory and inhibitory signaling between hippocampal neurones. Changes in the balance of 
excitatory and inhibitory systems may result in pathological conditions such as epilepsy. 
Understanding the properties of hippocampal cells and networks at multiple levels and in both 
physiological and pathological conditions is thus an important task for research on the healthy 
and diseased brain.   
Genomic tools provide access to an essential level of organisation, that of gene expression 
and regulation in hippocampal cells. They may serve as a marker to study how a cell 
population responds to a physiological stimulus or identify genes specific to a defined cell 
type. Genetic approaches are also used to examine how gene expression is changed during 
pathological conditions and may help identify novel processes or molecules thus providing 
new pharmacological targets. 
In the first part of my thesis, microarray analysis of gene expression was used to compare 
patterns of gene expression in a subfamily of Somatostatin containing hippocampal 
interneurons and principal glutamatergic excitatory cells. GABAergic interneurons constitute a 
heterogeneous group while pyramidal cells are probably a rather homogeneous population. 
Interneurone diversity is important for the function hippocampal networks, and this genomic 
analysis will help understand this diversity. 
I found significant differences in genes expressed in interneurones and pyramidal cell 
populations. Protein products of differentially expressed genes are mainly involved in transport 
and signalling, together with some proteins coding for neurotransmitter receptors and channels 
and a cluster of transcription factors.  Although these data need to be confirmed with RT PCR 
and immunocytochemical experiments, further work is necessary to identify genes involved in 
the development of the distinct phenotypes, in the control of different physiological properties or 
for use as cell type markers.   
The second part of my thesis examined changes in gene expression during the establishment of 
an epileptic network after intra-hippocampal injection of kainic acid.  Many genes were changed 
with different time courses and spatial localisation with respect to the injection site.  The altered 
genes are often involved in immune and inflammation responses but also in cell death and 
growth processes. Some genes coding for proteins that control cellular excitability and 
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neuronal communication were also changed.  The major implication of inflammatory and 
immune processes is consistent with previous work on animal models of epilepsy or human 
epileptic tissue.  I confirmed changes in some individual genes with qPCR analysis.   
My work suggests that kainate injection changes the expression of early response genes near 
the lesion at 6hrs, but also induces distinct alterations at distant sites in contralateral 
hippocampus. A maximum number of changed genes was identified during the latent phase at 
15 days after kainate injection but before the emergence of spontaneous seizures.  At 6 
months, recurrent spontaneous seizures have emerged and changes in gene expression are 
limited to the area near the lesion.  
The progression of epilepsy in this animal model was confirmed with EEG and slice records 
and anatomical work was done to characterize the time course of cell death and fibre 
degeneration.  Alterations in gene regulation correspond quite well to these electrical and 
anatomical data.  Furthermore immuno-histochemical stains for specific proteins produced by 
differentially regulated genes revealed their expression by proliferating astrocyte precursors 
and by activated astroglial cells that were differentially localized in the two hippocampi. 
In conclusion multiple different processes are triggered with different spatial patterns and 
timing during the emergence of an epileptic network. However, during the expression of 
recurrent seizures, few genes are changed except at sites surrounding the sclerotic lesion.  
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Introduction 
 
1. The Hippocampus 
 
1.1 Structural Organization 
 
The hippocampus is one of best characterized brain structures, since its layered organization 
(Andersen, Bliss et al. 1971) is especially suitable for anatomical and physiological studies. In 
his book “De Humano Foetu liber” (Rome, 1564) Giulio Cesare Aranzi (1529-1589) named 
this brain structure “hippocampus” after the sea horse monster of Greek mythology (in Greek 
hippo means “horse” and kampos means “sea monster”) due to a distinctive, curved shape that 
he likened to the famous mythological beast. The resemblence of the hippocampus to the horns 
of a ram, prompted another name - “cornu arietis” later changed by René Croissant de 
Garengeot (1688-1759) to “cornu ammonis” because of the ancient Egyptian god of Theba 
Amun who was presented as a ram headed man, or a ram headed sphinx. The shape of the 
hippocampus is maintained across the range of mammalian species, from hedgehog to human. 
Ramon y Cajal (1852-1934) made major advances in understanding the microscopic structure 
of the nervous system, using a modification of the Golgi (1843-1926) staining method, which 
completely stains a small proportion of cells. His discoveries on the cellular architecture of the 
hippocampal formation and its regional subdivisions remain a keystone of present day 
knowledge of the hippocampus as part of the archicortex. 
The hippocampus plays a major role in some forms of learning and memory (Kandel 2001).  
Deep structures of the temporal lobe, including the hippocampus (Amaral and Witter 1989), 
are involved in the storage of long-term traces in humans and other mammalian species (Milner, 
Squire et al. 1998; Eichenbaum, Dudchenko et al. 1999; Kim and Baxter 2001; Burgess, 
Maguire et al. 2002). The rodent hippocampus is involved in spatial navigation and some 
hippocampal cells called “place cells” respond specifically with a high rate of firing when the 
animal moves through a specific location in an environment (O'Keefe 1983).  
The hippocampus also has a high seizure susceptibility (Green 1964). Many human epilepsies 
originate in the temporal lobe and these seizures are often the most difficult to control with 
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anti-epileptic drugs. The hippocampus is especially vulnerable to ischemic and anoxic insults 
and parts of the hippocampal formation, particularly the enthorinal cortex, are prime targets 
for the pathology associated with Alzheimer’s disease.  
Anatomically, the hippocampus is an elongated structure located on the medial wall of the 
lateral ventricle, whose longitudinal axis forms a semicircle around the thalamus. Figure 1 
shows the location of the hippocampal formation in the rat brain. With a layered organisation, 
cutting the hippocampus across its transverse, septo-temporal axis, results in a familiar 
structure well preserved in all slices with this orientation. The hippocampus proper and its 
neighbouring regions, the dentate gyrus (DG), subiculum and enthorinal cortex, are collectively 
termed the “hippocampal formation”. Cajal divided it into four regions or “cornu ammonis” 
areas CA1-CA4 based on the size and appeareance of neurons. CA1 and CA3 are the largest 
zones, CA4, or the hilus, corresponds to the initial part of CA3 and in rodents the CA2 region is 
small. While CA1 represent a small-celled distal region, CA3 and CA2 fields are equivalent to 
a larger-celled region closer to dentate gyrus. Evenmore CA1 and CA3 present a clear 
connectional difference that will be discussed in the next section. The CA2 field was originally 
defined as a zone of large cells like CA3 but that did not receive innervation like the CA1. In 
CA3 area Lorente de Nó (1934) identified 3 subareas by anatomical position: CA3a (the bend of 
the CA3), CA3b (the ventral portion between the bend and the lateral end of the DG) and CA3c 
(the portion incapsulated by the blades of the DG). Pyramidal cell somata are arranged in a layer, 
the stratum pyramidale, in all these regions. Other identified layers include stratum oriens, the 
site of pyramidal neuron basilar dendrites, stratum radiatum, and stratum lacunosum-
moleculare where the apical dendrites of pyramidal cells are radially oriented. The principal cells 
of the dentate gyrus, granule cells, possess only apical dendrites. 
2. The Hippocampal circuitry 
 
2.1 Fibres inputs, outputs and internal connexions 
 
The main input to the hippocampus is the perforant path. It originates in the enthorinal cortex, 
mainly in layers II and III, but also in layers IV and V. It passes through the subicular complex 
and terminates mainly in the dentate gyrus, making synapses on granule cells.  
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Fig. 1.  NEURONAL ELEMENTS OF THE HIPPOCAMPAL FORMATION. Labelled areas 
include the subiculum, part of the enthorinal cortex, the fornix, the dentate gyrus and the region 
CA1 to CA4. The hippocampus proper is divided into stratum oriens (1), stratum pyramidale (2; 
cell bodies drawn as ovals), stratum radiatum (3) and stratum lacunosummoleculare (4). (Modified 
from Ramón y Cajal, 1911) 
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The distinctive unmyelinated axons of the granule cells, the mossy fibres (MF), give rise to 
large en passant swellings and terminal expansions on CA3 principal neurons or mossy cells 
seen as giant boutons at the electron microscopic level. These presynaptic swellings adapt 
very well to specialized postsynaptic elements present on proximal dendrites of CA3 principal 
cells, called thorny excrescences. The MF synaptic complex contains multiple active zones 
(up to 50) associated with postsynaptic densities. In addition MF make synaptic contacts with 
GABAergic interneurons present in the hilus and in the CA3 area and these represent the 
majority of all MF connections. These have either the shape of small boutons or filopodial 
extensions. Differences in morphology between MF terminals at principal cells and 
interneurons may account for the distinct functional properties of these synapses which appear 
to be regulated in a target specific way. The axons of CA3 pyramidal cells ramify locally and 
also form Schaffer collaterals which contact CA1 pyramidal neurones. CA1 pyramidal cells 
project to the subiculum and the deep layers of enthorinal cortex. . 
 
 
 
 
 
 
 
 
 
 
Thus, neuronal signals entering the entorhinal cortex from a specific cortical area can traverse the 
complete tri-synaptic hippocampal circuit before returning to the cortical area from which they 
originated.  
Commissural associative fibres connect mainly CA3 pyramidal neurons of ipsi- and contralateral 
hippocampi, via the fornix. CA3 pyramidal cells also make synapses with their neighbouring 
Fig. 2. THE HIPPOCAMPAL NETWORK. Hippocampus forms a uni-directional network with inputs 
from the Entorhinal Cortex (EC) that forms connection with the Dentate Gyrus (DG) and CA3 
pyramidal neurons via the perforant path (PP-split into lateral and medial, LPP and MPP 
respectively). CA3 neurons receive also input from the DG via the Mossy Fibres (MF). They send 
axons to the CA1 pyramidal cells via the Schaffer Collateral Pathway (SC) as well as to CA1 cells in 
the controlateral hippocampus via the Associational Commissural Pathway (AC). CA1 neurons also 
receive inputs directly from the PP and send axons to the Subiculum (Sb). These neurons in turn 
send the main hippocampal output back to the EC forming a loop. 
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cells via axon collaterals. The simultaneous activation of these connections may be involved in 
generating epileptiform activity, characterised by synchronised and rhythmic firing in the CA3 
cell population (Miles and Wong 1986; Traub and Miles 1991). These connections may 
contribute to the initiation of seizures in this region when convulsive drugs are applied (Ben-Ari 
and Cossart 2000). Physiologically, the recurrent associative network in the CA3 region may 
contribute to the associative memory recall (Nakazawa, Quirk et al. 2002) 
 
2.2 Synaptic Transmission 
 
Most synaptic contacts between neurons are made between synaptic boutons, either at an axon 
terminal or along (en passant) axons of a presynaptic neuron, and finger-like processes, or 
spines, of postsynaptic dendrites (axo-dendritic synapses). Synaptic contacts may occur also 
between axon terminals and soma (axo-somatic), between two axons (axo-axonic) and between 
dendrites (dendro-dendritic synapses). 
Chemical synapses operate via the release of neurotransmitters from presynaptic nerve terminals. 
Once released, neurotransmitters diffuse in the synaptic cleft and bind to selective membrane 
proteins (receptors) present on the postsynaptic membrane in close opposition to presynaptic 
release sites. The bind of the transmitter to the receptors induces the opening of ion channels and 
electrical changes in the postsynaptic cells. The resulting depolarizing or hyperpolarizing 
voltage changes (the excitatory postsynaptic potentials or EPSPs and the inhibitory 
postsynaptic potentials or IPSPs) move the membrane potential towards or away from action 
potential threshold, respectively. IPSPs usually reduce cell excitability.  The reduction in 
excitability may result from (either or both) a shift in membrane potential towards negative 
values or by a reduction in membrane resistance (also known as a shunting effect). An 
inhibitory current can be elicited by the inflow of negative charged ions or by the outflow of 
positive charges through ligand or voltage-activated channels. In the adult brain, GABA is the 
main inhibitory neurotransmitter (Sivilotti and Nistri 1991; Kaila 1994) and glutamate (Glu) is 
the major excitatory transmitter (Storm-Mathisen 1977; Roberts and Sharif 1981). Ionotropic 
receptors for Glu were first classified, on the basis of their most effective agonists, as alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA), kainate or N-methyl-D-aspartate 
(NMDA). These receptors not only bind neurotransmitter but also open a membrane channel 
permeable to Na+, K+ and sometimes Ca++ (Ascher and Nowak 1986). Calcium in turn can 
activate different signaling pathways. GABA activates ionotropic receptors permeable to Cl- 
 11 
and to a lessser degree to HCO3- (Bormann, Hamill et al. 1987; Schofield, Darlison et al. 1987; 
Polenzani, Woodward et al. 1991). 
The second major class of post-synaptic receptor has been termed metabotropic because they  do 
not form ion channels but are indirectly linked to ion channels through GTP-binding proteins 
(G-proteins). The nature of the ion channels and of the G-protein interaction determines the 
functional effects of metabotropic transmission. Eight distinct metabotropic receptors which 
operate via several distinct intracellular signalling cascades have been identified for glutamate: 
mGluR1-8 (Schoepp and Conn 1993; Pin and Duvoisin 1995). Their activation tends to induce 
a post-synaptic excitation often by the suppression of specific K-channels. Activation of 
mGluRs expressed on axon terminals enhances transmitter release. G-coupled receptors for 
GABA, known as GABAB receptors (Hill and Bowery 1981; Wilkin, Hudson et al. 1981; 
Kaupmann, Huggel et al. 1997), inhibit neurones via inward rectifying K+ conductances (Gage 
1992; Mott and Lewis 1994; Misgeld, Bijak et al. 1995) or by suppressing voltage-sensitive 
Ca2+ conductances (Kamatchi and Ticku 1990) and they may reduce transmitter release when 
expressed at pre-synaptic sites.   
 
3. Cellular components of the Hippocampus 
 
3.1 Major neuronal types in the hippocampus 
 
Pyramidal cells, which account for about 90% of hippocampal neurons, are a rather uniform cell 
population with homogenous morphology. They are named for their somatic shape and possess 
apical and basal dendrites. Pyramidal cells are excitatory and liberate the neurotransmitter 
glutamate (Storm-Mathisen 1977; Roberts, J. et al. 1981).  
In contrast, inhibitory interneurons, which form about 10% of hippocampal neurons constitute 
a heterogeneous population of cells (Freund and Buzsaki 1996) and liberate the transmitter γ-
aminobutyric acid (GABA).  They play a critical role in controlling communication between 
pyramidal neurones and the balance between excitation and inhibition, a critical factor in 
hippocampal function. Interneurons are distributed across all layers of the hippocampus and 
have a highly variable morphology.  They differ from pyramidal cells in their active and passive 
membrane properties. For instance, pyramidal cells accommodate (during a steady current 
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pulse the firing is not maintained but decline with time) while interneurons usually do not 
accommodate and can fire at frequencies up to 400 Hz with little reduction in frequency 
(Lacaille 1991). This may be due to major differences in transcript expressions for distinct 
subunits of voltage-gated K+ channels. Kv3.1 and Kv 3.2 would be preferentially expressed in 
basket cell interneurons while Kv4.2 and Kv4.3 in pyramidal cells (Martina, Schultz et al. 
1998). The resting membrane potential of pyramidal cells and interneurons also differs being 
in interneurons 10-15 mV more depolarized. Moreover, in comparison with principal cells, 
interneurons  exhibit a higher input resistance (Morin, Beaulieu et al. 1996; Cauli, Audinat et 
al. 1997; Savic, Pedarzani et al. 2001). These differences seem to depend on the differential 
expression of pH-sensitive leak potassium channel TASK, a subtype of KCNK channel that 
regulates resting membrane potential and input resistance. TASK channel subunits 1 and 3 
seem to be more highly expressed in pyramidal cells than in interneurons (Taverna, Tkatch et 
al. 2005). 
Pyramidal cells and interneurones also differ in peptide composition, neurotransmitter 
receptor subunit expression and neurotransmitter release mechanisms (Buzsaki 2001). Further 
studies and novel techniques may uncover additional differences between these two classes of 
neurons. Global gene expression profiling for instance (see Section 6) may provide a useful 
strategy for identifying different neuronal subtypes (Mott and Dingledine 2003; Markram, 
Toledo-Rodriguez et al. 2004). Microarray mRNA expression analysis has been used to 
compare the cellular heterogeneity of excitatory and inhibitory neurons in different brain 
areas (Sugino, Hempel et al. 2006) including the CA1 region of the hippocampus (Kamme, 
Salunga et al. 2003). 
Hippocampal function is thought to depend on the balance between synaptic excitation and 
inhibition and changes in this balance may lead to aberrant activities including seizures. 
Differences in the expression of subunits for Glu and GABA receptors may thus be finely 
tuned to generate appropriate and different behaviours of pyramidal cells and interneurons.  
Differences in subunit composition have been examined by immunohistochemistry 
(Macdonald and Olsen 1994; Pickard, Noel et al. 2000), by combined patch – single cell PCR 
studies (Martina, Schultz et al. 1998; Taverna, Tkatch et al. 2005) and by work on mRNA 
expression profiles (Telfeian, Tseng et al. 2003).  However, without full information on 
differences in genes expressed by these two cell types, knowledge of factors underlying 
distinct physiologies and diversities will remain incomplete.   
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3.2 Glial Cells 
 
Glial cells comprise two major subclasses: microglia and macroglia with different origins, 
morphology and function. While glial were thought to support and maintain neurones, recent 
evidence suggests their involvement in synaptic transmission and modulation of neuronal 
excitability as well as other further functions that remain to be clarified. 
 
3.2.1 Microglia 
 
Microglial cells, which are distributed throughout the CNS, form about 20% of brain glial cells 
(Lawson, Perry et al. 1990). They have a myeloid origin, deriving from bone marrow precursor 
cells (Ling and Wong 1993) and form a resident, stable population of innate immune cells whose 
phenotype seems to represent an adaptation of the monocyte and macrophage cells of the blood 
to a neural environment.  
In normal brain, microglial phenotype is downregulated and characterized by a low expression of 
the CD45 leukocyte antigen. Microglia normally have no phagocytitotic or endocytotic activity 
and proteins that induce or mediate typical macrophage functions are poorly expressed or absent 
(Kreutzberg 1996). Normal levels of neuronal activity apparently act to maintain this inactivate 
microglial cell phenotype via neurotrophin signalling (Neumann, Misgeld et al. 1998; Wei and 
Jonakait 1999) as well as neurotransmitter and peptide levels (Hetier, Ayala et al. 1991; Delgado, 
Carlin et al. 1998). It has recently been suggested that neurons signal directly to microglia, in 
cell-to-cell fashion, with an inhibitory signal involving the membrane glycoprotein OX2 (Hoek, 
Ruuls et al. 2000; Wright, Puklavec et al. 2000). 
A wide range of injuries can quickly transform resting microglia to an activated state in which 
they act as the main immune effector cells of the brain (Gehrmann, Matsumoto et al. 1995). 
Microglial activation or “maturation” involves a stereotyped sequence of steps including 
proliferation, expression of new molecules and movement to the injury site. This response can be 
induced via direct interaction with pathogens and microbial structures (Medzhitov and Janeway 
2000) or may involve membrane receptors for different cytokines liberated in the CNS during 
inflammation (Aloisi 2001). Microglia also respond quickly to increases in potassium, due to 
their expression of a unique palette of potassium channels, in this way providing a feedback from 
a cell-firing dependant increase in extracellular potassium (Gehrmann, Mies et al. 1993). 
When activated, microglia has phagocytic capacity and secretes multiple signalling molecules 
including pro- and anti-inflammatory cytokines (i.e. IL-1, TNF-α, INF-γ), chemokines (i.e. IL-8, 
MIP-1 and RANTES) and prostanoids (i.e. PGD2 and PGE2). These factors stimulate and 
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modulate humoral and cell mediated immune responses, recruit and regulate T-cell responses and 
also have cytotoxic actions (for a review see Aloisi 2001). 
Beside the resident population in many types of neuroinflammatory, neuroinfectious or 
neurodegenerative processes, recruitment of new cells from the bone marrow occurs (Davoust, 
Vuaillat et al. 2008) leading to a renewal of the microglial population (Lassmann, Schmied et al. 
1993; Flugel, Bradl et al. 2001; Priller, Flugel et al. 2001). In vitro studies suggested a role from 
astrocytes (see next section) in the differentiation of the bone marrow derived progenitors into 
microglial cells (Schmidtmayer, Jacobsen et al. 1994; Sievers, Parwaresch et al. 1994).   
 
3.2.2 Macroglia  
 
Macroglia are a large cell class including oligodendrocytes and astrocytes. They originate, as do 
neurones, from the differentiation of multipotent neural stem cells (NSCs).  
Oligodendrocytes, located in white matter, act primarily to form myelin (Bunge 1968) an 
insulation of modified plasma membrane that surrounds myelinated axons. They govern the 
speed and efficacy of axonal impulse conduction and so are essential to CNS function.  
Astrocytes were thought to support neuronal function by supplying essential substrates and 
removing toxic substrates, but recent data suggests they are intimately involved in the 
neurogenesis occuring in restricted brain regions of adult mammals including the hippocampus 
(Doetsch and Scharff 2001; Song, Stevens et al. 2002).  Astrocytes can retain stem cell like 
properties (Doetsch 2003) and induce differentiation in adult neural stem cells (Song, Stevens et 
al. 2002) or direct differentiation in neuronal cell types (Berninger, Costa et al. 2007). 
Another interesting role for astrocytes is as a third partner, with pre- and post-synaptic elements 
in the structural and functional organization of synapses. Porter and colleagues have shown that 
astrocytes express receptors and respond to several neurotransmitters including glutamate (Porter 
and McCarthy 1996; Porter and McCarthy 1997) and GABA (Kang, Jiang et al. 1998; Araque, 
Martin et al. 2002). Astrocytes modulate also neurotransmission by controlling ambient 
transmitter levels with glutamate transporters and instruct the development, maintenance and 
recovery of synapses. 
Synaptic stimuli from neurones can evoke astrocytic responses including increases in 
intracellular Ca²+ and release of “gliotransmitter”. Self propagating waves of Ca²+ signals are 
reported to spread long distances to other glial cells via gap junctions or ATP signals (Newman 
2001).  Reciprocally, reports suggest that astrocytes can release glutamate (Bezzi, Carmignoto et 
al. 1998; Araque, Li et al. 2000; Pasti, Zonta et al. 2001; D'Ascenzo, Fellin et al. 2007; Fellin, 
D'Ascenzo et al. 2007) or D-Serine, an endogenous ligand for NMDA receptors (Mothet, 
Pollegioni et al. 2005) and depolarize neurones in several regions including hippocampus 
(Hassinger, Atkinson et al. 1995). Studies also suggest that a potentiation of hippocampal 
synaptic transmission induced by repetitive inhibitory cell firing may depend on glutamate release 
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from nearby astrocytes (Kang, Jiang et al. 1998).   These results confirm that astrocytes have a 
real role in synaptic transmission. 
 
 
 
4. Interneurons of the hippocampus 
 
4.1 Overview 
 
Since the anatomical studies of Ramón y Cajal (1911) and Lorente de Nó (1934) on the 
hippocampal cortex, it has been clear that the morphology and connectivity of local circuit 
neurons are heterogeneous while those of principal seem to be more uniform. 
The term interneuron was originally used to describe invertebrate cells that were neither input 
nor output neurons. As the concept of synaptic inhibition developed (Eccles 1964), it came to be 
used as a synonym for inhibitory cells with short axons.  These cells were seen to play an 
essential role in the regulation of local circuit excitability, while principal cells, with long axons, 
were considered as channels to project information to distant brain regions. The continued 
emergence of functional, biochemical and anatomical data on principal and inhibitory cells has 
revealed exceptions to this definition such that the original views on interneurons are clearly an 
oversimplification. Glutamatergic cells make synapses locally as well as at a distance, and 
GABAergic cells can make synapses at a distance as well as locally.  Thus the short axon cells 
of Golgi, non pyramidal cells of Ramón y Cajal and Lorente de Nó, and inhibitory interneurons 
of Eccles may be identical but they are far from the full story.   
For this work, ‘non-principal cells’ of the hippocampus may be a sufficiently simple and 
accurate term to describe GABAergic local circuit inhibitory cells, even while recognizing that 
some of these cells may have long-range extra-hippocampal or commissural projections. At the 
same time, glutamatergic neurons such as the mossy cells which have a purely local connectivity 
are not considered to be interneurons. Since most, if not all, non-principal cells use GABA as a 
transmitter (Freund and Buzsaki 1996), the definition “GABAergic non-principal cells” 
appears to be the most adequate for hippocampal interneurons. 
With a unifying criterion established, attention has turned to a search for how to classify 
GABAergic non-pyramidal cells, with a goal of constraining interneuron diversity into a 
manageable number of precisely defined and non-overlapping subgroups.  The different 
approaches to this goal will be described in detail.    
 
4.2 Towards a classification of the interneurons 
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The problem of a classification of interneurones remains to be completely resolved.  Ideally a 
combination of functional, chemical and anatomical markers should permit separation of 
hippocampal GABAergic cells into neat sub-populations. Multiple schemes have been proposed: 
they vary from 10-20 classes defined in terms of morphology and neurochemistry (Freund and 
Buzsaki 1996; McBain and Fisahn 2001; Maccaferri and Lacaille 2003; Somogyi and 
Klausberger 2005) to suggestions that while groups exist, interneurons may be difficult to 
classify when anatomy, physiology and the expression of receptors for modulating transmitters 
are all taken into account (Mott, Turner et al. 1997; Parra, Gulyas et al. 1998).  
 
 
 
Interneurons illustrate the wider problem of the definition of a cell type.  There are both 
theoretical and practical difficulties in such a definition.  The criteria to define a cell type are not 
universally accepted, but also conclusions must sometimes be based on small data-sets using 
Fig. 3. INTERNEURONS IN THE CA1 AREA OF THE HIPPOCAMPUS. Somata and dendrites of 
interneurons innervating pyramidal cells are shown in orange, those innervating other 
interneurons are shown in pink. Axons are green and the main termination zone of GABAergic 
synapses are shown in yellow. Molecular cell markers in combination with the axonal patterns 
help the recognition and characterisation of each class. Further data may lead to lumping of some 
classes and to the identification of additional cell types. CB, calbindin; CR, calretinin; LM-PP, 
lacunosum-moleculare–perforant path; LM-R-PP, lacunosum-moleculare–radiatum–perforant 
path; m2, muscarinic receptor type 2; NPY, neuropeptide tyrosine; PV, parvalbumin; SM, 
somatostatin; VGLUT3, vesicular glutamate transporter 3. (Somogyi and Klausberger 2005) 
 17 
partial criteria.  Furthermore we should recognize that variability does, and perhaps must, exist 
within a single cell population (Aradi, Santhakumar et al. 2002; Foldy, Aradi et al. 2004) even 
though it can complicate cell classification. 
The following sections provide an overview of a different interneuron features used in 
classification schemes (see Maccaferri and Lacaille 2003). It is probable that measurements of 
many parameters should permit a given cell to be clustered with similar cells in a region of 
parameter space corresponding to a cell type. Experimentally only a few parameters may be 
available, so it is important to establish which partial measures can best situate a cell correctly 
within its class, in a cortical area, across areas or across species. Progress towards this goal may 
be most rapid in simple cortical areas such as the CA1 region of the hippocampus (Somogyi and 
Klausberger 2005). 
 
4.2.1 Morphological classification 
 
The idea that neurones with different shapes have distinct roles in the cortex was implicit in the 
early work of Ramón y Cajal and was elegantly elaborated by Janos Szentagothai (1975). A 
differential and highly selective location of synaptic terminals made by short axon cells on all 
target neurones suggests that different cells may have specific and distinct functional roles 
(Ramon y Cajal 1893; Szentagothai 1975). Indeed, interneuron anatomy alone provides insights 
into how different cell types contribute within hippocampal circuits, by relating the 
somatodendritic location to the layer specificity of synaptic input and the axonal projections to 
the postsynaptic target domain. 
Based on Golgi staining Ramon y Cajal (1893) and Lorenté de No (1934) distinguished ~20 
different types of hippocampal interneurons. Distinct cell types were first described according to 
features of their axonal or dendritic processes (e.g. basket cell, horizontal cell and stellate cell). 
Labelling techniques can now reveal the entire dendritic and axonal processes of recorded cells 
(Buhl, Halasy et al. 1994). The large number of interneuron types was matched by an equally 
rich terminology including both classical descriptions such as basket cells and new terms 
emphasizing different aspects of interneuron anatomy (Gulyas, Miles et al. 1993). The 
postsynaptic target domain has been highlighted for the ‘axo–axonic cells’, which innervate the 
axon initial segment of pyramidal cells (Buhl, Halasy et al.1994). The site of layers containing 
the soma and axonal processes is noted in the names of O-LM cells (oriens–lacunosum 
moleculare, Freund and Buzsáki 1996), P-LM cells (pyramidale–lacunosum moleculare, Oliva, 
Jiang et al. 2000) and O-OR bistratified cells (oriens–oriens and radiatum, Maccaferri, Roberts 
et al. 2000). For long-range projecting interneurons, the origin and target brain regions were 
embedded in the terminology, as for hippocampo–septal neurons. Other names have emphasized 
the orientation of interneuron dendrites, as in stellate cells, and the vertical or horizontal cells of 
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stratum oriens, as well as the nearby excitatory synapses on post-synaptic sites such as the 
Schaffer-collateral associated interneurons. 
However, without a universal nomenclature the same type of interneuron has been named 
differently by different investigators (e.g. horizontal cells in McBain, DiChiara et al. 1994, and 
O–LM cells in Maccaferri, Roberts et al. 2000; vertical cells in McBain, DiChiara et al. 1994, 
and basket or bistratified cells in Buhl, Halasy et al. 1994).  There is a strong need for an 
accepted interneuron vocabulary as was pointed out very recently by the foundation of The 
Petilla Interneuron Nomenclature Group (PING) a representative group of researchers that 
provided a set of terms to describe the anatomical, physiological and molecular features of 
GABAergic interneurons of the cerebral cortex (Ascoli, Alonso-Nanclares et al. 2008). 
Despite the descriptive power of an accurate anatomical characterization, the role of an 
interneuron in an active brain network is also crucially shaped by its functional properties which 
must, therefore, be included in its definition. 
 
4.2.2 Functional classification 
 
Interneurons are not completely defined by their anatomy.  Cells with a similar morphology may 
have widely varying electrical and molecular properties. The first physiological descriptions were 
based on action potential firing patterns, and again different investigators made different 
classifications : accommodating or non-accommodating, bursting, fast-spiking cells and regular-
spiking cells (Lacaille, Mueller et al. 1987; Traub, Miles et al. 1987; Kawaguchi and Hama 
1988). More recently, interneurons have been divided according to their steady-state or initial 
responses to stimuli, or spontaneous firing pattern, distinguishing for instance between cells that 
fired in a regular, irregular or clustered fashion (Parra, Gulyas et al. 1998). Such classifications 
are useful, but as for the morphology, few studies have attempted to demonstrate that discrete 
classes exist rather than a continuum. 
Furthermore, firing patterns result from a combination of the activities of numerous voltage-
gated conductances. The proteins responsible have distinct somato-dendritic expression 
patterns in different interneurons. During firing their effects overlap in time, to impart subtle 
characteristics to action potential timing and waveform. So, while practically useful, this 
classification may become problematic with the large number of membrane channels known 
to contribute to the distinct electrical activity of inhibitory neurons (Vinet and Sik 2006). 
Another physiological basis for interneuron classification derives from the nature of 
transmission at afferent excitatory synapses. In particular the facilitation or depression of 
EPSPs, recorded in experiments on connected pairs of neurons, during repetitive afferent 
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activation is suggested as a useful descriptive criterion.  However, the utility of such schemes 
can be questioned, since single axons can transmit information in a target-specific manner 
(Maccaferri, Toth et al. 1998; Scanziani, Gahwiler et al. 1998). 
4.2.3 Neurochemical classification 
 
Differences in chemical markers expressed by interneurons, determined with immuno-
histochemical tools, have provided data for classification schemes.  Even while no single marker 
defines a specific interneuron type, neuropeptides and Ca-binding protein distribution has been 
especially useful to distinguish cell types (Freund and Buzsaki 1996). 
Interneurons all contain GABA (Storm-Mathisen, Leknes et al. 1983), and the GABA-
synthesizing enzymes GAD65 and GAD67 (Ribak 1978). Specific interneuron populations 
contain different peptides, including somatostatin, cholecystokinin (CCK) and substance P, or 
Ca2+-binding proteins, such as calbindin, parvalbumin and calretinin, (Somogyi, Hodgson et al. 
1984). These markers have been used to produce a neurochemical classification which may also 
imply functional differences (Freund and Buzsaki 1996; Baraban and Tallent 2004). 
Parvalbumin, calbindin or calretinin expression seems to discriminate between interneurons with 
different dendritic geometry, postsynaptic target selection and synaptic input density (Gulyas, 
Megias et al. 1999). However, morphologically defined interneurons may co-exist in a single 
neurochemically identified subgroup. For example, O–LM, O–bistratified, P–LM and radiatum–
lacunosum moleculare (R– LM) interneurons of the CA1 hippocampal subfield are all 
immunoreactive for somatostatin (Katona, Acsady et al. 1999; Maccaferri, Roberts et al. 2000; 
Oliva, Jiang et al. 2000; Losonczy, Zhang et al. 2002). Similarly, parvalbumin is expressed by 
basket and axo–axonic cells (Kosaka, Katsumaru et al. 1987; Klausberger, Magill et al. 2003) as 
well as at lower levels in the soma and dendrites but not terminals of  O–LM cells (Maccaferri, 
Roberts et al. 2000; Losonczy, Zhang et al. 2002). Furthermore distinct markers may be 
expressed in morphologically similar interneurons with different functional properties. Basket 
cells for instance express parvalbumin or CCK (Freund 2003). Therefore, a combined 
neurochemical and anatomical classification will be more useful than a scheme based on either 
one of these parameters. Addition of physiological properties results in further overlap since for 
instance somatostatin-expressing neurons exhibit a high degree of electrophysiological 
variability (Ma, Hu et al. 2006). 
Recent in vivo data suggest a functional approach based on axonal and dendritic anatomy, 
chemical markers and cellular firing pattern during population activities such as theta oscillations 
and sharp waves may be useful.  Parvalbumin-positive basket cells, axo–axonic cells and 
somatostatin-containing O–LM cells fired in distinct patterns (Klausberger, Magill et al. 2003). 
More data is needed on further cell types, but these results suggest that specific types of 
interneuron are selectively recruited for distinct functions in different brain states. 
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4.3 Functional role of interneurons 
 
Many principles of interneuron function were first defined in the hippocampus, especially the 
dentate gyrus (Freund and Buzsaki 1996). This work suggested that GABA-releasing 
hippocampal interneurons act to regulate the activity of principal cells. Recent evidence indicates 
that interneurons may also be intimately involved in the generation and control of rhythmic brain 
activities.  Their highly divergent network connectivity, the existence of interneurons that 
specifically target other interneurons and the complex inhibitory cell firing patterns due to 
specific distributions of voltage-gated currents are finely tuned to permit inhibitory interneurons 
to regulate network oscillations. Perisomatic interneurons in particular exert a strong control on 
pyramidal cell population discharges, and thus cognitive operations, (Freund 2003). The diverse 
yet precise connectivity of different types of interneurons (Ramon y Cajal 1893; Lorente de Nó 
1934) enables them to carry out multiple tasks.  
Interneurons are excited by synaptic input from several sources both intrinsic and extrinsic to 
the hippocampus (Lacaille, Mueller et al. 1987; Kawaguchi and Hama 1988; Freund and 
Buzsaki 1996; Oliva, Jiang et al. 2000) which exhibit various activity-dependent plasticity 
(Losonczy, Zhang et al. 2002). Gulyas, Megias et al. (1999) studied differences in excitatory 
innervation of CA1 interneurons containing parvalbumin, calretinin and calbindin. Both 
parvalbumin and calretinin interneurons received synapses from all strata, while calbindin 
cells were excited primarily by Schaffer collaterals in stratum radiatum. This suggests 
calbindin cells are activated by feed-forward circuits, while parvalbumin and calretinin 
containing cells receive both feed-forward excitation from the Schaffer collaterals, entorhinal 
fibres and thalamic afferents, and feed-back excitation by CA1 recurrent collaterals. Activity-
dependant plasticity at synapses that excite interneurons appears to differ from synapses that 
excite principal cells (Maccaferri and McBain 1996; McBain, Freund et al. 1999).  
Several evidences revealed that inhibitory interneurons of the hippocampus are interconnected by 
electrical synapses. An electrical synapse is a mechanical and electrically conductive junction 
between two cells woth a narrow gap between pre- and postsynaptic cell known as a gap 
junction. Dendrodendritic gap junctions between interneurons are frequently seen in areas CA1 
and CA3 (Kosaka and Hama 1985) and in the dentate gyrus (Kosaka 1983). Several types of 
gap junction–coupled interneurons have been identified (Katsumaru, Kosaka et al. 1988; Fukuda 
and Kosaka 2000). The structural proteins comprising gap junctional channels are called 
connexins. Single-cell RT-PCR experiments has revealed the presence of mRNA encoding for 
connexin 36 (Cx36) in interneurons (Venance, Rozov et al. 2000). Furthermore, although 
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electrical coupling between pairs of interneurons was abundant in the CA3 and in the dentate 
areas of wild-type mice, it was absent in cells of Cx36 knockout mice (Hormuzdi, Pais et al. 
2001). 
The functions of electrical coupling between hippocampal interneurons are not yet well 
understood. Many studies have focused on the possibility that gap junctions play a role in 
generating or modulating synchronous oscillations or seizure-like activity (Draguhn, Traub et al. 
1998; Hormuzdi, Pais et al. 2001; Traub, Draguhn et al. 2002; Buhl, Harris et al. 2003). 
 
4.4 Molecular and genetic variety of interneurons 
 
Recent technical developments, including single-cell reverse transcriptase polymerase chain 
reaction (RT-PCR), in vivo labelling and other molecular biological methods now permit a 
molecular approach to interneuron diversity (Meyer, Katona et al. 2002; Blatow, Rozov et al. 
2003; Monyer H 2004). The generation of transgenic mice expressing fluorescence in 
parvalbumin positive interneurons allowed Meyer and colleagues to study electrical coupling 
between these cells. They showed  an interesting developmental regulation of the presence and 
strength of electrical coupling in distinct brain areas (Meyer, Katona et al. 2002). Blatow and 
collagues used the same animals to identify a new subclass of PV positive interneurons that 
differed physiologically from the fast-spiking interneurones which also express parvalbumin.  
These distinct Multipolar Bursting cells (MB) also express calbindin while fast-spiking cells 
do not (Blatow, Rozov et al. 2003). Can this approach determine whether interneurons should 
be divided into discrete classes, or rather considered as a continuum of different neurons?  
The acceptance of distinct anatomical classes of interneurons has been facilitated by the evident 
functional differences between cells that for instance target different somato-dendritic domains 
of pyramidal cells.  At the molecular level, some markers are expressed only by certain 
interneuron types. However, it seems clear that no single marker defines a single anatomical 
or electrical interneuron sub-type, but rather multiple markers must be analysed.  At the 
electrical level, the diversity might seem arbitrary, probably due to the lack of defined 
functions for the different behaviours. The class-versus-continuum issue can probably only be 
resolved objectively by studies that examine variations in gene expression.  
The electrical diversity of neocortical interneurons results from the somato-dendritic pattern of 
expression of distinct ion-channels as well as neuronal form.  Ion-channel gene expression 
seems to correlate with interneuron physiology falling into three clusters according to 
expression of different calcium-binding proteins (Markram, Toledo-Rodriguez et al. 2004). The 
correlation between expression profiles and electrical phenotypes, constraints in co-
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expression profiles and the ‘flip’ of entire expression profiles into opposing electrical 
phenotypes, suggest that expression of distinct combinations of just a few transcription 
factors, may define a finite number of distinct interneuron classes (Toledo-Rodriguez, 
Blumenfeld et al. 2004; Toledo-Rodriguez, Goodman et al. 2005). Recent work in this field 
suggests the Lhx and Dlx families of transcription factors are especially important.  Ghanem 
and colleagues have shown that different enhancers of the Dlx1 and 2 locus (i12b and URE2) 
are expressed in distinct subsets of cortical interneurons (Ghanem, Yu et al. 2007). Zhao and 
colleagues have provided new detail on how Lhx6 controls the specification and development 
of interneurons (Zhao, Flandin et al. 2008). 
So, most interneurons probably belong to distinct electrical, morphological and molecular 
classes. Detected diversity is much less than that expected for a continuum of electrical types 
with more than 100 available ion-channel genes. This points to strong constraints on diversity 
which can be studied with molecular and genetic tools, permitting perhaps a resolution of the 
class-versus-continuum debate for interneurons. 
This work has already begun with the use of transgenic animals to examine molecular variability 
of interneurons. The use of knock out mice has already helped understand links between the 
chemical content of GABAergic interneurons and their network functions (Deans, Gibson et al. 
2001; Hormuzdi, Pais et al. 2001). At a practical level, transgenic mice now permit easy 
visualisation of specific interneuronal subfamilies (Oliva, Jiang et al. 2000; Meyer, Katona et al. 
2002) greatly facilitating classification studies. 
 
5.  Temporal Lobe Epilepsy 
5.1 Epilepsy 
 
The hippocampus is vulnerable to anoxia and ischemia and it is affected early in the pathology 
associated with Alzheimer’s disease. The hippocampal formation also has an especially low 
threshold for certain forms of epilepsy (Green 1964).  The word “Epilepsy” derives from the 
greek Epilambanein, meaning "to take hold of" or "to seize". A seizure corresponds to a sudden 
abnormally synchronous neuronal activity at one or more brain regions. The clinical 
characteristics of the seizure depend on the regions involved.  
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5.2 Epileptic Syndromes 
 
Multiple epileptic syndromes exist and together affect ~1% of the world population 
(McNamara 1999). The incidence in developed countries is ~50/100.000 persons per year.  
The incidence is higher in infants and elderly people and also in non developed countries 
(MacDonald, Cockerell et al. 2000; Sander 2003; Forsgren, Beghi et al. 2005).  
Epileptic syndrome classsification has evolved over the years.  Systems were published in 
1969 and 1981, then again in 1985 and 1989 by the Commission on Classification and 
Terminology of the International League Against Epilepsy (TFCT-ILAE 1981; TFCT-ILAE 
1989). The 1969 / 1981 classification was based exclusively on clinical and electro-
encephalographic criteria. The more recent classification of 1985 / 1989 also takes the 
presumed origins of the pathology into account.  The first system made a major distinction 
between focal, or partial, seizures, generalized convulsive seizures and generalized non 
convulsive seizures, also known as absence seizures. The second classification introduced 
idiopathic, symptomatic and cryptogenic syndromes.  
Partial seizures originate in a defined unilateral region, known as the epileptic focus. Often the 
focus of partial epilepsies is located inside the temporal lobe (66%), but frontal (25%) and 
more rarely occipital (3%) and parietal (2%) epileptic foci also occur (Semah, Picot et al. 
1998). Generalized seizures involve abnormal activity which seems to originate 
simultaneously in extended cortical and sub cortical regions of both hemispheres.  
Idiopathic syndromes occur in the absence of an evident, organic cerebral lesion, while for 
symptomatic syndromes a focal or diffuse lesion can be detected, usually by non-invasive 
imaging. Cryptogenic lesions differ from idiopathic syndromes but no lesion can be detected.  
   
5.3 Etiology of epilepsies 
 
Some epilepsies are inherited, while others are induced by acquired factors which create a lesion. 
Epileptic syndromes with Mendelian genetics are rare, so most syndromes with an inherited 
component probably involve multiple genes as well as interactions with environmental factors.  
Genetic epilepsies corresponding to idiopathic syndromes account for ~30% of cases (Hauser, 
Annegers et al. 1993; Jallon, Loiseau et al. 2001). Acquired epileptic syndromes due to events 
such as cranial traumas, developmental malformations, post-infections lesions or tumours are 
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collectively termed symptomatic and account for ~25% of patients (Hauser, Annegers et al. 1993; 
Jallon, Loiseau et al. 2001). 
 
5.3.1 Symptomatic syndromes 
 
Multiple external factors contribute to the etiology of an epileptic syndrome. Some anomalies 
of cortical development, often with a genetic component, are associated with severe and drug-
resistant epilepsies (Benlounis, Nabbout et al. 2001; Guerrini and Carrozzo 2001; Guerrini and 
Carrozzo 2002).  If the malformation is focal, a partial epileptic syndrome may result 
(Barkovich, Kuzniecky et al. 2001). 
Two broad classes of malformation produce an epileptic brain: defects in neuronal migration, 
or errors in cortical organization. Neuronal migration syndromes include the lissencephalies, 
where the cortex has a smooth rather than a sulcated phenotype and heterotopias of the grey 
substance, where groups of neurons are abnormally situated and localized. Heterotopias may 
be sub-cortical (or laminar) band heterotopias also known as “double cortex” syndromes 
(Barkovich, Guerrini et al. 1994) and periventricular heterotopias.  
While symptomatic epilepsies are considered acquired, recent data suggested they may have a 
significant genetic component. Specific syndromes have been linked to mutations in genes 
coding for proteins associated with the cytoskeleton including Filamin1 (FLN1; (Sheen, Dixon 
et al. 2001; Guerrini, Mei et al. 2004), Doublecortin (Dclx) (des Portes, Pinard et al. 1998) or 
reelin which is associated with the extracellular matrix. 
Cortical organization errors associated with epileptic syndromes include different dysplasias, 
polymicrogyrias and schizencephalia. Of them, focal cortical dysplasia is the most frequent 
cause of intractable epilepsy in children. It corresponds to a cortical cellular expansion with 
grey matter less differentiated than white matter, a disorganised laminar architecture and glial 
and neuronal abnormalities including the presence of abnormally large  balloon cells (Palmini, 
Najm et al. 2004). 
A distinct group of factors in the etiology of epileptic syndromes are those that induce 
convulsions in childhood which are succeeded by adult onset epilepsy.  They include CNS 
infections such as viral encephalitis and bacterial meningo-encephalitis (Annegers, Hauser et 
al. 1988). Cerebral febrile affections occuring at ages up to five years old may induce febrile 
convulsive sizures in genetically predisposed persons (Maher and McLachlan 1995; Camfield 
and Camfield 2002). 
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Brain tumours may induce epileptic syndromes (Cascino 1990; Smith, Hutton et al. 1991). 
Most frequently they include oligodendrogliomas, astrocitomas, meningiomas, metastasis and 
glioblastomas of frontal central cortex. Cranial trauma may induce a post-traumatic epilepsy 
(Annegers, Hauser et al. 1998). Seizures typically appear at one week to two years after the 
trauma (Willmore 1992; Pohlmann-Eden and Bruckmeir 1997) usually without a chronic state. 
In the elderly, a stroke may trigger an epileptic syndrome (Loiseau, Loiseau et al. 1990), 
usually within two years, and more frequently for ischemic than  hemorrhagic accidents. 
 
5.3.2 Idiopathic Syndromes: channelopaties. 
 
Hippocrate in 400 B.C may have been the first to note that epileptic syndromes could be 
inherited. Patterns of transmission of distinct syndromes differ and genetic variation may have 
a major impact on treatment response, prognosis and consequences.  
Mutations in more than 70 genes have now been linked to epileptic syndromes or other 
episodic cortical dysrhythmias. Many of these genes code for membrane ion channels involved 
in the transmission of the nerve impulse or the control of neuronal excitability, recalling the 
necessity for a balance between brain excitation and inhibition for normal function. Other 
genes with quite different functions have also been linked to distinct epileptic syndromes. 
They include transcription factors regulating early development and plasticity as well as 
structural proteins and those related to the cytoskeleton.  
These “epilepsy” genes have usually been identified starting from linkage analysis and then 
genetic DNA sequencing in order to discover the pathological mutation, to functional assays to 
show how the mutation affects network properties (George 2004).  Since many of them code 
for proteins that form or are associated with voltage-gated or receptor-operated membrane 
channels these conditions have been termed “channelopathies”. They include both regulatory 
and pore-forming subunits of voltage gated channels as well as receptors for neurotransmitters 
and neuromodulators (Noebels 2003).  
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1) Na+ channels: mutations in several subunits of Na+ channels have been linked to epileptic 
syndromes (Grieco, Afshari et al. 2002). Three different genes (Scheffer and Berkovic 1997) 
have been associated with the syndrome GEFS+, generalized epilepsy with febrile seizures 
plus, first described by Scheffer and Berkovic (1997).  Mutations in an alpha subunit, SCN1A 
(Escayg, MacDonald et al. 2000; Escayg, Heils et al. 2001; Wallace, Scheffer et al. 2001) have 
been characterized (Spampanato, Escayg et al. 2001; Lossin, Wang et al. 2002; Cossette, 
Loukas et al. 2003; Lossin, Rhodes et al. 2003; Spampanato, Escayg et al. 2003). Some of 
Fig. 4: MAJOR INHERITED EPILEPTIC SYNDROMES AND GENES ASSOCIATED. In the 
table in the picture are listed the major syndrome associated with a genetic inheritance, in the 
second column the chromosomal loci candidate or demonstrated to be linked to the pathology. In 
the third and fourth columns are listed the different genes associated, in case of mutation, to the 
distinct syndromes 
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these mutations are associated with a gain in function probably leading to neuronal 
hyperexcitability while paradoxically others seem to induce a loss-of-function but evidences 
have been reported that the loss of function is specific to inhibitory PV positive interneurones 
(Ogiwara, Miyamoto et al. 2007). Distinct alpha-subunit mutations (SCN2A; (Sugawara, 
Tsurubuchi et al. 2001) and beta sub-unit mutations (SCN1B) associated with GEFS+ 
(Wallace, Wang et al. 1998) have not yet been functionally characterized.  Sodium channel 
mutations are associated with other syndromes including SCN1A mutations that cause 
trafficking problems linked to severe myoclonic epilepsy of infancy (Claes, Del-Favero et al. 
2001; Fujiwara 2006).  
 
2) K+ channels: Many distinct subunits participate in voltage-gated family K+ channels 
assemblies, and in consequence many combinatorial possibilities of the subunit proteins exist.  
As yet, few of them have been associated with inherited epileptic disorders.  Mutations of 
KCNA1 affecting channel assembly, targeting or kinetics (Rea, Spauschus et al. 2002) are 
linked to temporal lobe epilepsies. For this gene too, different mutations have been linked with 
distinct pathologies - some KCNA1 mutations are associated with neuromyoatonia (Zuberi, 
Eunson et al. 1999; Eunson, Rea et al. 2000). Another mutation in the subunit KCNAB2 may 
be associated with the 1p36 deletion syndrome (Heilstedt, Burgess et al. 2001) that has an 
epileptic phenotype, but the association is not yet proven (Kurosawa, Kawame et al. 2005).  
Mutations in the genes KCNQ2 and KCNQ3 were discovered by cloning material from 
patients with a benign familial neonatal convulsion syndrome (Charlier, Singh et al. 1998; 
Singh, Charlier et al. 1998; Leppert and Singh 1999). These genes, members of the Q family, 
named for the link between KCNQ1 and the congenital cardiac long Q-T syndrome, 
coassemble in different ways.  They generate persistent voltage and transmitter-modulated 
currents, first known as M-currents, since they are blocked by muscarine. Activation of Q-
family currents reduces neuronal excitability and suppresses repetitive firing (Wang, Pan et al. 
1998). Mutations in KCNQ2 and KCNQ3 induce a loss-of-function but as other inhibitory 
influences on neuronal excitability predominate; this pathology recedes after few weeks of life. 
These two genes both expressed in pyramidal cells of neocortex and hippocampus (Saganich, 
Machado et al. 2001) and KCNQ2 is expressed in inhibitory neurons (Cooper, Harrington et al. 
2001).  Novel mutations associated with this benign epileptic syndrome are still being 
discovered (Tang, Li et al. 2004; Li, Li et al. 2008; Sadewa, Sasongko et al. 2008). 
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3) Ca2+ channels: Changes in internal calcium concentration act as a trigger for many 
biological processes including neurotransmitter release, excitation-contraction coupling and 
gene expression. Relations between subunit mutations and inherited epilepsies are therefore 
somewhat different for voltage-gated Ca2+ channels and for Na+ or K+ channels. Changes in 
the biophysical properties of Ca2+ channels modify synaptic strength and promote aberrant 
synchronies. Several spontaneous mice mutants exhibit epileptic syndromes linked to 
mutations in proteins coding for Ca2+ channels subunits and have been associated with 
absence-type seizures. Mutants in CACNA1A, coding for the α1a subunit are detected in mice 
strains including totterer, leaner, rocker, roller. Mutations in CACNB4 are associated with the 
lethargic mouse phenotype, in CACNA2D2 coding for the α2δ subunit in the mouse ducky, 
and in the γ2 Ca channel subunit coded by CACNG2, in stargazer and waggler mice exhibit 
absence seizures as well as ataxia (Burgess and Noebels 1999; Crunelli and Leresche 2002).  
Ca channel mutations underlying human inherited epilepsies are less frequent but have been 
detected for the α1 (Jouvenceau, Eunson et al. 2001) and β4 subunits (Escayg, De Waard et al. 
2000).  Mutations in the CACNA1H gene, coding for T-type voltage-gated Ca channel have 
been linked to Childhood absence epilepsy (CAE). In two studies, fifteen distinct mutations 
have been described (Chen, Lu et al. 2003; Heron, Phillips et al. 2004). 
 
4) Cl- channels: Chloride channels gated by voltage are involved directly and indirectly in 
inhibitory processes, both by hyperpolarizing cells directly and also by contributing to internal 
Cl- levels which affect the polarity of GABAergic signalling.  The CLCN2 gene codes for a 
chloride channel widely expressed by pyramidal, interneurones and astrocytes (Sik, Smith et 
al. 2000) that contributes to Cl- homeostasis by a voltage-sensitive inwardly rectifying chloride 
conductance (Staley 1994). Mutations in this channel have been linked to an idiopathic 
generalized epilepsy syndrome with seizures of diverse phenotype (Haug, Warnstedt et al. 
2003). In families with mutations in this gene, the epileptic phenotypes do not always 
segregate as true monogenic traits, suggesting that modifier genes contribute to the phenotype. 
 
5.3.3 Idiopathic Syndromes: mutations on not-channel genes. 
 
Genes coding for neurotransmitter receptors and other aspects of synaptic function have been 
linked to epileptic syndromes.  
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1) GABA transmission: GABA receptors are receptor-operated channels, permeable to chloride 
and bicarbonate, that mediate synaptic inhibition in higher brain regions. Mutations of the γ2 
subunit, coded by the gene GABRG2 are associated with GEFS+, the same syndrome linked 
with SCN1A mutations (Baulac, Huberfeld et al. 2001; Wallace, Marini et al. 2001).  
Mutations in GABRA1, which codes for the α1 subunit, have been related to an adolescent 
epileptic syndrome, Juvenile myoclonic epilepsy (Cossette, Liu et al. 2002). 
Genes that affect GABA release, synthesis and recapture could be associated with epiletic 
phenotypes.  Probably the best known example is that of mutations in GAD65, one of the two 
isoforms of the enzyme involved in GABA synthesis (Kash, Johnson et al. 1997).  
 
2) Glu transmission:  Mutations of genes associated with glutamatergic neurotransmission and 
linked to epileptic syndromes include one in GluRB, the gene conding the βsubunit of the 
glutamate receptor, (Brusa, Zimmermann et al. 1995) as well as a mutation of the transporter 
EEAT1 that removes glutamate from the active zone (Sepkuty, Cohen et al. 2002), and a 
deficiency of EEAT2, a distinct glutamate transporter (Tanaka, Watase et al. 1997). 
 
3) Ach transmission: Mutations of two different subunits of a neuronal nicotinic receptor have 
been linked to an epileptic syndrome termed Autosomal dominant nocturnal frontal lobe 
epilepsy. They concern the gene CHRNA4 that codes for the α4 subunit (Steinlein, Mulley et 
al. 1995; Hirose, Iwata et al. 1999; Tenchini, Duga et al. 1999) and CHRNB2 which codes for 
the β2 subunit (De Fusco, Becchetti et al. 2000). 
 
Many knockout mice of genes involved in the physiology of synaptic transmission and 
electrical activity possess an epileptic phenotype. Genes include those coding for proteins 
expressed at the synapse and involved in transmitter mobilization and release such as the 
SNARE and RAB proteins as well as vesicle-associated proteins. Other genes whose deletion 
or mutation is associated with epileptic syndromes include those involved in cellular 
proliferation, migration and other developmental processes. This family of proteins also 
includes transcription factors (see for review Noebels 2003). These developmental errors often 
correspond to different forms of dysplasia where neurones are misplaced in focal or band 
patterns.   
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Genetic variations have been linked even to symptomatic epilepsy syndromes. Epileptic 
syndromes of Mendelian inheritance with a single altered gene are clearly a minority. With a 
complex genetic equilibrium involving multiple genes as well as changes in protein function or 
expression induced by external factors, subtle genetic and genomic variations may contribute 
to a wider range of epileptic syndromes than presently admitted.   
 
5.4 Mesial Temporal Lobe Epilepsy - MTLE 
 
The focal site for seizures in partial epileptic syndromes is often located in the temporal lobe. 
Mesial Temporal Lobe Epilepsies (MTLE) account for ~60% of the adult human epilepsies 
(Bancaud 1987; Semah, Picot et al. 1998). While they are often seen as a single syndrome, 
several types of epilepsies with different properties arise from the temporal lobe.  In humans, 
such epilepsies typically emerge in adolescence, but may often be traced to an initial 
precipitating event (IPI) of childhood, such as a febrile seizure, hypoxia, trauma, intracranial 
infection, partial onset status-epilepticus, brain tumors and strokes. Pharmaco-therapy may be 
effective, and usually involves multiple molecules often with different targets.  In many 
patients, however, the efficacy of anti-epileptic drugs is reduced with time. 
Pharmacoresistant epilepsies affect 20% of patients with partial epilepsies; (Hauser 1992). In 
these cases, a unilateral removal of seizure-generating circuits of the hippocampus and 
amygdala may be an effective treatment (Gloor 1991; Engel, Williamson et al. 1997). 
Physiological work on resected tissue demonstrates an abnormal hyperexcitability of dentate 
granule cells and hippocampal pyramidal neurons (Schwartzkroin 1986; Masukawa, 
Higashima et al. 1989).  
5.4.1 Semiological remarks and histological features 
 
Epilepsies of the mesial temporal lobe are diagnosed principally from electroencephalogram 
(EEG) records and functional magnetic resonance images (fMRI). They show:  
 
• Temporal seizures arise in the temporal lobe, especially the hippocampus/amygdala. 
• An intercritical pathological EEG activity is generated in focal areas between seizures. 
• Hippocampal volume is reduced (de Lanerolle, Brines et al. 1992)  
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Resected human tissue has permitted work on the causes of the reduction in volume.  It reflects 
a  hippocampal sclerosis corresponding to a selective neuronal loss accompanied by a gliosis 
in the CA3 and CA1 areas (Babb, Lieb et al. 1984; Engel 1992).  Synaptic contacts are 
reorganised in sclerotic human temporal lobe.  The best example is from the dentate gyrus 
where mossy fibres sprout and form aberrant synapses with nearby granule cells (Sutula, 
Cascino et al. 1989). While CA1 and CA3 are reduced in size, the area of the dentate gyrus 
sometimes increases, with a dispersion of granule cells, and even an abnormal giant 
morphology and an ectopic location (Houser, Miyashiro et al. 1990).  It is difficult to 
determine whether these changes in the dentate are a cause or a consequence of either repeated 
seizure activity or of the sclerotic neuronal loss in the CA3 region.  
One major problem in studies on patients lies in relating such pathological changes to an initial 
injury such as a febrile seizure.  Tissues become typically available many years later after a 
latent period between the IPI and the onset of recurrent seizures. Severe prolonged insults like 
prolonged febrile convulsions may lead to a shorter latency period (VanLandingham, Heinz et 
al. 1998). There is also a period of several years during which seizures can be controlled by 
pharmacotherapies (Berg, Langfitt et al. 2003) before they become pharmacoresistant. The 
mechanisms underlying the delayed emergence of recurrent seizures in MTLE have not yet 
been completely resolved. 
 
5.4.2 Hippocampal Sclerosis 
 
Hippocampal sclerosis (HS), with neuronal loss and glial proliferation, was first associated 
with temporal lobe epilepsies by Bouchet and Cazauvieilh in 1825. More than 50% of 
pyramidal cells in the CA1 and CA3 areas and the hilus may die, resulting in a severe atrophy.  
Both temporal lobes are usually affected but one side is almost always more sclerosed than the 
other hemisphere (Margerison and Corsellis 1966). CA2 pyramidal cells and dentate granule 
cells are much less affected, and dentate granule cells may disperse and take abnormal 
morphologies (Houser, Miyashiro et al. 1990; Houser 1992; Lurton, Sundstrom et al. 1997; 
Mathern, Babb et al. 1997). Mossy fibre axons of dentate granule cells re-organize, probably in 
response to the loss of their targets in CA3. Aberrant and pro-epileptic connections are formed 
with the dendrites of nearby dentate cells (Mathern, Babb et al. 1997).  
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The existence of a causal association between hippocampal sclerosis and temporal lobe 
seizures remains unclear.  In patients sclerosis usually preceeds the emergence of seizures, but 
it is mild or even absent in some patients.  In contrast, sclerosis does not necessarily lead to 
mesial temporal lobe seizures.   
 
 
 
Very similar patterns of cell loss are described in geriatric patients with neurocognitive 
impairments and dementia (Dickson, Davies et al. 1994; Vinters, Ellis et al. 2000). 
Morphometric studies on sclerosis in post mortem or surgically removed tissue has shown 
major differences in the form, extent and severity of scerosis in epileptic patients. Marguerison 
and Corsellis (1996) detected a pattern of cell death involving primarily the hilus and CA3c 
region.  Bruton (1988) proposed three categories: classic sclerosis, total sclerosis and sclerosis 
limited to CA3c-hilus (Bruton 1988). The limited sclerosis accounts for about 5 % of cases, 
with the majority following a classical pattern of cell death in the hilus, CA3 and CA1 regions.  
Neuronal death and gliosis is detected, to a lesser extent, in extra-hippocampal regions 
including the entorhinal cortex and the amygdala  in about 60% of cases (Yilmazer-Hanke, 
Wolf et al. 2000; Bocti, Robitaille et al. 2003). Typical anti-epileptic surgery removes the 
amygdala as well as the regions of hippocampal cell death (Gloor 1991; Wieser 1998).  
 
Fig.5: TEMPORAL LOBE EPILEPSY WITH HIPPOCAMPAL SCLEROSIS. On the left panel 
EEG recordings showing aberrant electrical activity in a patient affected by Temporal Lobe 
Epilepsy. On the right panel MRI of brain in an epileptic patient, presenting evidence of 
Hippocampal Sclerosis marked by the red arrow. 
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5.4.3 Natural history of MTLE 
 
Patients with mesial temporal lobe epilepsies tend to share a similar history (Mathern, Babb et 
al. 1996; Engel, Williamson et al. 1997) with a common progression of clinical features that 
reinforces the notion of a disease that evolves over a long time period: 
 
1) IPI.  In patients with MTLE, it is often possible to identify a childhood incident, frequently 
associated with a convulsion or status-epilepticus. Both external insults and innate conditions 
may be involved but careful studies on the progression from such an incident to adolescent 
seizures are rare. Febrile seizures are the most common precipitant but not all such events lead 
eventually to adult epilepsies. Infant hypoxia, brain trauma and intracranial infection also act 
as precipitants. A distinct genetic background may be associated with either the predisposition 
to childhood convulsions or to an enhanced susceptibilty for the development of either 
hippocampal sclerosis or adult epilepsy.   
Kunz et al (2000) have related a specific mitochondrial dysfunction to the susceptibility for 
MTLE (Kunz, Kudin et al. 2000). Evidence has also grown for a role of inflammatory 
processes in the development of pro-epileptic circuits (Vezzani and Granata 2005) and Crespel 
and colleagues have suggested that such  processes may be activated both by the initial 
precipitating episode and during the formation of a glial scar (Crespel, Coubes et al. 2002).  
Some gene polymorphisms may be related to the susceptibility to develop adult seizures. 
Preliminary data supports associations with polymorphisms in genes coding for the GABAB1 
receptor (Gambardella, Manna et al. 2003), prodynorphin (Stogmann, Zimprich et al. 2002; 
Gambardella, Manna et al. 2003) and members of the Interleukin 1 pathway (Kanemoto, 
Kawasaki et al. 2000),  
 
2) Latent period: There may be a delay, of weeks to many years, between the IPI and the 
emergence of recurrent seizures. The processes occuring during this latent period remain to be 
fully characterized. Possibly interictal activity, which may be limited to the hippocampus, is 
generated before recurrent seizures that propagate to extra-hippocampal sites. Such activity 
could induce further cell death and so contribute to a progressive evolution of the sclerosis, 
(Saukkonen, Kalviainen et al. 1994; Mathern, Pretorius et al. 1995; Mathern, Pretorius et al. 
1995; Lombardo, Kuzniecky et al. 1996; Pitkanen, Tuunanen et al. 1998). Other processes that 
presumably occur during this period include the formation of novel connections, formation and 
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evolution of populations of activated glial cells, the generation of new neurons perhaps in sites 
outside the dentate and changes in inhibitory synaptic function. These processes will be 
discussed in the following sections. 
 
3) Emergence of recurrent seizures: After a delay, recurrent seizures may last for several tens 
of seconds. They are initiated in the hippocampal formation and propagate to extra-
hippocampal sites. Initially seizures may be controlled with paharamcotherapy, but later they 
become pharmacoresistant (Engel, Williamson et al. 1997). Seizure frequency can vary from 
several per day to monthly and it may vary according to hormonal or emotional factors. 
 
5.4.4 Animal models of MTLE 
 
Physiological and molecular mechanisms underlying the development of temporal lobe 
epilepsies after an initial convulsion cannot be followed in experiments on humans.  Studies on 
mechanisms can be performed in animal models of the syndrome which should mimic the 
human condition as closely as possible.   
 
1) Kindling models: A spontaneously epileptic state is induced after several weeks of daily 
electrical stimulation of moderate intensity.  This process was first described by Grahame 
Goddard (Goddard 1967; Goddard, McIntyre et al. 1969). The amygdala and hippocampus 
have especially low thresholds, but other brain structures are also susceptible to kindling 
(McNamara, Bonhaus et al. 1985; Racine, Mosher et al. 1988; Sutula, He et al. 1988). The 
kindling procedure does not mimic status epilepticus, but probably does engages similar plastic 
processes to those of epileptogenesis. Discharges generated during kindling are not equivalent 
to a status-epilepticus and it is difficult to identify a latent phase (McNamara 1984). A single 
prolonged stimulation of the perforant pathway (Olney, deGubareff et al. 1983; Sloviter 1983) 
may also generate spontaneous, persistent seizures (Lothman, Bertram et al. 1990; Bertram 
1997; Mazarati, Wasterlain et al. 1998) associated with a severe sclerosis of the dentate gyrus 
(Sloviter 1983; Sloviter, Dean et al. 1996) and mossy fibre sprouting.  
 
2) Hyperthermia and hypoxia models: Two models mimic conditions that induce seizures in 
infants. A heating protocol can induce prolonged febrile seizures in young rodents (Baram, 
 35 
Gerth et al. 1997). Spontaneous seizures emerge in the following weeks (Dube, Richichi et al. 
2006) but are not associated with a classical hippocampal sclerosis even though there is some 
cell loss (Toth, Yan et al. 1998; Bender, Dube et al. 2003; Dube, Yu et al. 2004). Changes are 
reported in the Ih current (Chen, Aradi et al. 2001; Santoro and Baram 2003) which indirectly 
affects GABAergic signalling (Chen, Baram et al. 1999; Chen, Ratzliff et al. 2003). The 
association between these changes and spontaneous seizure activity remains to be established 
(Baram, Eghbal-Ahmadi et al. 2002).  
Neonatal hypoxia may be a precipitating factor for adult seizures (Bergamasco, Benna et al. 
1984; Volpe 1994). Jensen and colleagues developed a model (Jensen, Applegate et al. 1991) 
in which a perinatal hypoxia of 15 min duration induced seizures in young rats (P7 to P15) but 
activities were not maintained and hippocampal sclerosis did not develop in adult animals.  
 
3) Neurotoxin injection: Lesions that mimic hippocampal sclerosis are induced by focal or 
systemic injection of neurotoxic or convulsant substances.  Cell death and gliosis is followed 
by the emergence of an epileptic phenotype after several weeks or months.   
Kainic Acid (KA) is an agonist at a family of glutamatergic receptors. Systemic injection of 
KA generates a status-epilepticus and induces severe cell loss in the hippocampus, some 
cortical regions, lateral septum and amygdale, and mossy fibre sprouting (Ben-Ari, Tremblay 
et al. 1981; Olney, Collins et al. 1986). Spontaneous, recurrent seizures emerge after a latent 
phase of several weeks (Ben-Ari, Tremblay et al. 1981; Lothman and Collins 1981; Zaczek 
and Coyle 1982). Partial seizures are initiated in the hippocampal formation and rapidly 
generalize to frontal cortical areas. 
Pilocarpine, a muscarinic receptor agonist, induces a similar epileptic phenotype to KA. 
Systemic injection induces a status-epilepticus (Cavalheiro 1995). A bilateral sclerosis is 
induced in the hippocampus and other limbic structures with a severe cell loss and a moderate 
gliosis (Honchar, Olney et al. 1983; Turski, Cavalheiro et al. 1983; Cavalheiro, Leite et al. 
1991; Cavalheiro 1995). Mossy fibre sprouting occurs as does dispersion of the dentate 
structure (Mello, Cavalheiro et al. 1993). Recurrent seizures emerge after a latent period of 1-6 
weeks. Seizures arise in either hippocampus, and become generalized to involve wide frontal 
regions over time (Leite, Bortolotto et al. 1990; Cavalheiro, Leite et al. 1991).  
Intra hippocampal injection of tetanus or botulinum toxin has been used to create another 
animal model of temporal lobe epilepsy (Mellanby, George et al. 1977). These toxins inhibit 
transmitter release by proteolitic cleavage of the presynaptic protein synaptobrevin (Schiavo, 
Benfenati et al. 1992). While their injection does not induce a status-epilepticus, in the days 
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after injection epileptiform activity emerges in the hippocampus and evolves towards recurrent 
seizures which generalize (Hawkins and Mellanby 1987; Jefferys, Borck et al. 1995; Finnerty 
and Jefferys 2002). Cell loss is limited to CA1 region and does not always occur (Mellanby, 
George et al. 1977). The seizure state tends to be transient, expressed over a restricted period 
of several months. Presumably seizures do not induce further cell loss in this model, and it is 
suggested that adaptive changes in GABAergic circuits underly the cessation of spontaneous 
seizures (Whittington and Jefferys 1994). 
 
5.4.5 Intrahippocampal injection of Kainic acid  
 
In the first studies using Kainic acid to produce epileptic animals, Ben-Ari and colleagues, 
made focal intra-amygdaloid rather than systemic injections (Ben-Ari and Lagowska 1978; 
Ben-Ari, Lagowska et al. 1979). Focal injections produce a unilateral and spatially restricted 
cellular lesion (Magloczky and Freund 1993; Suzuki, Junier et al. 1995). This restricted 
cellular damage also permits separation of local and distant effects of both cell death and 
epileptiform activity.   
The status epilepticus induced by focal KA injection lasts up to 24 hours (Ben-Ari 1985; Ben-
Ari and Cossart 2000). During this phase pyknotic neurons appear in the hilus and the CA1 
and CA3 regions exclusively in the injected hemisphere (Suzuki, Junier et al. 1995). Le 
Duigou showed that during status epilepticus, cellular activity was almost abolished near the 
injection site, and epileptiform discharges were generated at distant sites (Le Duigou, Wittner 
et al. 2005).  
After one week, cell death is observed close to the injection site (Bouilleret, Ridoux et al. 
1999). After 3-4 weeks pyramidal cells of the CA1 and CA3c regions of the injected 
hippocampus have largely disappeared (Riban, Bouilleret et al. 2002) and some specific types 
of interneurons are also lost (Magloczky and Freund 1993; Bouilleret, Loup et al. 2000).  Over 
the same period, the dentate gyrus becomes enlarged, granule cells disperse (Suzuki, Junier et 
al. 1995; Bouilleret, Ridoux et al. 1999; Knuesel, Zuellig et al. 2001), and mossy fibres sprout 
to establish novel contacts in the subgranular molecular layer of the dentate gyrus and stratum 
oriens of ipsilateral hippocampus. Mossy fibre sprouting may sometimes even extend to the 
contalateral hippocampus (Bouilleret, Ridoux et al. 1999). Gliosis, as evident in an increased 
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number of GFAP positive cells, occurs over a similar time period in the dentate gyrus as well 
as in the CA3 and CA1 regions.  
While morphological changes occur over a period from days to months after KA injection, 
physiological alterations detected by EEG traces evolve more slowly and with a delay.  Up to 
3-4 weeks only sporadic interictal events occur. They may evolve to short discharges but seem 
to be limited to the injected hippocampus and there is no behavioural correlate. In the chronic 
state after 4 weeks, EEG records show interictal and recurring seizure activity.  Seizures are 
associated with immobilization or convulsive behaviours. Both the unilateral sclerosis and the 
recurrent seizures persist and, in this respect, the KA injection model is similar to the human 
MTLE syndrome (Magloczky and Freund 1993; Magloczky and Freund 1995). 
 
5.4.6 Comparison of the different animal models 
 
Comparison of different animal models for MTLE must consider both physiological and 
anatomical changes, including hippocampal sclerosis. All models except for kindling and 
tetanus toxin injection induce an initial status epilepticus. However, factors other than the 
status epilepticus may contribute to the emergence of a chronic epileptic syndrome. It is not 
easy to identify an equivalent of the latent period in the kindling model, where all discharges 
are induced by direct stimulation. The presence of a latent phase in an animal model may 
provide insights into the evolution of factors in the exacerbation of the lesion (Bragin, Engel et 
al. 1999; Bragin, Wilson et al. 2000; Riban, Bouilleret et al. 2002). The efficiency of the 
different models for induction of recurrent spontaneous seizures varies. Seizures induced by 
systemic KA and by Tetanus toxin may tend to disappear with time. Furthermore, focal 
injection of convulsants such as KA or pilocarpine clearly induces a unilateral sclerosis, 
whereas systemic injection tends to affect both hippocampi to a similar extent.  In conclusion, 
consideration of all factors suggests that focal pilocarpine or KA injection produce a syndrome 
most similar to human MTLE.  
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5.5 Molecular Mechanisms of MTLE 
 
While the sequence of anatomical and physiological changes associated with the emergence of 
mesial temporal lobe epilepsies are relatively clear, the molecular mechanisms remain to be 
clarified. Understanding at this level will be crucial, both to identify causal relations and 
eventually to develop new therapies. It seems important to establish for instance whether 
seizures cause cell death or whether a hippocampal sclerosis is crucial for the emergence of an 
epileptic brain. In animal models, can changes induced by convulsants be separated into pro-
epileptic factors and homeostatic mechanisms that act to counter epileptogenesis? Does the 
synaptic reorganization induced by cell death promote aberrant discharge patterns or might it 
act to stabilize hippocampal excitability? Here, recent progress on understanding molecular 
factors and putative mechanisms for the genesis of the chronic epileptic phenotype will be 
reviewed.   
 
5.5.1 Cell loss 
 
The initial event during the evolution of hippocampal sclerosis is a massive, selective cell 
death. After a convulsant is injected, neurons die either by necrosis or by activation of 
apoptotic programmes both of which are triggered by a massive Ca2+ entry (Pollard, Charriaut-
Marlangue et al. 1994; Fujikawa, Shinmei et al. 2000).  
Oliva et al visualised morphological changes in dendrites of EGFP-Somatostatin  positive O-
LM interneurons during the early stages of cell death due to KA application (Oliva, Lam et al. 
2002). Indeed intereneurones seem to be more sensitive to cell death induced by KA and 
pilocarpine and death ensues within hours (Bouilleret, Ridoux et al. 1999; Bouilleret, Loup et 
al. 2000; Dinocourt, Petanjek et al. 2003). Patterns of interneuron death are not uniform: 
interneurones of the hilus are most susceptible (Leranth and Ribak 1991; Obenaus, Esclapez et 
al. 1993; Sloviter, Dean et al. 1996; Buckmaster and Dudek 1997; Sloviter, Zappone et al. 
2003) then CA1 interneurones while CA3 interneurones are resistant (Bouilleret, Loup et al. 
2000; Cossart, Dinocourt et al. 2001; Kobayashi and Buckmaster 2003; Sloviter, Zappone et 
al. 2003).  
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Distinct subtypes of interneurons are differentially susceptible, with SOM-containing cells of 
the CA1 region being especially sensitive (de Lanerolle, Kim et al. 1989; Magloczky and 
Freund 1995; Buckmaster and Jongen-Relo 1999; Cossart, Dinocourt et al. 2001; Wittner, 
Magloczky et al. 2001; Dinocourt, Petanjek et al. 2003; Kobayashi and Buckmaster 2003). 
Parvalbumin-containing interneurones are differentially sensitive: basket cells survive while 
axo-axonic cells tend to die (Cossart, Dinocourt et al. 2001; Dinocourt, Petanjek et al. 2003). 
Patterns of death of Calretinin and Calbindin containing interneurons vary according to their 
location (Bouilleret, Ridoux et al. 1999; Bouilleret, Loup et al. 2000). The differential 
susceptibility of distinct types of interneurone may depend on changes in internal Ca2+ 
according to their expression of distinct KA (Cossart, Esclapez et al. 1998; Frerking, Malenka 
et al. 1998; Cossart, Epsztein et al. 2002) or Ca2+-permeable AMPA receptors (Koh, Geiger et 
al. 1995; Leranth, Szeidemann et al. 1996).  
Two different mechanisms with distinct kinetics induce pyramidal cell death after KA 
treatment: necrotic death occurs first due to excitotoxic processes initiated by an increase in 
intracellular Ca2+ (Choi, Maulucci-Gedde et al. 1987; Fujikawa, Shinmei et al. 2000) and 
activation of the apoptotic pathway induces death which occurs with a slower time course 
(Pollard, Charriaut-Marlangue et al. 1994).  In the hilus and the CA3 region, KA or pilocarpine 
induce an almost complete death of pyramidal cells (Riban, Bouilleret et al. 2002). Pyramidal 
cell loss in the CA1 regions may reach 60% of the total, in the subiculum  20-30% (Knopp, 
Kivi et al. 2005) but granule cells of the dentate gyrus and CA2 pyramidal cells are preserved 
(Covolan, Ribeiro et al. 2000). KA is reported to induce a reduction in expression of the GluR2 
subunit in CA3 and hilar pyramidal cells. AMPA receptors lacking this subunit are Ca2+ 
permeable (Pellegrini-Giampietro, Gorter et al. 1997) which may exacerbate susceptibility to 
necrotic or apoptotic processes. In contrast, reduction of the Ca-binding protein calbindin 
(Nagerl, Mody et al. 2000) or increased mGluR4 expression (Lie, Becker et al. 2000) may be 
an adaptive response.  
Some studies have provided evidence for cell death contralateral to focal KA injection 
including a decreased expression of calbindin in the CA1 region, and changes in the peptides 
CCK and neuropeptide Y (Bouilleret, Loup et al. 2000; Arabadzisz, Antal et al. 2005).  During 
hippocampal sclerosis, changes in expression have also been noted for molecules that induce 
or regulate cell death. Proteins including IL-1RA (receptor for Interleukin 1) or TNF may be 
upregulated in homeostatic fashion to aid neuronal survival (Liu, D'Amore et al. 1993; Bruce, 
Boling et al. 1996; Panegyres and Hughes 1998), while growth factors including GDNF and 
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aFGF may act to reduce seizure frequency and so enhance neuronal survival (Cuevas, Revilla 
et al. 1994; Martin, Miller et al. 1995; Cuevas and Gimenez-Gallego 1996). 
 
5.5.2 Fibre sprouting 
 
Death of post-synaptic target neurons can induce reactive sprouting of pre-synaptic axons and 
the establishment of novel synaptic contacts (Scheff, Benardo et al. 1977; Nadler, Perry et al. 
1981; Frotscher and Zimmer 1983). Mossy fibre sprouting has been especially well studied 
since mossy fibre terminals have high levels of the metal zinc, which is detected by the 
Timm’s stain. Axons of the dentate granule cells sprout following the loss of hilar cells. They 
occupy and form synapses in novel regions including the inner molecular layer of the dentate 
gyrus (Frotscher and Zimmer 1983; Sutula, He et al. 1988) and the CA3 stratum oriens. 
Sprouting is first detected at 5 days after KA injection, peaks at about 3 weeks and may persist 
up to 18 months after the lesion (Cavazos, Golarai et al. 1991; Cavazos, Golarai et al. 1992).  
Novel synaptic terminals are formed with the spines of granule cells and with inhibitory 
interneurons including basket cells (Ribak and Peterson 1991; Buckmaster, Zhang et al. 2002; 
Cavazos, Zhang et al. 2003). Physiological studies have shown that these new connections are 
functional (Tauck and Nadler 1985; Wuarin and Dudek 1996; Lynch and Sutula 2000; Wuarin 
and Dudek 2001). 
Axons of CA1 pyramidal cells also sprout into previously non-innervated regions after KA 
treatment. Axon collaterals extend to the CA1 stratum lacunosum-moleculare and radiatum 
where they presumably form new excitatory synapses with other CA1 pyramidal cells and also 
into the subiculum (Perez, Morin et al. 1996; Esclapez, Hirsch et al. 1999; Morin, Beaulieu et 
al. 1999; Cavazos, Jones et al. 2004).  The establishment of recurrent connections in the 
dentate and CA1 regions (Deuchars and Thomson 1996) creates novel feedback mechanisms 
that may contribute to epileptiform behaviours (Smith and Dudek 2001; Smith and Dudek 
2002; Sadewa, Sasongko et al. 2008).  
Several molecules, including cytokines and growth factors, have been identified as stimulators 
of axonal sprouting and guidance factors. Brain derived neurotrophic factor (BDNF) and basic 
Fibroblast growth factor (bFGF) induce sprouting in vitro (Lowenstein and Arsenault 1996). 
The expression of both BDNF (Ernfors, Bengzon et al. 1991; Isackson, Huntsman et al. 1991; 
Zafra, Lindholm et al. 1992) and bFGF (Humpel, Lippoldt et al. 1993; Follesa, Wrathall et al. 
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1994; Simonato, Molteni et al. 1998) are upregulated in several different seizure models. The 
first discovered neuronal growth factor (NGF) is involved since its inhibition decreases axonal 
outgrowth (Holtzman and Lowenstein 1995; Van der Zee, Rashid et al. 1995). Gall and 
Isackson (1989) first described NGF upregulation in epilepsy, and this has been repeatedly 
confirmed (Zafra, Hengerer et al. 1990; Ballarin, Ernfors et al. 1991). 
Evidence for a sprouting process for inhibitory axons is contradictory. An increase in GAD-
positive terminals was detected in the dentate of rat epilepsy models (Houser 1992; Gruber, 
Greber et al. 1993) and in the subiculum of tissue from epilepsy patients (Arellano, Munoz et 
al. 2004), but other work found no consistent change (Wittner, Magloczky et al. 2001; Wittner, 
Eross et al. 2005). It is likely that inhibitory cell axonal sprouting differs between regions and 
between different types of interneurons.  
 
5.5.3 Cellular excitability 
 
Neuronal expression of both voltage-gated and receptor-operated channels is changed in 
animal models of epilepsy. 
Three sodium channel subunits, Scn2a1, Scn8a and Scn1b are upregulated after pilocarpine 
treatment (Ellerkmann, Remy et al. 2003) and may contribute to neuronal hyperexcitability.  In 
contrast the subunit Scn2a1 is reported to be downregulated in the sclerotic zones of tissue 
obtained from patients (Lombardo, Kuzniecky et al. 1996). An increase in expression of the 
Ca+-channel subunit Cacna1c has been detected in activated astrocytes (Westenbroek, Bausch 
et al. 1998).  Upregulation might be associated with an increased neuronal excitability, but 
existing evidence suggests that the Cacna1a subunit is rather downregulated following KA 
treatment (Vigues, Gastaldi et al. 1999). 
A reduced expression or efficacy of K+ channel subunits would also have pro-epileptic 
consequences.  Bernard and colleagues described changes in the Kcnd2 and Kcnb1 subunits as 
“acquired channelopathies” after pilocarpine treatment (Bernard, Anderson et al. 2004).  Both 
a transcriptional down-regulation and a post-translational reduction in efficacy of dendritic 
conductances due to alterations in phosphorylation by ERK for Kcnd2 and PKC for Kcnb1 
were detected (Bernard, Anderson et al. 2004; Misonou, Mohapatra et al. 2004).  
In the kainate model, Shah and colleagues (Shah, Anderson et al. 2004) showed a down-
regulation of HCN1 and 2, hyperpolarization-activated, cyclic nucleotide-gated channels 
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underlying the h-current which generates a depolarization when cells are hyperpolarized.  
Changes in the expression of these two subunits have also been noted in human tissue 
(Brewster, Bender et al. 2002). 
These modifications may alter intrinsic neuronal properties so as to produce a hyperexcitable 
pro-epileptic phenotype as reported for subicular pyramidal cells after KA-treatment (Wellmer, 
Su et al. 2002). 
Changes are also reported in the expression of molecules associated with chemical synaptic 
transmission.  Glutamate receptor subunit expression is altered by treatment with KA or 
pilocarpine. GluR1 and GluR2/3 expression is upregulated both in human tissue and animal 
models (Babb, Mathern et al. 1996; Mathern, Pretorius et al. 1998). There is also evidence for 
altered phosphorylation or redux modulation of GluR subunits (Lieberman and Mody 1999; 
Sanchez, Wang et al. 2000; Rycroft and Gibb 2004).   
The expression of the metabotropic receptors mGluR1 and 5 is reduced in pyramidal cells 
(Akbar, Rattray et al. 1996; Tang, Lee et al. 2001) of KA-treated animals.  In contrast 
astrocytic expression of mGluR5 is increased (Ulas, Satou et al. 2000) and in human tissue 
mGluR 2, 3, 4 and 8 subunits are upregulated on astrocytes (Tang and Lee 2001).  
Changes in gene expression or protein regulation can also affect ambient levels of extracelluar 
glutamate.  Thus, the neuronal glutamate transporters EAAT3 and 1 are upregulated in granule 
cells and CA3 pyramidal cells while EAAT2 is downregulated in astrocytes of the CA1 region 
and hilus in human tissue (Mathern, Mendoza et al. 1999). In KA-treated mice the murine 
homologue of the transporter EAA1, GLAST, is upregulated in CA3 and hilus after status 
epilepticus (Nonaka, Kohmura et al. 1998), while EACC1 (homologue to EAAT3) and GLT1 
(homologue to EAAT2) seem to be downregulated (Simantov, Crispino et al. 1999). 
Changes in expression of GABA receptor subunits also occur in human tissue and animal 
models of epilepsy. Expression is often downregulated in sclerotic regions (Schwarzer, 
Tsunashima et al. 1997; Fritschy, Kiener et al. 1999; Bouilleret, Loup et al. 2000), but 
increases have been reported for the α1 and α2 subunits in temporal lobe epilepsy patients 
(Loup, Wieser et al. 2000). Interestingly the α5 subunit of GABA-A receptors is 
downregulated in CA1 pyramidal cells (Houser and Esclapez 1996) since this subunit is 
specific for extra-synaptic GABA receptors (Mody 2001; Semyanov, Walker et al. 2004). 
GABAB receptor subunits Gabbr1 and Gabbr2 are downregulated in the CA1 and CA3 areas of 
KA-treated animals (Straessle, Loup et al. 2003). Changes have also been described in 
molecules associated with GABA-A receptors including the structural proteins gephyrin 
(Kumar and Buckmaster 2006) and dystrophin (Knuesel, Zuellig et al. 2001).  
 43 
 
5.5.4 Neurogenesis 
 
The subgranular zone of the dentate gyrus is one of the two areas of rodent brain where adult 
neurogenesis is maintained (Altman and Das 1965; Kuhn, Dickinson-Anson et al. 1996). 
Progenitor cells of this area develop a granule cell morphology (Cameron, Woolley et al. 1993; 
Seki and Arai 1993). Seizures trigger proliferation of precursor cells of the sub-granular zone 
(Parent, Yu et al. 1997; Thom, Sisodiya et al. 2002; Crespel, Rigau et al. 2005). Parent and 
colleagues showed that pilocarpine treatment stimulates differentiation of these proliferating 
cells into young granule cells (Parent, Yu et al. 1997).  This process may be related to granule 
cell dispersion.  Newly differentiated neurons also migrate to CA3 where they form novel 
connections that may contribute to epileptogenesis (Scharfman, Goodman et al. 2000).  
Neuronal proliferation in the dentate is induced by status epilepticus not only in a KA-treated 
hippocampus but also in the contralateral non-injected hippocampus even in the absence of cell 
death (Kralic, Ledergerber et al. 2005). On the contralateral side, the newly generated elements 
differentiate largely into dentate granule cells and to a lesser extent into astrocytes. In contrast 
most cells in the injected hippocampus are GFAP-positive suggesting they remain trapped as 
astrocytes. The effects of spontaneous recurrent seizures on cellular proliferation and 
differentiation are much smaller than those of convulsant injection.   
Differential expression of several markers for neurogenesis and astrogliosis has been 
described:  
The identity of cascades of signalling pathways that control cell proliferation and 
differentiation is still being clarified.  Markers for proliferative cells (PCNA), for new born 
neurons (DCX and PSA-NCAM) and for newly generated glial cells (GFAP) have been 
examined in KA-treated animals (Ledergerber, Fritschy et al. 2006). The basic Fibroblast 
Growth Factor (bFGF) is upregulated in and around the proliferative zone following seizures 
(Humpel, Lippoldt et al. 1993; Bugra, Pollard et al. 1994; Ballabriga, Pozas et al. 1997; 
Gomez-Pinilla, Dao et al. 1997).  In vitro studies suggest that bFGF may be involved in the 
differentiation of neural precursors towards a neuronal phenotype, rather than in cellular 
proliferation (Basilico and Moscatelli 1992). Further work is clearly needed on reciprocal 
interactions between seizures and the proliferation and differentiation of neuronal and glial 
progenitor cells.   
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5.5.5 Inflammatory response and glia activation 
 
It has become increasingly clear that different types of glial cells contribute to the development 
of MTLE. Experimental and clinical studies have associated inflammatory processes and 
epileptogenesis (Billiau, Wouters et al. 2005; Vezzani and Granata 2005; Gorter, van Vliet et 
al. 2006; van Gassen, de Wit et al. 2008). A gene profiling study from Gorter and colleagues 
has described a significant activation of immune responses during the latent period before 
seizure emergence (Gorter, van Vliet et al. 2006).   
Microglial cells are associated with brain immune responses and after seizures these cells are 
activated: they proliferate, their morphology and gene expression change (Niquet, Ben-Ari et 
al. 1994; Represa, Niquet et al. 1995). Microglia is also activated by infection and fever which 
are among the most frequent precipitating events for MTLE.  Activated glial cells secrete 
molecules including cytokines, neurotoxic substances, chemokines, growth factors (Giulian 
1993; Chao, Hu et al. 1995) which have rapid effects on neurones but also initiate structural 
and genetic changes occuring over a longer time scale. The complement system, part of the 
immune system, is activated in epileptic human tissue (Jamali, Bartolomei et al. 2006) and 
seems to be differentially expressed during different phases of epileptogenesis in animal 
models (Gorter, van Vliet et al. 2006; Aronica, Boer et al. 2007) 
Astrocytes are also activated after convulsant injection in animal models. Although it is 
unclear whether cell death or electrical activity of the status epilepticus is the effective 
stimulus, they proliferate as well as they change their shape and gene expression. Astrocyte 
activation stimulates precursor cell production. There is evidence that neuronal precursors 
move towards an astrocytic phenotype at sclerotic sites (Ledergerber, Fritschy et al. 2006) 
even though astrocyte-like cells are a precursor element for newly generated neurones 
(Berninger, Costa et al. 2007). Astrocytes may aid granule cell migration in the dentate gyrus 
(Crespel, Coubes et al. 2002) and it is suggested that astrocyte proliferation after seizures 
serves to repopulate sclerotic regions (Borges, McDermott et al. 2006), but the maintained 
presence of a glial scar suggests the process remains incomplete (Crespel, Coubes et al. 2002). 
Astrocyte activation also affects electrical properties. Sodium channel expression is increased, 
and events similar to action potentials can be generated (O'Connor, Sontheimer et al. 1998). 
Astrocytes become more sensitive to glutamate (Seifert, Schroder et al. 2002) and participate 
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in the inflammatory response by releasing NFkB in models of epilepsy (Lerner-Natoli, 
Montpied et al. 2000). Calcium imaging studies suggest that astrocytes may even generate 
slow, coupled oscillations in internal calcium and membrane potential (Wang, Lou et al. 2006; 
Jourdain, Bergersen et al. 2007; Winship, Plaa et al. 2007) 
Changes in intracellular Calcium in astrocytes may liberate neuroactive molecules like 
glutamate (Bezzi, Carmignoto et al. 1998), interleukins and growth factors. Among them, 
bFGF, IL-2 and TNF-α may modulate cellular excitability or increase seizure susceptability by 
alternative pathways (Nistico and De Sarro 1991; Liu, D'Amore et al. 1993; De Sarro, Rotiroti 
et al. 1994; Probert, Akassoglou et al. 1995; Liu and Holmes 1997; Yuhas, Shulman et al. 
1999). Other liberated growth factors, like aFGF and GDNF (Martin, Miller et al. 1995; 
Cuevas and Gimenez-Gallego 1996), may counteract these effects by decreasing seizure 
intensity and duration.   
The timing and consequences of activation of diverse types of glial cell during the 
development of an epileptic brain remains a vital subject for further work.   
 
5.5.6 Transcription activity and conclusion 
 
Changes in gene expression are clearly involved in the proliferation and differentiation of new 
cells and modify the physiology of existing cells. Presumably they are orchestrated by cell-
specific transcription factors activated sequentially during the process of epileptogenesis.  
Early-response genes which are upregulated in the hippocampus during status epilepticus 
include c-fos, EGR-1 and EGR-2 (Ben-Ari 2001; Rakhade, Yao et al. 2005). Elliott and 
colleagues described changes in the basic helix-loop-helix (bHLH) transcription factors 
(Elliott, Khademi et al. 2001) while altered expression is also described for ICER (Porter, 
Lund et al. 2008), p53, MDM2 (Engel, Murphy et al. 2007), NFkB (Lubin, Ren et al. 2007) 
and REST (Spencer, Chandler et al. 2006).  Upregulation of transcription factors is known to 
induce cascades of activities leading eventually to gene transcription, as exemplified by the 
induction of CREB and the pro-inflammatory gene COX-2 (Lee, Dziema et al. 2007). The role 
of these factors in the establishment of an epileptic brain remains to be assessed. 
In a typical case of MTLE an initial insult acts as a precipitating event often inducing a status 
epilepticus. The complex cascade of events that follows is not completely understood.  The 
effects of neuronal cell death and glial cell activation, the involvement of inflammatory and 
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immune responses, the modifications of synaptic connectivity and the expression of voltage-
gated and receptor-operated channels combine but it remains difficult to separate causes and 
effects, pro-epileptic responses and anti-epileptic homeostatic mechanisms. A molecular or 
genetic approach offers a distinct way to characterize how a healthy brain evolves into a 
pathological network.  
 
6 Genomic tools to approach the complexity of the brain 
 
6.1 Gene Expression Analysis 
 
Molecules of mRNA are the products of transcription of the genetic heritage of a cell. A 
quantitative and qualitative description of transcribed mRNA in a cell gives a vision of its state 
and the activity of its genes. As precursors of translated proteins, changes in mRNA molecules 
determine the future proteome. Changes in gene expression have classically been analyzed by 
Northern blot and RT-PCR and by more advanced methods including differential display and 
SAGE (serial analysis of gene expression). While these techniques have identified novel 
differentially expressed genes (Kozian and Kirschbaum 1999), they are restricted to a limited 
number of genes. Larger-scale studies on gene expression have been enabled by microarray 
technology which permits the parallel analysis of thousands of genes in a single assay. These 
techniques include oligonucleotide microarrays (Lockhart, Dong et al. 1996) and cDNA 
microarrays (Schena, Shalon et al. 1995; Schena, Shalon et al. 1996).  
 
6.1.1 Microarrays and DNA-Chips 
 
Micro-arrays consist of miniaturised hybridisation assays that permit analysis of thousands of 
nucleic acid fragments. Nucleic acid sequences, or “probes”, are immobilised on an array and 
fluorescently labelled “target” samples are hybridized against the array. Fluorescent signals 
related to the quantity of hybridized target are read by a detection system for analysis. cDNA 
microarrays consist of preformed nucleic acid sequences immobilized onto several thousand 
spots of several µm diameter on a glass wafer support. The cDNAs usually consist of clones 
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amplified by polymerase chain reaction (PCR) from a collection of transcripts. DNA-chips, in 
contrast, are produced by proprietary technologies (Gene Chip®, Affymetrix). Oligo-
nucleotides of 20-25 base pairs are synthesized and spotted directly onto a solid support by 
photolithography (Watson, Mazumder et al. 1998). 
For gene expression analysis with spotted arrays, mRNA samples are converted into labelled 
populations of target nucleic acids. These populations consist of complex collections of many 
thousands of fragments which are labelled with fluorescent dyes, such as the cyanines Cy3 and 
Cy5. The use of more than one dye permits comparison of two or more samples on the same 
microarray. In GeneChip® RNA molecules are directly labelled and hybridized on the Chips. 
With a high reproducibility across chips, single channel analysis may be the better choice. In 
either case, labelled fragments form duplexes with immobilized complementary probes. The 
number of duplexes reflects the number of each specific fragment in the target. Two or more 
differently labelled samples can be hybridised simultaneously, and from measurements on the 
distinct fluorescent signals the relative abundance of specific sequences can be determined.  
 
6.2 Gene expression profile studies in brain 
 
Neurons are among the most actively transcribing cells of an organism. Even while neuronal 
shape, connectivity, intercellular communication and electrical activity are richly diverse, it is 
thought that neuronal cell types should share physiological properties, morphology or 
molecular markers. The characterization of such families remains however incomplete. It is 
suggested that gene expression profiles may offer an unbiased framework for neuronal 
classification (Mott and Dingledine 2003; Markram, Toledo-Rodriguez et al. 2004). The basic 
assumption is that the complete profile of genes transcribed by a cell underlies the highly 
specialized phenotype while in a neuron defines its physiological properties. During the 
transition to disease states, such as epilepsy, changes in gene profile seem likely to accompany 
pathological alterations to the normal features of a neuronal cell type.  Thus gene expression 
profile studies have been used to answer question on both physiological and pathological 
conditions. The complexity of the brain makes such work both interesting and challenging. 
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6.2.1 Gene expression profile analysis and brain. 
 
Most genomic approaches to the brain have examined specific regions (Sandberg, Yasuda et 
al. 2000; Zhao, Lein et al. 2001; Zirlinger and Anderson 2003) where tissue heterogeneity 
may average important signals from different or minority cell types.  A better comprehension 
of neuronal taxonomy from gene expression profile may be achieved by first separating 
functionally distinct cell types. There are technical difficulties with this approach: cells of 
interest may constitute a small minority of the total or may share features with cells from 
different subclasses making recognition complex. Gene expression profiles of single cells 
have often been compared to electrophysiological features (Monyer and Markram 2004; 
Yano, Subkhankulova et al. 2006). Such approaches based on genetic material from a single 
cell have been used for some time (Eberwine, Yeh et al. 1992), but technical problems persist.  
A single cell yields small amounts of mRNA and one may still ask whether sufficient material 
can be reliably obtained from a single cell.  Nevertheless, following such an approach, 
Kamme and colleagues have found that interneurons and pyramidal cells of the CA1 region of 
the hippocampus express specific subsets of different genes (Kamme, Salunga et al. 2003).  
Paradoxically, they also revealed differences in gene profile within the putatively 
homogenous pyramidal cell population.  
Technical advances aid such work. Laser capture microdissection (Emmert-Buck, Bonner et al. 
1996) permits RNA to be obtained from small groups of single cells and methods for PCR-
based amplification of small quantities of RNA improve continuously (Eberwine, Yeh et al. 
1992; Luo, Salunga et al. 1999).  Specific subsets of neurons can now be recognized in tissue 
from transgenic animals made by fusing fluorescent proteins with molecules specific to a given 
cell type (Feng, Mellor et al. 2000; Oliva, Jiang et al. 2000; Chattopadhyaya, Di Cristo et al. 
2004; Lopez-Bendito, Sturgess et al. 2004). Application of cell sorting techniques such as 
Fluorescent activated cell sorting (FACS) or Laser capture microdissection has permitted the 
analysis of gene expression profiles of isolated groups of homogeneous cells (Arlotta, 
Molyneaux et al. 2005; Sugino, Hempel et al. 2006). Gustincich and colleagues used such a 
transgenic animal to examine gene expression in catecholaminergic neurons of the retina, a 
retinal cell type (Gustincich, Contini et al. 2004). Sugino and colleagues, exploited several 
transgenic mice to compare gene expression in twelve different inhibitory and excitatory cell 
types from different brain regions (Sugino, Hempel et al. 2006). 
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In conclusion, mcroarray analysis of gene expression is becoming an increasingly useful tool 
to examine cellular heterogeneity in the brain as better techniques are applied to the separation 
of functional neuronal families. 
 
6.2.2 Gene expression profile analysis in epilepsy. 
 
Microarray technology has also been used to explore modifications in gene expression during 
changes and pathologies of the brain such as development (Geschwind, Ou et al. 2001; Mody, 
Cao et al. 2001) ischemia (Matzilevich, Rall et al. 2002) and aging (Lee, Weindruch et al. 
2000; Jiang, Tsien et al. 2001) as well as disorders including Alzheimer’s disease (Ginsberg, 
Hemby et al. 2000), multiple sclerosis (Whitney, Becker et al. 1999; Lock, Hermans et al. 
2002) and schizophrenia (Mirnics, Middleton et al. 2000; Hakak, Walker et al. 2001). 
Characterization of gene expression in epileptic tissue obtained from patients or from animal 
models of epilepsy may suggest novel therapeutic targets.  In one early study, gene expression 
in sclerotic human hippocampus obtained after operations on pharmacoresistant patients was 
compared with that in control or lesioned hippocampi (Becker, Chen et al. 2002). They found 
that 21 genes were differentially regulated. A closed examination of a subset of these revealed 
that two (ataxin-3 and glial fibrillary acid protein: GFAP) were upregulated while one 
(calmodulin) was down regulated. Differentially regulated genes were classed as neuronal- or 
glial- specific, or as for calmodulin, related to a structural modification rather than to a change 
in the expression of a specific cell type. Jamali and colleagues made expression profile 
analysis on genes expressed in the entorhinal cortex of epileptic patients (Jamali, Bartolomei et 
al. 2006). They linked six genes to human MTLE: a serotonin receptor (HTR2A), a 
neuropeptide Y receptor type 1 (NPY1R), a protein (FHL2) associating with the KCNE1 
(minK) potassium channel subunit and with presenilin-2 and three immune system-related 
proteins (C3, HLA-DR-gamma and CD99).  
In contrast to work on tissues obtained from epileptic patients, animal models offer the 
possibility to follow changes in gene expression at several time points during epileptogenesis. 
These works demonstrate immediate genetic effects of several precipitating factors. Thus, the 
pro-epileptic effects of traumatic brain injury on hippocampal gene expression has been 
examined at 1 hr, 4-8 hrs and 1 day after the damage (Matzilevich, Rall et al. 2002; Long, Zou 
et al. 2003). Matzilevich and colleagues found that about 6% of 8.800 identified transcripts 
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were differentially expressed. These transcripts were involved in oxidative stress, metabolism, 
inflammation, structure and cellular signaling. Long and coworkers found that the expression 
of 253 genes was altered: 106 increased, 147 decreased. Most up-regulated genes were 
involved in cell homeostasis and calcium signaling, downregulated genes coded for 
mitochondrial enzymes, metabolism, and structural proteins, while genes coding for proteins 
involved in inflammatory reactions were both up and down regulated.  Comparison of the 
effects of KA treatment on gene expression in parietal cortex on the day of injection and one 
day later (Tang, Lu et al. 2002) revealed 186 differentially expressed genes mostly involved in 
inflammation. 
Distinct changes in genetic profile occur during the latent phase in the dentate gyrus of rat 14 
days after treatment (Elliott, Khademi et al. 2001). Lukasiuk, Kontula and Pitkanen used 
amygdala kindling in the rat and analysed the effects in microarray analysis of hippocampal 
and temporal lobe tissue at delays of 1, 4 and 14 days. Pooling mRNA from both ipsi-lateral 
and contralateral hippocampi provided evidence for a complex network of gene expression 
with changes specific to the different time points (Lukasiuk, Kontula et al. 2003). They 
identified 282 genes whose expression changed during epileptogenesis: 87 hippocampal and 
207 temporal lobe transcripts.  13 genes were common to both structures, but only four genes 
(all expressed sequence tags) changed in the same direction at the same time in both regions. 
Similar time points were combined in a hippocampal kindling model by Gorter and coworkers 
with a regional analysis that compared changes in CA3, the entorhinal cortex and the 
cerebellum (Gorter, van Vliet et al. 2006). Gene expression changed even in the unstimulated 
cerebellum. The largest changes occurred for genes associated with immune responses, such as 
cytokines, complement factors and interleukins, and these changes were maintained for several 
months after stimulation. Genes associated with synaptic transmission, including the GABA-A 
receptor subunits α5 and δ, tended to be downregulated during both the acute and latent phase.  
These studies led to the identification of several epilepsy candidate genes, and had great 
importance in giving more insights in the complex networks of events that lead from a first 
injury to the establishment of an epileptic brain.  
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Introduction 
 
Hippocampal neurons can be broadly divided into pyramidal cells and interneurons.  Pyramidal 
cells liberate glutamate to excite post-synaptic neurons while interneurons release GABA which 
inhibits principal cells and other inhibitory cells. Even though GABAergic interneurons form a 
minority of about 10% of hippocampal neurons, they are diverse in terms of their anatomy, their 
expression of neuropeptide co-transmitters and Ca-binding proteins as well as in 
neurophysiological properties (Ramon y Cajal 1893; Freund and Buzsaki 1996).  
Attempts made to classify interneurons according to these criteria (Freund and Buzsaki 1996; 
Parra, Gulyas et al. 1998) have been only partially satisfactory (Parra, Gulyas et al. 1998; 
McBain and Fisahn 2001). It remains a challenge to find a classification scheme that 
encompasses anatomical, physiological, pharmacological, developmental and phylogenetic 
aspects of the interneuron phenotype in the face of novel molecular data.  A promising approach 
may involve a systematic analysis of the expression of large numbers of molecules.  Recent 
work has used techniques including RT PCR (Toledo-Rodriguez, Goodman et al. 2005) and 
gene profile expression derived from microarray systems (Sugino, Hempel et al. 2006) to 
explore the molecular composition of distinct groups of GABAergic cells. 
Such molecular approaches to interneuron classification may be usefully combined with the 
recent development of transgenic techniques for identification of subsets of interneurons. In 
these animals, enhanced green fluorescent protein (EGFP) is coupled to a promoter that controls 
the expression of a specific peptide or calcium binding protein (Monyer and Markram 2004). 
Oliva et al. (2000) have used this technique to generate transgenic mice that express EGFP 
under the control of the regulatory sequence of the gene coding for the Glutamate 
Decarboxylase 1 protein (67 KDa, Gad1 or Gad67). EGFP was found, in one transgenic mouse 
strain, to be expressed in hippocampal and neocortical interneurons containing Somatostatin. 
This strain has been named GIN for GFP-expressing Inhibitory Neurons. These GFP-
expressing cells seem not to express (Oliva et al, 2001) other markers such as Calbindin (CB) 
and Neuropeptide Y (NPY) that are present in some SOM-expressing hippocampal interneurons 
(Kohler, Eriksson et al. 1987; Toth and Freund 1992). They did not express parvalbumin (PV) 
or calretinin (CR), but systematically expressed the “a ” spliced form of the metabotropic 
glutamate receptor 1 (mGluR1a, Oliva et al. 2000).  
The identification of fluorescent EGFP-positive cells of GIN mice has facilitated anatomical and 
physiological studies on this subset of GABAergic cells. The axon of nearly all EGFP positive 
cells with somata in stratum oriens of the CA1 region projects to stratum lacunosum-
moleculare (O-LM; Oliva et al. 2000). Multiple physiological studies have also been made on 
O-LM interneurons both before and after the emergence of the GIN mouse strain (Lacaille, 
Mueller et al. 1987; Lacaille and Williams 1990; McBain, DiChiara et al. 1994; Maccaferri and 
McBain 1996; Maccaferri, Roberts et al. 2000; Maccaferri and Lacaille 2003; Maccaferri 2005). 
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In this study, I used microarray techniques to compare gene expression of EGFP+ fluorescent 
interneurons from the GIN mouse strain and non-fluorescent CA1 pyramidal cells. These cell 
types were sorted on the basis of their fluorescence after dissection with laser capture 
microscopy (Oliva, Jiang et al. 2000).  This work identified 443 differentially expressed genes: 
260 of them were more highly expressed by interneurons and 183 genes were expressed at 
higher levels in pyramidal cells. The differentially expressed genes included several proteins 
involved in tramission of nerve impulse or modulation of synaptic activity, as well as 37 
transcription factors or genes associated with transcription regulation which displayed distinct 
expression patterns.   
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Materials and Methods 
 
All experiments were carried out in accordance with the European Community Council Directive 
of 24 November 1986 (86/609EEC) and were approved by local authority veterinary service. 
 
Dissociation of hippocampal neurons 
 
Experiments were performed on wild-type FVB mice and GIN mice, aged P15-P20 (GIN mice: 
Jackson Laboratories, Maine, USA; (Oliva AA Jr 2000). Animals were decapitated after 
anaesthesia induced by intraperitoneal injection of urethane (2 g/Kg body weight) and both 
hippocampi were dissected.  
Several different procedures were tested to optimise the stability and quantity of RNA that 
could be isolated from GFP-positive interneurons and pyramidal cells of the hippocampus. 
The first procedure used a fluorescence activated cell sorter to sort fluorescent interneurones 
from pyramidal cells. Hippocampi were placed in ice-cold phosphate buffer solution (PBS) and 
cut into small pieces (~2x2 mm) with a scalpel blade, removing white matter as far as possible to 
facilitate cell dissociation. These pieces were then put in a Falcon tube containing 5 ml of cold 
EBSS (Earle’s Balanced Salt Solution: 10X EBSS, Sigma, St Louis, MO, USA; 7.5% NaHCO3;  
1M HEPES, Sigma, St Louis, MO, USA; 0,35g/ml of Glucose; pH adjusted to 7.4 with 1N 
HCl). This solution was briefly washed with 5 ml of a Digestion Solution (137 mM NaCl, 
5mM KCl, 7 mM, Na2HPO4, 25 mM HEPES, 4.2 mM NaHCO3, 200 mM Kynurenic Acid, 
pH adjusted to 7.4). It was then replaced by 5 ml of the same solution containing 20 U/ml 
papain (Worthington Biochemical Co., Freehold, NJ). Papain was pre-activated by incubation 
at 37°C for 30 min in the presence of 1 mM L-cysteine and 0.5 mM EDTA. After adding 
activated papain, 250 µl DNAseI was added to the digestion solution and the tube was gently 
agitated at 37°C for 20 min. The digestion medium was then removed and the contents 
washed briefly in EBSS. An additional wash (5 min at 4°C) was then performed with 5ml of 
EBSS containing 500 µl of 1% Ovomucoid Inhibitor (Worthington Biochemical Co, 
Freehold, NJ) and 1% BSA (Sigma, St Louis, MO, USA). This inhibitor was then removed, 
the tissue was briefly washed in EBSS before treating the tissue again with 750 µl of 
dissection buffer and 250 µl of DNAse in EBSS. Hippocampi were mechanical triturated with 
fire-polished glass pasteur pipettes in this solution before centrifugation at 1000 rpm for 5 
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min. Pelletted cells were then resuspended in 2 ml of extracellular solution or RNAlater 
(Qiagen, Chatsworth, CA, USA). 
 
Fluorescence Activated Cell Sorting 
 
Fluorescence Activated Cell Sorting was done in collaboration with Dr. Myrza Suljagic using 
a FACSCalibur System (BD Biosciences, Franklin Lakes, NJ USA) kindly provided by Prof. 
Oscar Burrone at the Centre for Genetic Engineering and Biotechnology in Trieste. 
Resuspended cells were diluted with PB and the solution was passed through the machine. 
Fluorescence acquisition and data analysis were performed with CellQuest Pro Software (BD 
Biosciences, Franklin Lakes, NJ USA). Sorted cells were collected in 50 ml Falcon Tubes.  
 
Laser Capture Microdissection 
 
As an alternative approach, we used laser capture microdissection to separate EGFP+ 
interneurons and CA1 pyramidal cells according to C. Vlachouli et al; manuscript in 
preparation. For these experiments, brains were dissected and incubated in 1X Zinc Fix (BD 
Biosciences, Franklin Lakes, NJ USA) in H2O treated with Diethyl Pyrocarbonate (DEPC, 
Sigma, St Louis, MO, USA) solution for 6 hours. After fixation, brains were exposed 
overnight to a 1X Zinc Fix + 30% sucrose solution. They were then included in section 
medium Neg-50 (Richard Allan scientific, Kalamazoo, MI, USA) and placed on an 
isopentane layer (Sigma, St Louis, MO, USA) that had been frozen in liquid nitrogen. Blocks 
of tissue were placed in a freezing cryostat (Microm International, Walldorf, Germany) and 
maintained at -21°C for 30 min.  Frontal sections of whole brain were then cut at a thickness 
of 16 µm and transferred to Superfrost Plus glass slides (Menzel-Glaser, Menzel GmbH & co 
KG, Braunschweig, Germany). EGFP-positive interneurons cells were identified in unstained 
tissue using a Zeiss P.A.L.M. LCM microscope (Carl Zeiss Inc., Germany). Sections were air 
dried for 2 min and fluorescent cells were microdissected, collected in adhesive caps (PALM 
Microlaser Technologies GmbH, Bernried, Germany) and their mRNA was rapidly extracted. 
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Pyramidal cells were collected using similar procedures in experiments on FVB wild type 
mice, aged P15-P20. Pyramidal cell bodies were recognised by applying a modified Nissl 
stain protocol to coronal sections. Cells of the pyramidal layer were identified on dry sections, 
microdissected, collected and mRNA was rapidly extracted.  
 
Modified Nissl Staining  
 
A modified rapid Nissl staining was needed to reduce the possibility that sections dried during 
the time between cryostat cutting and use of the laser capture microdissector (C.Vlachouli, 
personal comunication). Slices on glass slides were washed for 30sec in PBS 1X and stained 
for 10 min in a Cresyl Violet solution (0.5X Cresyl Violet, 1% Acetic Acid, 0.04X Sodium 
Acetate in nuclease-free H2O). They were then passed through PBS, 70% EtOH, and 95% 
EtOH for 30 s in each solution. Laser micro-dissection was then performed. 
 
RNA extraction and probe synthesis 
 
mRNA from EGFP-positive interneurons and pyramidal cells was extracted, isolated, purified 
and amplified with the µMACS SuperAmp kit (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to manufacturer’s protocol (C. Vlachouli et al.; manuscript in 
preparation). GlobalPCR product was purified with the High Pure PCR Product Purification 
Kit (Roche diagnostics GmbH, Mannheim, Germany) and the DNA concentration of samples 
was measured with ND-1000 spectrophotometer (Nanodrop technologies, Wilmington, DE, 
USA). For hybridization on two microarray slides (SISSA1/SISSA2), 350 ngm of globalPCR 
were labelled with µMACS SuperAmp kit with added Klenow Fragment (20 units, Fermentas 
Inc., Glen Burnie, MD, USA) and 25nmol cy3-dCTP (GE Healthcare, UK) according to 
manufacturer’s protocol. When labelled, the probe was purified with Illustra CyScribe GFX 
Purification kit (GE Healthcare, UK). Dye incorporation and DNA concentration were 
measured with a ND-1000 spectrophotometer.  
For total hippocampus hybridizations, animals were decapitated and tissue removed into ice-
cold PBS 1X in DEPC-treated H2O. Hippocampi were dissected in RNAse free conditions and 
placed in Eppendorf containing 1 ml TRIzol (Invitrogen, Carlsbad, CA, USA). Total RNA 
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was isolated according to the manufacturers instructions. Samples were treated to avoid 
genomic contamination with 2 units of RNAse-free DNAse (2 units/µl; Ambion, Austin, TX 
USA) for 15 min at 37°C. Total RNA was further purified with RNeasy Mini Kit (Qiagen, 
Chatsworth, CA, USA). The quality of purified RNA quality was assessed using an Agilent 
2001 Bioanalyzer (Agilent, Palo Alto, CA, USA) and quantified with a ND-1000 
spectrophotometer (Nanodrop technologies, Wilmington, DE, USA).  In hybridization 
experiments, 10 µg of purified RNA were used.  
 
Standard RNA processing for microarray experiments 
 
For hybridization on two microarray slides (SISSA1/SISSA2), 10 µg of Universal mouse 
reference RNA (Stratagene, La Jolla, CA, USA) was mixed with 5 µl of Random Primers 
(Concentration, Manufacturer) and 2 µl of smart T7-24 primer.  
After 5 min at 70°C, 4 µl of 5X First Strand Buffer, 2 µl of DTT (both reagents from 
Invitrogen, Carlsbad, CA, USA), 2 µl of amino allyl dUTP-dNTPs, 1 µl of SuperScript II 
(Invitrogen, Carlsbad, CA, USA) and 0.5 µl of RNAse Out (Invitrogen, Carlsbad, CA, USA) 
were added to this pre-mix. The reaction mix was incubated for 2 hours at 37°C and for 5 min 
at 70°C to inactivate the enzyme. After adding 1 µl of 0.5M EDTA pH 8.0 and 10 µl 1M 
NaOH, the reaction was performed at 70°C for 10 min before adding 20 µl of 1M HEPES. 
The standard probe was precipitated at 4°C for 30 min by adding 3M NaOAc to a final 
concentration of 0.3M, 1 µl of Linear Acrylamide (Ambion, Austin, TX, USA), 150 µl of 
Nuclease Free H2O and 150 µl of Isopropanol. Samples were centrifuged for 30 min at 
15000xg, isopropanol was removed and pellets washed with 70% EtOH. They were re-
suspended in 4.5 µl of Nuclease Free H2O and 4.5 µl of 0.1M NaHCO3 and incubated for 15 
min at RT. Cy5 dye (GE Healthcare, UK) in 2 µl of DMSO was then added and coupling was 
done overnight at RT. The coupling reaction was quenched with 4.5 µl of 4M hydroxyamine 
incubated at RT in the dark for 15 min before adding 35 µl of 100mM NaOAc pH 5.2. The 
labelled probe was purified with PCR purification kit (Qiagen, Chatsworth, CA, USA). Dye 
incorporation and DNA concentration were measured with an ND-1000 spectrophotometer. 
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Microarray hybridization 
 
Before hybridization, SISSA1/SISSA2 slides were incubated for 1 hr at 55°C in 0.2X SSC 
(Ambion, Austin, TX USA) buffer filtered through a 0.22 µm filter, washed in distilled water 
and centrifuged at 2000 rpm for 5 min. For each slide pair, ~2 µg of probe were mixed with 2 
µg of standard RNA probe together with 1.3 µl of 3.5 mg/ml Salmon Sperm (Sigma, St Louis, 
MO, USA), 1.3 µl of 1 mg/ml Cot-1 mouse (Invitrogen, Carlsbad, CA, USA), 6.6 µl of PolyA 
and 6.6 µl of 11.8 mh/ml tRNA (Sigma, St Louis, MO, USA). Sample volume was brought to 
150 µl with distilled H2O, before adding 150 µl of 2X formamide-based hybridization buffer 
(Genisphere, Hatsfield, PA, USA) pre-heated to 65°C for 10 min. Slides were mounted on a 
GeneMachines Hyb4 Microarray Station (Genomic Solutions, MI, USA) and after pre-heating 
to 80°C for 10 min. 150 µl of the sample was pipetted onto each slide. Hybridization was 
achieved with the sequence: 65°C for 2 hr, 55°C for 2 hr and 44°C for 12 hr. Slides were 
washed 5 times with 2X SSC + 0.2 SDS at 65°C, 5 times with 2X SSC at 55°C, and 5 times 
with 0.2 SSC at 42°C. Each wash included 10s of flowing solution, and 30s at holding 
temperature. Before scanning, slides were centrifuged at 2000 rpm for 10 min in the dark. 
 
Analysis of expression profile data 
 
Slides were scanned with a GenePix Personal 4100A microarray scanner (Molecular Devices 
Corporation, CA, USA). Pre-processing, including slide reading and intra- and inter-array 
normalization, was done independently for each group. Loading, normalization and statistical 
analysis were done with the LIMMA package from BioConductor or statistical computing in 
the R programming environment (Gautier L 2004). Normalization within arrays was done 
with the function “normalizeWithinArrays” based on the LOWESS algorithm: 
“normalizeWithinArrays(RG,method="loess",bc.method="normexp",offset=50)”. 
Normalization between arrays was done with the function “normalizeBetweenArrays” based 
on the quantile method: “normalizeBetweenArrays(MA,method="quantile")”. 
After loading and normalization, all signals were merged before statistical analysis. Our 
hybridization design permitted two distinct types of analysis: a) to compare single cell or 
tissue RNA levels to a control (universal mouse RNA): similar to the ’single-channel 
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hybridization'; b) to compare RNA expression levels between two different cell types or 
tissues, using the same reference (universal mouse RNA) for both hybridizations. All 
statistical analyses were done using the eBayes function of the LIMMA package. Filters used 
are the widely accepted: fold change ≤ log2 (-1) or fold change ≥ log2 (1) (corresponding to a  
± 2 fold change on a linear scale) and corrected p-value ≤ 0.05. 
Heatmaps were generated by submitting gene lists to the MultiExperiment Viewer program 
(Institute for Genomic Research, Rockville, MD, USA; www.tigr.org). Fold Changes for each 
experiment compared the sample to the Standard Reference and were then normalized to 
perform Hierarchical Clustering (Eisen, Spellman et al. 1998) based on Euclidean Distance. 
Gene Ontology analysis was performed using tools for annotating gene lists available at 
DAVID Bioinformatics Resources: http://david.abcc.ncifcrf.gov/ (Dennis, Sherman et al. 
2003). 
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Results 
 
Dissociation and FACS analysis of EGFP positive cells. 
 
Data was obtained from mice of the GIN strain at P10-P15. The optimum cell dissociation 
protocol (see methods section) was based on papain rather than trypsin or pronase digestions. 
Microscopic observation of dissociated cells plated onto a poly-lysine coated petri suggested 
that up to 106 cells of healthy appearance based on a Trypan Blue vitality test (data not 
shown) could be obtained from the hippocampi of 4 animals.  
We first attempted to separate fluorescent interneurons and non-fluorescent pyramidal cells 
with a fluorescence activated cell sorting machine (Herzenberg, Sweet et al. 1976), which 
analyzed the fluorescence and size of cells passed through it.  Parameters measured were 
Forward Scattering (FSC-H) which reflects cell size, Side Scattering (SSC-H) related to cell 
shape and Green (FL1-H) or Red (FL2-H) fluorescence signals. The same analysis was 
performed on dissociated hippocampal cells from WT animals as a control. 
We first used a resuspension media containing RNAlater (Qiagen, Chatsworth, CA, USA).   
However, analysis of FSC-H and SSC-H signals (Fig. 1A) suggested that while this solution 
preserved RNA, it also induced a significant cell shrinkage.  Signals from tissue dissociated 
from WT or GIN animals were dispersed due to cell bodies and debris and a high percentage 
of data points were close to the lowest levels of detection.  We then switched to a standard 
extracellular solution which permitted detection of two distinct cell populations in both EGFP 
and WT animals.  These cell groups showed different levels of Forward Scattering, with more 
cells in a group with a lower FSC-H.  
Cell shrinkage induced by RNAlater was associated with a loss of fluorescence evident in 
plots (Fig. 1B) of green fluorescence (FL1-H) against forward scattering (SSC-H)). It 
revealed an accumulation of cells at the lowest levels of fluorescence with detection 
thresholds set between 101 and 102 to exclude detection of cells from WT samples.  
Comparing specific and aspecific fluorescent signals by plotting red (FL2-H) against green 
fluorescence (FL1-H) revealed a specific green signal in a population of selected cells.  
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fluorescence and dimension, while observing samples resuspended in Extracellular Solution 
we could clearly see a difference in fluorescence level between wild type and GIN Mice. We  
Fig.1: FACS ANALYSIS OF DISSOCIATED CELLS FROM WILD TYPE AND GIN MICE 
HIPPOCAMPI.  Each panel compares Side Scattering (SSC) to Forward Scattering (FSC). 1A, there 
was signal dispersion from cells resuspended in RNAlater, while two populations, in terms of size 
and shape, were evident for cells resuspended in fresh extracellular solution. 1B,  comparison of 
green fluorescence (FL1) with respect to SSC (1B) revealed no difference between wild type and 
GFP positive cells when RNAlater was used, and the signal accumulation near threshold levels is 
suggestive of a large cellular shrinkage. Cells from GIN and WT mice resuspended in extracellular 
solution showed different levels of fluorescence, permitting isolation of up to 104 cells with 
fluores ence higher than a s t threshold (1B). Iso at d cells are shown as green spots in all graphs. 
The specific fluorescence is evident in comparisons of FL1 and FL2 (1C). 
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Using this threshold, 0.5 - 1*104 cells could be sorted from a suspension of about 106 
dissociated cells derived from the hippocampi of two GIN mice. This represents 0.9 - 1.2 % 
of the number of cells analyzed. It is consistent with estimates that EGFP positive 
interneurons of GIN mice account for ~1% of hippocampal neurons (Oliva et al, 2000).  
All fluorescent cells fell into the population of smaller cells based on FSC-H values and most 
of them showed high SSC-H values.  However, isolated cells were collected from the sorter in 
a volume of ~50 ml of PBS which was too large for further steps towards gene profiling.  We 
therefore searched for an alternative method to distinguish between EGFP-positive 
interneurons and pyramidal cells.   
We next used laser capture microscopy to collect mRNA from fluorescent interneurons and 
from pyramidal cells. In this technique, a laser beam precisely cuts small areas of tissue and 
focal laser pulses can then be used to catapult cut tissue into a collection tube (Emmert-Buck, 
Bonner et al. 1996).  
 
Slice preparation. 
 
GIN mice, aged P15-P20 were sacrificed, and their brains dissected in RNAse-free conditions. 
Brains included in cutting medium were then frozen in isopentane and cut at a cryostat in 16 µm 
thick slices. Due to the nature of the tissue, and given the lack of fixation (to preserve RNA 
integrity) slices were immediately moved under the microscope to perform Laser Capture 
Dissection. In order to identify the pyramidal layer and collect pyramidal cells slices were 
stained with Cresyl Violet before laser capture. Nissl staining protocol was modified to be faster 
in order to avoid drying of slices and RNA degradation.. 
 
Laser Capture Dissection. 
 
Cells of tissue derived from GIN animals were selected on the basis of their fluorescence and 
the location of their soma in the stratum oriens of the CA1 region. In each experiment ~300 
EGFP positive cells were collected from the sections.  While axonal projection patterns could 
not be determined, most of these fluorescent cells probably corresponded to O-LM 
interneurons. For comparison, about 300 pyramidal cells were dissected from the stratum 
pyramidale of CA1 and CA3 regions of tissue from same animals.  
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RNA extraction and hybridization. 
 
Samples from these cells were processed for mRNA extraction and amplification with 
µMACS SuperAmp kit (Miltenyi Biotec, Bergisch Gladbach, Germany) which uses magnetic 
beads to specifically isolate messenger RNA. This RNA was then amplified, labelled with 
fluorofores and hybridized on home-made microarrays. The same analysis was performed on 
total hippocampal mRNA extracted from isolated hippocampi of GIN animals. The arrays 
used were home-spotted with the FANTOM 2 collection of mouse transcripts (Okazaki, 
Furuno et al. 2002); (FANTOM international Consortium). We chose ~14 000 well 
characterized and non-redundant transcripts from ~60 000 transcripts in the collection.  Genes 
Fig.2: STATISTICAL ANALYSIS OF DIFFERENTIALLY EXPRESSED PROBES. Three distinct 
microarray hybridizations were done on EGFP+ Interneurons, Pyramidal Cells and total 
Hippocampus. Each sample was hybridized against a reference RNA. Statistical analysis identified 
transcripts differentially expressed between the single sample and the reference RNA. In the circles 
are reported the numbers of transcripts passing the statistical analysis for sample type. In the 
intersected areas the number of transcripts shared between the different analyses. 
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were represented in triplicate and the whole collection was printed on two slides which were 
both hybridized in each experiment. Hybridizations were repeated three times for each cell 
population, and were always hybridized against a standard universal mouse reference RNA 
sample.  
 
Differentially expressed genes. 
 
Fig.2 shows the number of transcripts in EGFP-positive interneurons, identified pyramidal 
cells and total hippocampal tissue that were differentially expressed with respect to reference 
RNA. After application of threshold procedures described in the methods, we detected 1956 
transcripts expressed by interneurons, 1831 by pyramidal cells, and 1379 transcripts by the 
total hippocampal tissue. As shown in Fig. 2, some of these transcripts were common to the 
different groups. For example, 1175 probes, differentially expressed with respect to reference 
RNA, were common to both EGFP+ cells and pyramidal cells.  
We next attempted to separate genes that were expressed differently by EGFP-positive 
interneurons and pyramidal cells. Data from the two populations were reanalysed using a 
Bayesian algorithm to identify statistically significant differences. After filtering according to 
p-values and Log-fold changes (see methods) we detected 443 genes that were differently 
expressed in these two cell groups. In the heatmap shown in Fig.3, where slots are coloured 
according to expression levels with respect to the reference for each experiment, two major 
clusters were detected corresponding to the different cell types.  It shows 260 transcripts were 
more represented in EGFP positive interneurons, and 183 had higher expression levels in 
pyramidal cells.  
 
 
Fig.3, next page: HEATMAP OF GENES DIFFERENTIALLY EXPRESSED BETWEEN SOM-
CONTAINING INTERNEURONS AND PYRAMIDAL CELLS. Each slot represents the differential 
expression of the gene in the row as Fold Change in logarithmic scale between the cell type/tissue in 
the column and the Reference. The gradient goes from green to red. Two main clusters of genes were 
identified: those overrepresented in the interneuronal population (260) and those overrepresented in 
the pyramidal cells (183) 
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Association of differentially expressed genes with Gene Ontology terms.  
 
We examined associations of differentially expressed genes with cellular component, 
molecular function and biological process terms of the Gene Ontology database. 400 of 443 
transcripts were present in the database for mice. 328 of them were clustered for association 
with one or more terms after application of a threshold p-value, ≤ 0.05, provided by the 
clustering analysis (http://david.abcc.ncifcrf.gov/; (Dennis, Sherman et al. 2003) .  
More than half of the differentially expressed genes were associated with cytoplasmic 
compartment and intracellular region from the cellular component terms.  
Of molecular function terms, more than 10% of differentially expressed genes (52 transcripts) 
were associated with nucleotide binding.  
The most differentially expressed was the gene Rab3b, a member of the Rab family, more 
highly expressed in interneurons with a log-fold change of 3.1. Rabs are GTP-binding 
proteins involved in regulating membrane traffic (Darchen and Goud 2000; Deneka, Neeft et 
al. 2003) and Rab3b is one of four Rab proteins implicated in exocytosis (Touchot, Chardin et 
al. 1987; Matsui, Kikuchi et al. 1988; Zahraoui, Touchot et al. 1989).  
Pyramidal cells showed a higher representation of the Transient receptor potential cation 
channel, subfamily C, member 4 associated protein (Trpc4ap) from the molecular component 
terms. This gene is expressed in the brain (Soond, Terry et al. 2003) and recent data suggests 
polymorphisms exist which may be associated with a susceptibility to Alzheimer’s Disease 
(Poduslo, Huang et al. 2008). 
 
Among the biological process terms, multiple differentially expressed genes were associated 
wih transport activity and signal transduction. Of 57 genes related to these functions, 36 were 
more highly expressed in interneurons and 21 more expressed in the pyramidal cells. These 
genes included a differential expression of GABAA receptor subunits with α4, δ and γ2 
(Gabra4, Gabrd and Gabrg2) more highly expressed in interneurons and the θ subunit 
(Gabraq) more expressed in pyramidal cells.  
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Among the genes that may be involved directly in the determination of the distinct 
phenotypes of interneurons and pyramidal cells, we also detected differences in the 
expression of transcription factors (TF).  Thus differentially expressed TFs may form a 
“fingerprint” to recognize and classify cell types. From biological process terms 
corresponding to differentially expressed genes, a subset of 37 genes was associated with 
Regulation of gene expression.  As shown in the heatmap of Fig. 5, 13 of them were more 
highly expressed in pyramidal cells and 24 were more highly represented in the subset of 
EPFP-positive GABAergic neurons.  
Fig.4 : Differential expression in all hybridizations of genes associated with molecular function: 
nucleotide binding. Rab3b was more highly expressed by EGFP+ interneurons than by pyramidal 
cells according to fold-changes between the different cell types and Standard RNA in all 
hybridizations. In contrast Trpc4ap is more highly expressed by pyramidal cells.  
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Fig.5: HEATMAP OF DIFFERENTIALLY EXPRESSED GENES ASSSOCIATED WITH 
REGULATION OF GENE EXPRESSION. Each slot represents the differential expression of the 
gene in the row as Fold Change in logarithmic scale between the cell type/tissue in the column 
and the Reference. The genes in the red box are more highly expressed in pyramidal cells, and 
those in the green box are more highly represented in SOM containing interneurons. 
 69 
Discussion 
 
We have analyzed differences in gene expression by CA1 pyramidal cells and a subset of 
hippocampal interneurons labelled with green fluorescent protein in the GIN mice (Oliva, 
Jiang et al. 2000). These cells seem to correspond to a subpopulation of interneurons that 
express somatostatin (SOM).  The somata of cells that we analysed were located in the 
stratum oriens of the CA1 region and it seems likely that they correspond to the O-LM group 
of interneurons whose axon projects to the stratum lacunosum-moleculare.  Using gene arrays 
based on the FANTOM collection, we detected differential expression of 443 mRNA 
transcripts, with 260 species more represented in EGFP-positive interneurons, and 183 more 
highly expressed in pyramidal cells. 
  
Technical issues.   
 
The combination of fluorescence activated cell sorting and microarray analysis has been used to 
determine differential gene expression in neurons (Arlotta, Molyneaux et al. 2005; Marsh, 
Minarcik et al. 2008). We found that resuspension of dissociated cells in RNAlater medium to 
preserve genetic material caused a significant cell shrinkage which seriously reduced fluorescent 
signals. Fluorescent cell sorting was achieved in extracellular solution with no added RNAlater. 
It permitted the separation of a population of green fluorescent cells (FL1-H reading > 101,2).  
Our yields were ~5000 fluorescent cells per hippocampus.  However after collection cells were 
suspended in a solution of 50 ml, too large for mRNA preparation.  We therefore turned to laser 
capture techniques to dissect EGFP positive cells from hippocampal slices (Lefebvre 
d'Hellencourt and Harry 2005; Yao, Yu et al. 2005; Sugino, Hempel et al. 2006). Pyramidal cells 
were collected in a similar way after staining tissue with a rapid variant of the cresyl violet Nissl 
stain to identify the location of pyramidal cell somata. Tissue fixation, cell harvest and RNA 
purification have been previously optimized for LCM-based gene expression profiling (C. 
Vlachouli; PhD thesis in preparation).  
Microarray experiments were performed by hybridizing RNA from the two cell populations as 
well as from total hippocampus against a standard reference RNA.  This permitted identification 
of differences in transcript expression in the two cell types.  The differences in gene expression 
should be confirmed with single cell or Real Time PCR data.  Immuno-histochemistry with 
antibodies raised against specific gene products of mRNA species showing distinct expression 
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patterns in pyramidal cells and O-LM interneurons may identify additional specific markers 
for these interneurons.  
 
Contribution to the molecular basis for the distinct phenotype of O-LM interneurons.  
 
Our data may contribute to the problem of the classification of GABAergic interneurons 
(Maccaferri and Lacaille 2003). They provide a gene profile for a well-characterized class of 
hippocampal interneuron and reveal several interesting differences in gene expression between 
these cells and pyramidal neurons of the same region. We should note that our data was 
obtained from ~300 cells of either type lumped together so masking possible variability in genes 
expressed by cells of the same group. A similar approach has been used to characterize 
parvalbumin positive (Meyer, Katona et al. 2002) and parvalbumin and calbindin-positive 
GABAergic cells (Blatow, Rozov et al. 2003). 
The O-LM group of interneurons has a distinct somatic site, axonal arborisation pattern and 
dendritic morphology from CA1 pyramidal cells. O-LM cell expression of Ca-binding proteins 
may be diverse (Parra, Gulyas et al. 1998), but they consistently express the peptide 
somatostatin (Oliva, Jiang et al. 2000) and type I metabotropic glutamate receptors (van Hooft et 
al, 2000).  Firing behaviour and the properties of afferent excitatory synapses differ between O-
LM interneurons and CA1 pyramidal cells (Ali and Thomson 1998).  These differences in 
phenotype presumably derive in part from differential gene expression between the two cell 
types.  Our data revealed that large numbers of genes were differentially expressed, although 
they did not include those coding for Ca-binding proteins, neuropeptides or mGluRs. In fact we 
could not provide data for well known differentially expressed genes described for these cells 
(Oliva, Jiang et al. 2000) like Somatostatin or mGluR1 because they are not present in our 
transcripts database. Instead we detected differences in genes associated with biological process, 
cellular component or molecular function terms from the Gene Ontology classification.   
As expected, many differentially expressed genes were associated with the cytoplasmic 
compartment of the cellular component division of the Gene Ontology. In terms of molecular 
function, genes associated with nucleotide binding were more strongly expressed in the 
EGFP-psotive intereneurons.  They included the gene coding for Rab3b (higher than 8 times 
difference in expression) which has been implicated in vesicular exocytosis (Touchot, 
Chardin et al. 1987; Matsui, Kikuchi et al. 1988; Zahraoui, Touchot et al. 1989). In contrast 
pyramidal cells showed a higher expression of Trpc4ap (Soond, Terry et al. 2003). 
Differentially expressed genes associated with terms from the biological process division of 
the Gene Ontology numbered 57, and included those related to transport activity and signal 
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transduction. Three GABAA receptor subunits α4, δ and γ2 (Gabra4, Gabrd and Gabrg2) were 
more highly expressed by interneurons and the θ subunit (Gabraq) was more expressed in 
pyramidal cells. The gene coding for the pre-synaptic protein Synaptotagmin I was expressed 
at higher levels in EGFP-positive interneurons than in CA1 pyramidal cells.   
Interestingly we detected differences in 37 genes associated with Regulation of gene 
expression with 13 transcripts more highly expressed in CA1 pyramidal cells and 24 detected 
at higher levels in O-LM interneurons. The expression of distinct combinations of such genes, 
including transcription factors, may define specific classes of interneurons by controlling the 
expression of cytoplasmic and membrane proteins that distinguish their phenotype from that 
of pyramidal cells (Toledo-Rodriguez, Blumenfeld et al. 2004; Toledo-Rodriguez, Goodman 
et al. 2005).  
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• Gene expression changes associated with the emergence 
of epileptiform activity after injection of kainic acid into the 
mouse hippocampus. 
 
 
 
 
 
 
Gene expression changes associated with the emergence of 
epileptiform activity after injection of kainic acid into the mouse 
hippocampus.  
 
 
In preparation. 
 
 
Dario Motti, Caroline Le Duigou, Emmanuel Eugène, Nicole Chemaly, Lucia 
Wittner, Dejan Lazarevic, Helena Krmac, Remo Sanges, Elia Stupka, Enrico 
Cherubini, Stefano Gustincich and Richard Miles. 
 
 
 
 
 
 
 
 
 
 
 
 73 
Introduction 
 
Disease processes involve changes in expression and function of many proteins that may 
contribute to the pathology as well as to participate in adaptive responses.  Gene profiling 
techniques assays permit simultaneous measurements of changes in the expression of 
thousands of genes.  Importantly, gene expression studies using micro-arrays have helped 
identifying molecular defects associated with human diseases including cancer, asthma and 
neurodegeneration (Karp, Grupe et al. 2000; Lock, Hermans et al. 2002; van 't Veer, Dai et al. 
2002). 
Gene profile studies on the epilepsies have been facilitated by the availability of living brain 
tissue after surgery on patients with pharmacoresistant syndromes. Following these studies, 
human temporal lobe epilepsies have been associated with changes in the immune and 
complement systems (Jamali, Bartolomei et al. 2006; Aronica, Boer et al. 2007) as well as 
with altered glial function (Ozbas-Gerceker, Redeker et al. 2006).  While such micro-array 
data from human tissue is valuable, there are some difficulties in its interpretation.  First, 
adequate control tissue is hard to obtain.  Second, changes in gene expression may differ 
between sclerotic regions, sites of neuronal cell death and glial activation, and the regions that 
generate aberrant population activities (Arion, Sabatini et al. 2006; Jamali, Bartolomei et al. 
2006).   Third, at the time of their surgery, patients may have experienced seizures over 10-20 
years.  Therefore, adaptive changes may have occured in response to both pathological 
changes underlying the epilepsy and prolonged treatments with anti-epileptic drugs (Tang, 
Glauser et al. 2004; Aronica, Boer et al. 2007).   
Animal models of the epilepsies may provide solutions to some of these problems. Kindling is 
a widely used animal model that closely mimics temporal lobe epilepsies (Goddard 1967; 
Gorter, van Vliet et al. 2006), In these experimental settings, repetitive stimulation of the 
hippocampus or the amygdale initiates spontaneous seizures over days or weeks. Temporal 
lobe epilepsies can be also mimicked by the application of convulsants such as pilocarpine or 
kainic acid (Ben-Ari, Lagowska et al. 1979; Becker, Chen et al. 2003).  These convulsants 
initiate a prolonged status epilepticus, with a cell death pattern that is similar to human 
hippocampal sclerosis. Interestingly, spontaneous, recurrent seizures emerge after a period of 
several weeks. In both animal models control tissue is readily available.  Regions of sclerosis 
and those generating epileptiform activity can be identified and analyzed separately, if 
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needed. Furthermore, gene expression changes can be followed during the evolution of the 
disease.   
Animal models might also offer insights into the nature of the stimuli responsible for the 
emergence of an epileptic brain. Between convulsant injection and the emergence of 
spontaneous recurrent seizures, the hippocampus engages in a prolonged epileptic activity 
(Pitkanen, Nissinen et al. 2002; Williams, Hellier et al. 2007), During this period some 
neurones die (Sater and Nadler 1988; Magloczky and Freund 1993), expression and 
distribution of cell surface receptors and channels change (Misonou, Mohapatra et al. 2004; 
Shah, Anderson et al. 2004; Epsztein, Represa et al. 2005), different cohorts of glial cells are 
activated (Vezzani and Granata 2005; Wetherington, Serrano et al. 2008), immune and 
inflammatory responses are triggered (Andersson, Perry et al. 1991; Vezzani and Granata 
2005) and novel aberrant synaptic circuits are formed (Sutula, He et al. 1988; Patrylo and 
Dudek 1998).  How these events are related and how they are associated with the emergence 
of seizures is only partially clear.    
In an attempt to clarify some of these questions we used gene profile technology, in 
association with EEG recordings and anatomy, to examine the progression towards recurrent 
seizures in mice treated with kainic acid (KA).  Experiments were performed at three different 
time points corresponding to three different phases of progression of the model: 6 hours after 
injection (corresponding to the initial status epilepticus), 15 days after injection 
(corresponding to the latent phase) and 6 months after the injection (corresponding to the 
establishment of a recurrent epileptic activity). 
In our experimental settings, KA was injected into one hippocampus (Bouilleret, Ridoux et al. 
1999; Le Duigou, Wittner et al. 2005). In a former work we showed differential involvement 
of the ventral and dorsal part of both the injected and the contralateral hippocampus in the 
electric activity (Le Duigou, Wittner et al. 2005). Therefore experiments were performed 
separately in the injected area (Ipsilateral Dorsal area), in the ventral part of the same 
hippocampus (Ipsilateral Ventral area) and in the dorsal (Contralateral Dorsal area) and 
ventral area (Contralateral Ventral area) of the hippocampus contralateral to the injected one. 
As we shall show, focal intracranial KA application may allow separation of several stimuli 
that may be involved in the emergence of an epileptic brain.   
Both the injected and the contralateral hippocampi participate in a status epilepticus which 
lasts for several hours after KA injection. In contrast, cell death occurs exclusively in the 
injected hippocampus and is most evident near the injection site in the dorsal hippocampus.  
Axonal degeneration and the consequent de-afferentation is strongest near the site of KA 
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injection but also occurs in the ventral injected hippocampus and at mirror sites in the 
contralateral non-injected hippocampus.  We therefore compared changes in gene expression 
in the dorsal and ventral injected hippocampus and in the dorsal and ventral contralateral 
hippocampus.  The cell specificity and regional distribution of selected genes was further 
examined with immuno-histochemical techniques.   
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Materials and Methods 
 
Intrahippocampal KA injection  
 
Experiments were performed on adult C57BL/6J male mice (Janvier, Le Genest Saint Isle, 
France), weighing 30-35g and housed in a 12 hours light-dark controlled cycle. All 
experiments were performed in accordance with the European Committee Council Directive 
of November 24, 1986 (86/89/EEC) and with INSERM guidelines.  Male mice aged 2-3 
months were anaesthetized with 4% chloral hydrate (120 ml/kg; Sigma, St Louis, MO, USA) 
and 4% urethane (1000 ml/kg; Sigma, St Louis, MO, USA,) and placed in a stereotaxic frame. 
Injections were made by a stainless steel cannula of outside tip diameter 0.28 mm connected 
to a 500 nl microsyringe (Hamilton, Fisher Labosi, France). A volume of 50 nl kainic acid 
(Sigma, St Louis, MO, USA) dissolved at 20 mM in 0.9% NaCl was injected into the right 
dorsal hippocampus (Bouilleret, Ridoux et al. 1999). Control animals were prepared 
identically and injected with the same volume of 0.9% NaCl solution.  Injections were made 
at the stereotaxic coordinates: anterior-posterior = -1.8 mm, medial-lateral = - 1.8 mm, dorsal-
ventral = - 1.8 mm with respect to the bregma. These coordinates correspond to an apical 
dendritic site in the CA1 region of dorsal hippocampus. After recovery from anaesthesia, 
animals displayed behavioural signs of status epilepticus, specifically maintained turning 
movements.  
 
EEG recordings 
 
EEG records were made using nickel/chrome wire electrodes of external diameter 200 µm.  
Bipolar records were made using two wires twisted together from (1) a site near the position 
of kainate injection in the right, dorsal hippocampus, (2) the equivalent site in the 
contralateral hippocampus, (3) a ventral site in the injected right hippocampus and (4) a 
mirror ventral site in the non-injected contralateral hippocampus.  AP = - 3,28 mm, L = +/- 3 
mm, P = - 2.8 mm.  Monopolar records were made bilaterally from the parieto-occipital 
cortex. A monopolar reference electrode was implanted in the cerebellum and a neutral 
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electrode above the olfactory cortex.  EEG electrode connectors were fixed to the skull with 
dental cement.  Animals were housed singly after implanting EEG electrodes. EEG signals 
were recorded during sessions of duration 3-4 hrs typically in the afternoon during the period 
from 1 day to 6 months after KA-injection.  EEG signals were amplified with a 24-channel 
system (Medelec, Oxford Instruments, Abingdon UK) and acquired to a computer at 1024 Hz 
and 22-bit resolution.  Signals were filtered between 0.5 and 500 Hz. Recordings were made 
by Caroline Le Duigou and Nicole Chemaly at the INSERM U739 lab in Paris, France. 
 
Morphology 
 
Cell death and fibre degeneration was studied using Nissl Staining and the Fink-Heimer silver 
impregnation technique (Fink and Heimer 1967). For Fink-Heimer impregnation animals 
were perfused intracardially with cold ACSF followed by 100 ml of fixative containing 4% 
paraformaldehyde and 15% saturated picric acid dissolved in 0.1M phosphate buffer (PB). 
The brains were removed and 100 µm thick sections were cut with a Vibratome and washed 
in PB. After impregnation, sections were washed in PB, mounted on gelatine coated slides 
and covered with DePeX (Laboratoire DBH, France). As well as cell bodies, degenerating 
axons and synaptic terminals are coloured black by this silver-staining technique. Fink-
Heimer staining experiments were conducted by Lucia Wittner. 
 
Preparation of tissue for RNA extraction 
 
After decapitation both hippocampi, the injected ipsilateral and the contralateral one, were 
dissected in cold PBS 1X in DEPC-treated (Sigma, St Louis, MO, USA) H2O under RNAse 
free conditions.  Each hippocampus was divided into a ventral and a dorsal part which were 
placed in an Eppendorf containing 1 ml of TRIzol (Invitrogen, Carlsbad, CA, USA), frozen 
and packed in dry ice and then sent to Trieste, Italy, where samples were stored at -80°C 
before former treatments. In the end for each mouse we obtained four areas: ipsilateral dorsal 
(ID, close to where kainate was injected), ipsilateral ventral (IV), contralateral dorsal (CD) 
and contralateral ventral (CV) 
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RNA extraction and probe synthesis 
 
Total RNA was isolated according to the TRIzol Reagent Protocol provided by the 
manufacturer. To avoid genomic contamination samples have been treated with 2 units of 
RNAse free DNAse (2 units/µl; Ambion, Austin, TX USA) for 15 min at 37°. Total RNA was 
further purified with RNeasy Mini Kit (Qiagen, Chatsworth, CA, USA). RNA quality was 
assessed using an Agilent 2001 Bioanalyzer (Agilent, Palo Alto, CA, USA), samples with an 
R.I.N. index (RNA Integrity Number) higher than 8 were considered good and used for 
following hybridizations. Samples were then quantified with a ND-1000 spectrophotometer 
(Nanodrop technologies, Wilmington, DE, USA). 500 ng of Total RNA from each sample 
were used as a template to generate biotinylated cRNA following the protocol from Illumina 
Total Prep Amplification Kit (Agilent, Palo Alto, CA, USA).  
 
Hybridization and scanning  
 
Sample labelling, hybridization to arrays and image scanning were carried out as described in 
the Affymetrix Expression Analysis Technical Manual. cRNA was hybridized to Affymetrix 
murine 430A 2.0 gene chips which analyze the expression level of approximately 14,000 
well-characterized mouse genes. Chips were scanned with a laser Agilent 3000 Scanner. 
Image analysis was performed with GeneChip® Operating Software. WT samples for dorsal 
and ventral hippocampus were hybridized in double. For each time points 2 samples for each 
area from Kainate injected mice were hybridized, together with one sample per area from 
NaCl injected mice.  
 
Analysis of expression profile data  
 
Expression levels were calculated with the Bioconductor (Gautier L 2004) collection of 
packages in the R programming environment for statistical computing. They were calculated 
using the RMA function (Irizarry, Hobbs et al. 2003) in the ‘Affy’ package with default 
parameters which make use of the quantile normalization. To extract changes in gene 
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expression each single time point was compared to the wild type sample and to the NaCl-
injected control of the same area. Genes were considered as “changing” if both values of 
expression in the kainate treated samples were outside the range covered by the expression 
levels of the two wild type samples and the NaCl controls for the very same time point and 
area. “Changing” genes were then filtered by Fold Change (in logarithmic scale): in order to 
be included in downstream analysis a gene should have fold change (Kainate injected vs. WT 
AND Kainate injected vs. NaCl)  ≤ log2 (-1) or fold change ≥ log2 (1) (which is a fold change 
of ± 2 on a linear scale). Exceptions were included if fold change in respect to Wild Type or 
NaCl was ≤ -0.98 or ≥ 0.98 with the Fold Change in respect to the other value (either NaCl or 
WT) was ≤ -1.2 or ≥ 1.2 accordingly with the former one.  
When more than one probe for a single gene was found differentially regulated in one 
area/time point, only the highest Fold Change was taken in consideration. We never find 
probes screening for the same gene moving in opposite direction during the analysis (for 
instance one probe upregulated and another downregulated).  
Gene Ontology profiles were performed with GenMAPP 2.0 (http://www.genmapp.org) 
analysis software. The lists of selected genes for each area and time point were submitted 
together with the list of all the probes contained in our reference Chip: the murine 430 A 2.0 
as a background. Ontology terms were considered only if Z-Score was higher than 1.96 
(corresponding to a p-value ≤0.05).  
 
Real Time Experiments 
 
To validate some of the changes that were detected with Affymetrix Chips, real-time 
quantitative PCR analysis was performed using RNA obtained from injected mice at 6 hours 
after the injection extracted and treated in the same way as those used in the array 
experiments. For each gene that was chosen Forward and Reverse Primers were designed with 
the Beacon Designer™ 6.0 (PREMIER Biosoft International, Palo Alto, CA, USA). To design 
the primers, the transcripts’ sequences extracted from Ensembl (www.ensembl.org) were 
submitted to the program together with the following criteria: avoiding cross homology, 
primer length between 18 and 25 bp, product length between 75 and 200 bp and Tm between 
58°C and 62°C. The transcripts’ sequences were also processed with Mfold v3.2 (Zucker M., 
Nucleic Acids Res., 2005) to evaluate the secondary structure of the transcripts, to avoid 
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primers to anneal to unreachable positions. The analysis was performed with the default 
criteria except for: annealing reaction 60°C, Na+ concentration 50 mM and Mg++ 
concentration 5 mM. The genes selected and the relative primers are: Isl1 (Forward Primer: 
5’-ATTGTCCAACCACCATTTCACTG-3’, Reverse Primer: 5’-
GATTACACTCCGCACATTTCAAAC-3’), Lcn2 (Forward Primer: 5’-
ACGACAACATCATCTTCTC-3’, Reverse Primer: 5’-ATGCTCCTTGGTATGGTG-3’), 
Trpm7 (Forward Primer: 5’-CTTGGAACAGGCTATGCTTGATG-3’, Reverse Primer: 5’-
TGAGATGGAACAACATTGGATTGG-3’), P2ry12 (Forward Primer: 5’- 
ATTCACAGAAGAACACTCAAGG-3’, Reverse Primer: 5’-TTGACACCAGGCACATCC-
3’), Hspa1b (Forward Primer: 5’-TTCGTGGAGGAGTTCAAG-3’, Reverse Primer: 5’-
GTGATGGATGTGTAGAAGTC-3’), Hes5 (Forward Reverse: 5’-
GAGATGCTCAGTCCCAAG-3’, Reverse Primer: 5’- AAGGCTTTGCTGTGTTTC-3’), 
Gad2 (Forward Primer: 5’-GGCTCTGGCGATGGAATC-3’, Reverse Primer: 5’-
GACTATGCTCTGATGTGAACG-3’). As housekeeping genes we tested with Real Time 
PCR the levels of transcription of Actb (Forward Primer: 5’-
TGGGTATGGAATCCTGTGGCATC-3’, Reverse Primer: 5’-
GTGTTGGCATAGAGGTCTTTACGG-3’) and Gapdh (Forward Primer: 5’-
AGAAGGTGGTGAAGCAGGCATC-3’, Reverse Primer: 5’-
CGAAGGTGGAAGAGTGGGAGTTG-3’). All of the samples were run in duplicate. Real 
Time Experiments were performed on tissues from three distinct injected mice. All RNAs 
were diluted at the lowest concentration and 1 µg of it was used for the reaction of Reverse 
Transcription, together with 4 µl of 5x iScript Select reaction mix and 1µl of iScript reverse 
transcriptase from the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, 
USA). The final volume was adjusted with Nuclease Free H2O to 20 µl. The mix was kept for 
5’ at 25°C to allow primer annealing. Reverse Transcription was performed at 42°C for 50’, 
followed by 5’ at 80°C to inhibit the enzyme. 250 ng of cDNA per sample were mixed with 
10 µl of 2X iQ Supermix (Bio-Rad Laboratories, Hercules, CA, USA), and specific primers to 
a final concentration of 250 nM in 20 µl of final volume (reached with Nuclease Free H2O) to 
perform the Real Time PCR experiments. Time monitoring of PCRs was performed using the 
iQ5 Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). The 
mixture was incubated for 30’ at 43°C, for Reverse Transcription, then heated to 95°C for 
3’for initial denaturation. Following PCR reaction included the following cycling conditions: 
41 cycles of denaturation at 95°C for 20sec, annealing at 60°C for 20sec and extension at 
72°C for 30sec. Fluorescence was measured by a triple acquisition mode at 72°C after each 
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cycle. Primer dimers’ presence and specific/non-specific products ratio were detected by 
measuring a melting curve after the amplification by holding the temperature at 55°C for 1’ 
followed by a gradual increase in temperature to 95°C at a rate of 0.05°C/s. Analysis of data 
was performed using the iQ5 Optical System Software v2.0.  
 
Immunofluorescence 
 
To evaluate whether changes in gene expression correspond to changes in protein expression 
we performed immunofluorescence analysis on Vimentin and GFAP, genes we identified as 
differentially regulated during the latent phase of progression of the pathology and that are 
related to proliferation of astroglial cells. Kainate-injected mice and NaCl-injected control 
mice where perfused transcardially with 50 ml of PFA 4% in 1X PBS. Brains where extracted 
and put in PFA 4% for one hour of post fixation, then washed 3 times in 1X PBS, 15’ 
minimum per wash, and incubated in 30% in 1X PBS Sucrose solution overnight. After 
overnight incubation at 4°C the brains where frozen in dry ice and sectioned at a cryostat: 50 
µm horizontal sections were collected in Prolong Gold Antifade Reagents (Invitrogen, 
Carlsbad, CA, USA). To avoid non specific binding sections were incubated in TBS plus 
0.5% Triton X100 (Roche Diagnostics, France) for 1 hour at room temperature. Sections were 
incubated with primary antibody overnight at 4°C. All antibodies where diluted 1:1000 in 
TBS+. After incubation with the primary antibody sections were washed three times for 1 
hour per wash with 0.1M PB at room temperature and incubated with Cy2-conjugated anti-
chicken, Cy3-conjugated anti-rabbit and Cy5-conjugated anti-mouse secondary antibody 
(Jackson Immuno Research, West Grove, PA; diluted 1:1000 in TBS+) for 4 hours at room 
temperature. Antibody against Vimentin (anti-Vim; polyclonal chicken; Abcam, Cambridge, 
UK), Glial Fibrillary Acidic Protein were used (anti-Gfap; monoclonal rabbit; Promega, 
Madison, WI, USA) and NeuN (anti-NeuN; Chemicon, Temecula, CA, USA) 
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Results 
 
Experimental Settings 
 
Adult C57BL/6J mice, aged 2-3 months were anaesthetized and placed in a stereotaxic frame. 
Then 50 nl of KA or 0.9% NaCl was injected into the right dorsal hippocampus, the apical 
dendritic site in the CA1 region of dorsal hippocampus (for coordinates see Materials and 
Methods) (Bouilleret, Ridoux et al. 1999). After recovery from anaesthesia, animals displayed 
behavioural signs of status epilepticus, specifically maintained turning movements. Mice were 
then sacrificed at different time points and in different ways due to the specific experiment. A 
total of 80 mice were injected, 31 died during or immediately after surgery. 
 
Analysis of EEG recordings. 
 
To evaluate short-term electric activity, EEG recordings were made from dorsal and ventral 
sites in both injected and non-injected hippocampus for 24 hrs after KA injection.  A distinct 
large, slow EEG activity emerged first close to the injection site at 2-3 hrs after KA-injection.  
This activity grew in size and complexity with time and spread throughout both hippocampi 
(see Fig.1).  Propagation occurred from dorsal to ventral regions of the injected hippocampus, 
then to ventral and dorsal regions of contralateral non-injected hippocampus.  At 5 hrs after 
the injection all regions of both hippocampi participated in a status epilepticus which 
persisted for up to 24 hrs after injection.  
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In long term recordings made 3 to 4 days after KA injection, no epileptiform activity was 
detected. Simple bilateral spike and wave activities emerged over the next two weeks. More 
complex sequences of recurring, bilateral epileptiform activities were observed at 3-4 weeks.  
Electrographic tonic-clonic seizures with few clear behavioural correlates were detected in 
records made from this time-point up to 10 months after KA-injection. The seizure initiation 
usually seemed to be localised to the KA-injected hippocampus but in some cases seizures 
appeared to emerge from the non-injected hemisphere (Fig. 2). 
These data show that both dorsal and ventral portions of both ipsilateral injected and 
contralateral non-injected hippocampus participated in the status epilepticus provoked by KA-
injection. They suggest that further epileptiform activity was absent until 2-3 weeks later 
when spike and wave discharges and occasional tonic-clonic seizures were established. 
 
 
Fig.1: EEG RECORDINGS AT EARLY STAGES.  In panel A EEG recordings taken from the 
injection site (I-D), the ventral part of the same hippocampus (I-V) and the dorsal and ventral area 
of the contralateral hippocampus show propagation of the electrical  activity starting from I-V 
through to all of the evaluated areas following a scheme represented in panel B. At 5 hours after the 
injection all of the areas participate to the status epilepticus. 
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Analysis of cell death 
 
Previous work on KA-injected animals suggests that a significant pyramidal cell death occurs 
in the CA1, CA3 and hilar regions (Le Duigou, Wittner et al. 2005).  We performed Nissl 
staining which confirmed a severe cell loss around the injection site in dorsal hippocampus at 
4 weeks.  There was a lesser cell loss at the ventral injected hippocampus but no cell death 
could be detected in dorsal or ventral regions of contralateral hippocampus.  Cell loss were 
revealed by the disappearance of cell bodies in the hilar region and the thickening of the 
pyramidal layer in tha CA1 region. 
Then we performed Fink-Heimer staining, a procedure that shows both dead cells and 
degenerating fibres. To this purpose we examined hippocampi from three different KA-
Fig.2: EEG RECORDINGS DURING LATENT AND CHRONIC PHASE. In panel A recordings 
from the four different areas from a few days to 3 to 4 weeks after the injection show no epileptic 
activity. Bilateral spikes may be observed that are highlighted in the boxes. In panel B are shown 
recordings from hippocampi of mice 6 months after the injection. Bilateral epileptic activity is 
observed starting from both the injected and the contralateral hippocampus. 
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injected animals at 6-8 days after injection when fibre degeneration should be maximal. Mice 
were anesthetized and perfused with ACSF. Brains were then extracted and cut in slices 100 
µm thick that were than processed for Fink-Heimer impregnation. Both cell death and fibre 
degeneration were estimated semi-quantitatively from the dentate gyrus, CA1, CA3 and 
subiculum of sections prepared from the middle regions of dorsal and ventral injected 
hippocampus and from dorsal and ventral non-injected hippocampus. 
At 6-8 days after injection we detected a profound cell loss in dorsal injected hippocampus 
and a less extensive cell loss in ventral regions of this hippocampus.  Cell death was largest in 
the CA1 and CA3 regions while some black-staining somata were evident in the dentate gyrus 
and in the subiculum.  In the non-injected hippocampus, less than 0.1% black-staining cell 
bodies were detected. In contrast, fibre degeneration was apparent in both somatic and 
dendritic regions of both dorsal and ventral sites from the contralateral hippocampus.  The 
extent of degeneration was similar in the dentate gyrus, subiculum and in the CA1 and CA3 
regions.  Contralateral fibre degeneration was less than that detected in the ipsilateral KA-
injected hippocampus where diffuse Fink-Heimer staining of fibre-like elements was most 
strong in dorsal CA1 and in subicular regions close to the injection site.   
These data suggest that cell death is limited to the injected hippocampus and is most severe 
near the dorsal injection site.  At 6-8 days after injection, fibre degeneration is not limited to 
those sites but is also evident in dorsal and to a lesser extent ventral hippocampus.  This 
degeneration is presumably correlated with a partial de-afferentation of contralateral cells.   
In summary, these data show that epileptiform activity, both interictal-like and ictal-like 
events induced by tetanic stimulation, is not limited to the KA-injected hippocampus. All 
regions participated in the initial status epilepticus.  Cell death was maximal in dorsal, evident 
in ventral injected hippocampus, but absent from both dorsal and ventral contralateral 
hippocampus.  Fibre degeneration, and presumably partial de-afferentation, was maximal in 
dorsal and ventral injected hippocampus but was also detected in dorsal and to a lesser extent 
ventral contralateral hippocampus.  These data allowed some comparative procedures to 
examine the relative influence of status epilepticus, cell death and de-afferentation on gene 
expression changes leading eventually to the establishment of an epileptic hippocampus.   
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Fig.3: FINK-HEIMER STAINING. In panel A pictures taken from Dentate Girus (DG) and CA1 
regions (CA1) of dorsal and ventral areas of both hippocampi in mice 6 to 8 days after injection with 
dead cells stained with Fink-Heimer silver impregnation technique. We observe an accumumalation of 
dead cells in stratum granulosum of DG and stratum pyramidale of CA1 in the area close to the site of 
injection (Ipsi dorsal) and to a less extent in a more distal site of the same hippocampus (Ipsi ventral). 
No sign of dead cells is present in the contralaterl hippocampus. 
In panel B a graphical representation of the level of cell and axon degeneration in the four areas and 
different sites (Subiculum, CA1, CA3 and Dentate Gyrus) 6 to 8 days after kainate injection measured 
after Fink-Heimer staining. 
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Analysis of gene expression profile: experimental protocol. 
 
We examined changes in gene expression using the Affymetrix murine 430A 2.0 gene chips 
which analyzes the expression level of approximately 14,000 well-characterized mouse genes. 
Mice were injected as described before. Two KA-injected and one NaCl-injected were 
sacrificed at three different time point after the injection: 6 hours, 15 days and 6 months. 
Together with these, two WT mice were sacrificed with the same procedure. Hippocampi 
were dissected in nuclease-free condition. Both hippocampi were divided in two so changes 
could be compared in the dorsal ipsilateral hippocampus (the injection site) as well as the 
ventral ipsilateral hippocampus and the dorsal and ventral contralateral regions of the non-
injected hippocampus. Tissue samples included the dentate gyrus, areas CA1 and CA3 as well 
as the subiculum. 
Following treatment included RNA precipitation (following TRIzol protocol provided by the 
manufacturer) and purification (with the RNeasy Mini Kit from Qiagen, Chatsworth, CA, 
USA). RNA quality was assessed using an Agilent 2001 Bioanalyzer (Agilent, Palo Alto, CA, 
USA): only samples with an RNA Integrity Number (R.I.N.) higher then 8 were used to 
perform the analysis. 500 ng of Total RNA from each sample were used as a template to 
generate biotinylated cRNA following the protocol from Illumina Total Prep Amplification 
Kit (Agilent, Palo Alto, CA, USA). 
After overnight hybridization, Chips were scanned. Image files were then processed to obtain 
raw data as CEL files. These were then processed for normalization, and expression levels 
were calculated through Bioconductor (Gautier L 2004). 
From gene expression levels, two threshold procedures were used to define differentially 
expressed genes so that up- or down-regulated from kainate-treated animals differed from 
both wild-type animals and from animals injected with NaCl.  
 
Analysis of Gene expression profiles: summary of results   
 
Fig. 4 shows the tempo/spatial distribution of genes altered by kainate-treatment: not 
considering overlapping, a total of 1563 genes resulted differentially expressed in at least 1 
time and 1 space point (the complete list is in the Supplementary Table section).  
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In summary we found that: 
 
6 hours after injection: 
• Neglecting overlap, a total of 507 genes were changed.    
• Near the injection site in dorsal ipsilateral hippocampus, 157 genes were 
upregulated and 21 genes down-regulated.  
• The region with the largest number of changed genes was the contralateral non-
injected ventral hippocampus with 276 genes up-regulated and 16 genes down-
regulated.   
• Interestingly, the composition of these two groups of genes was rather different: 
150 of 178 genes changed (84%) in the dorsal ipsilateral hippocampus were 
Fig.4 : TEMPORAL AND SPATIAL DISTRIBUTION OF DIFFERENTIALLY EXPRESSED 
GENES AFTER KA INJECTION. In the graphs are reported the number of genes differentially 
regulated for each area at the three different time points. In each graphs on x-axe are reported the 
number of genes, on y the Fold Change in logarithmic scale. Below each graphs the number of Up- 
or Down-regulated genes are shown. 
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unchanged in contralateral ventral hippocampus and 90% of 276 genes changed in 
the contralateral ventral area were unchanged in the dorsal ipsilateral samples. 
• A smaller number of genes was changed in the dorsal contralateral (89 genes) and 
ventral ipsilateral areas (98 genes). They were mostly similar to genes changed 
close to the injection site, with a percentage of overlapping of 57% for the 
ipsilateral ventral and 43% for the contralateral ventral area. 
 
Therefore, we can conclude that at 6 hours after the injection a common pattern of 
expression was induced by kainate in dorsal and ventral ipsilateral as well as dorsal 
controlateral hippocampi. Surprisingly, a specific and large transcriptional response 
was present in the controlateral ventral hippocampus. 
 
15 days after injection: 
• This is the time point with the largest number of changed genes: 1218.  
• In the ipsilateral dorsal hippocampus 850 genes were up-regulated and 292 genes 
were down-regulated (a total of 1142 genes). 
• In the ventral ipsilateral hippocampus 417 genes changed their expression with 
95% of them common with the dorsal ipsilateral region.  
• In contralateral dorsal hippocampus the expression of 211 genes was changed 
with, again, 98% genes common to the expression at the site of injection. 
• In contralateral ventral hippocampus, changes occurred in the expression of 202 
genes, of which 26% differed from those changed in the dorsal ipsilateral 
hippocampus.  
 
We noticed a colocalization of changes in areas close to the site of injection, with 186 
genes in common to the ipsilateral dorsal, ipsilateral ventral and contralateral dorsal 
areas. Among these, only 32 (17%) were present in one or more of the areas at 6 
hours. A smaller overlapping has been reported with the contralateral ventral area, 
however the amount of specific genes is much less significant than at 6 hours with 47 
(23%) genes differentially expressed only in this area. Among them 21 (44% of the 
specific ones) were common to the controlateral ventral specific pattern at 6 hours. 
 
6 months after injection:  
• At this time point a total of 276 genes changed their expression.    
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• Nearly all the changed genes were located in the ipsilateral dorsal injected 
hippocampus (271 / 292 or 93%).  A relatively high proportion of these genes 
were down-regulated.   
• Six to eight genes were changed in each of the other regions.  In total, 10 of these 
genes differed from those altered in the dorsal ipsilateral region (4 in the IV, 4 in 
the CD and 2 in the CV).   
 
In conclusion 6 months after the injection of kainate almost all of the gene expression 
changes we identified were confined to the site of the injection, while the other areas 
account for a very small amount of changes and most of them overlap with changes in 
the ipsidorsal site. 
 
Comparison of the time course and spatial location of gene expression provided some insights 
into the structure of changes induced by kainate-treatment. With twelve different time/space 
points, 212 or 4096 different combinations of changed or unchanged expression were possible.  
We found that 134 different patterns of expression existed.  
Interestingly, more than half of these genes (n=911 of 1563; 58%) were changed only at a 
single site and at a single time point with the most evident groups being: 
- 545 genes were only changed at 15 days in ipsilateral dorsal hippocampus  
- 178 genes changed exclusively in contralateral ventral hippocampus at 6 hours.   
 
Several temporal and spatial patterns were evident in the 681 genes that were altered at 
multiple time points.  For these genes, maximal changes were detected at:  
- the ipsilateral dorsal injection site at 6hrs (n=58 genes) 
- at 15 days (n=471 genes)  
- at 6months (n=53 genes).  
 
The size of these changes in expression often followed a similar spatial order. The same gene 
showed the largest change in expression at the dorsal site of injected hippocampus, the next 
largest in ventral ipsilateral hippocampus, then in dorsal contralateral hippocampus and the 
smallest change occurred in ventral contralateral regions.   
 
A fourth set of genes showed maximal changes at 6hrs in the contralateral ventral 
hippocampus (n=53). Asmaller number of different patterns associated with smaller numbers 
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of genes were also detected (n=42).  Most clusters consisted of groups of upregulated genes, 
however a downregulation was detected most often (41 out of 53 genes) in the cluster of 
genes that changed at 6 months in ipsilateral hippocampus where were down-regulated.  
 
Analysis of Gene expression profiles: Correlation and verification of Affymetrix gene profile 
data with data from RT-PCR 
  
We decided to compare data on changes in gene expression determined by micro-array 
analysis with those estimated by real-time PCR analysis to define the accuracy of our 
methods.   
Three mice where injected with KA as previously described. 6 hours after injection they were 
sacrificed and tissue samples from the four different areas where collected in RNAse free 
conditions. RNA samples were collected from three wild type mice following the same 
procedure. RNA was extracted, purified and checked for good quality (see Materials and 
Methods). RNA samples where then used to perform quantitative analysis for seven 
transcripts where the chip analysis had reported a large change in expression at 6 hours after 
the injection in at least one site:  Lcn2 (log-fold changes of 5.28, 4.64, 4.80, 2.55 between 
KA-treated and WT tissue from ipsilateral dorsal, ipsilateral ventral area, contralateral dorsal 
area and contralateral ventral areas respectively), Hspa1b (3.98, 2.61, 2.94, 1.64), Trpm7 
(0.35, 0.02, -0.13, 1.95), Gad2 (0.15, 0.46, -0.57, 2.48), Hes5 (-1.42, -1.19, -1.13, -0.99), 
P2ry12 (-2.17, -2.54, -2.01, -0.63) and Isl1 (-2.18, -0.03, -2.92, 0.97) as well as two 
housekeeping genes Actb and Gapdh for calibration. 
Results showed that, overall, the direction of the change in expression detected with the q-
PCR technique agreed with that predicted by the micro-array work in 22 of 28 cases.  
Comparative values were best fitted with a linear relation of the form: qPCR value = 
0.57*(Affymetrix value) – 0.86 (r2 = 0.48).  As shown in Fig. 5, the data for changes in gene 
expression determined from the two techniques agree relatively well, with the array 
measurements rather more sensitive than those made with q-PCR.  Fig. 5 also presents a 
Table comparing the more significant fold-changes for up- and down-regulated genes from 
the array analysis and corresponding values from qPCR experiments.  
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Analysis of Gene expression profiles:  Gene Ontology terms  
 
The identity of genes whose expression changed provided clues on the time course and nature 
of pathological processes initiated by KA-treatment.  
For a general view of the time course of processes intervening between KA-injection and the 
emergence of an epileptic brain, we examined associations of groups of altered genes with 
Fig. 5: CORRELATION BETWEEN GENECHIP ANALYSIS AND qPCR EXPERIMENTS. Real 
Time PCR experiments were performed for 7 genes differentially expressed in the four areas at 6 
hours after injection. In tab A are reported the Fold Changes for the GeneChip analysis and for 
the qPCR for 6 representative highly variable points. In graph B all of the results of qPCR 
experiments were plotted against the corresponding Fold Changes according to Gene Expression 
Profiling for a total of 28 points. 21 out of 28 points show a good agreement between the results of 
the two techniques. The approximate linear correlation represented in the plot is: qPCR value = 
0.57*(Affymetrix value) – 0.86 
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terms from the Gene Onthology system.  As a first approach, we compared genes from 
injected and from contralateral hippocampus at all three time points pooling together genes 
from the dorsal or ventral areas. List of genes where submitted to GenMAPP 
(http://www.genmapp.org) and analysed. Gene Ontology terms were sorted according to Z-
score and percentage of number of altered genes associated/number of genes present on the 
Chip associated.  
 
 
 
 
 
 
 
Data for some of the most highly associated terms is shown in Fig. 6. We noted that: 
• Inflammatory and Immune responses were the terms with the highest proportion of 
genes whose expression was changed. At 6 hours ~10% of the genes were altered in 
the ipsilateral hippocampus, less than 5% in the contralateral. At 15 days there are 
more than 20% of them differentially expressed in the injected side with a consistent 
12% in the contralateral. Changes were still detected at 6 months in the area near the 
injection site.  
• Up to 10% of the genes associated with transcription factor activity present on the 
Chip changed after KA injection. These alterations were initiated at the 6 hr time 
Fig. 6: CHANGES IN GENE EXPRESSION ASSOCIATED WITH GENE ONTOLOGY TERMS 
The graph shows the number of genes changed as a percentage of the number measured for 8 GO 
terms.  Plots are made for each GO term, at each time point (6hr, 15 days and 6 months) for tissue 
from injected (IPSI) and from contralateral hippocampus (CONTRA).  
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point, at 15 days increased just in the injected side where some changes were 
maintained until 6 months.   
• Genes associated with both neurogenesis and axogenesis were more affected at 
contralateral sites at the 6 hr time point, but maximum activity occurred ipsilaterally to 
the injection site at 15 days.  
• Similar results were found for genes associated with apoptosis.   .  
• Terms associated with nerve impulse transmission and synaptic function also showed 
early activity in the contralateral hippocampus. These reached a maximum in the 
injected site of the hippocampus at 15 days but only minor alterations persisted at 6 
months.   
 
Analysis of Gene expression profiles:  Identification of gene clusters.  
 
We also examined the composition of smaller clusters of genes with similar spatial and 
temporal patterns and directions of altered expression. Fig. 7 shows a graphical representation 
of the differential expression in the clusters we identified: 
 
1. Genes upregulated only at 15 days at least in the ipsilateral dorsal site. The largest of 
these clusters consisted of genes upregulated at the ipsilateral dorsal injection site, at 
15 days.  This cluster consisted of 850 genes with a majority (594 genes) changing 
only at this time point and 346 changing only at this site.  Many of these genes 
participate in inflammatory processes such as interferon (Ifi47 or Isgf3g) and other 
cytokines (Tnfrsf13b, Il10ra and Cxcr6), while others are associated with apoptosis 
(Casp1, Casp7 and Casp8).  Genes associated with the extracellular matrix 
composition (Expi, Col20a1 and Mmp19) may participate in the development of the 
glial scar associated with neuronal death. Genes upregulated in other areas at this time 
point included caspases, chemokines, cytokines and receptors pointing to a wider 
activation of inflammation, cell death and sclerotic processes during the latent phase. 
2. Genes upregulated at both 15 days and 6 months at least in the ipsilateral dorsal site 
after KA-treatment were considered separately. Usually these genes were upregulated 
to a lesser extent at the later time point. These were often correlated with 
GeneOntology terms similar to those described in the former cluster. Interestingly we 
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also identified 7 genes participating in the complement cascade (C3ar1, C5ar1, C4b, 
C1qa, C1qb, C1qc and C3) a process implicated in the progression towards seizures 
(Jamali, Bartolomei et al. 2006; Aronica, Boer et al. 2007) present in this cluster. 31 of 
these genes were also showing alteration at 6 hours still in the injection area. This 
subset includes the gene Ctla2a which codes for a protein related to inflammation. The 
fold changes detected for this gene were 3.06, 2.07 and 1.38 fold at 6 hrs, 15 days and 
6 months respectively. This process seems reduced with time even though the number 
of genes that changed did not.  Vimentin, a marker of radial astroglial cells (Vim: 1.49, 
2.78 and 1.84) and the brain-derived neurotrophic factor (Bdnf: 1.49, 2.9 and 1.9) were 
also present in this subset. 
3. Genes downregulated at 6 months only in the ipsilateral dorsal site. In the ipsilateral 
hippocampus at 6 months the highest ratio of downregulated genes compared to the 
upregulated ones. So we considered as a separate cluster the downregulated genes in 
this area/time point (88 genes). Most of these genes were already downregulated at 15 
days but to a lesser extent. They included transcription factors (i.e. genes related to 
neurogenesis Isl1 and Neurod6) and genes associated with neuronal signalling (Trpv4 
and Rab20). Of these, three potassium channel genes (Kcnh2, Kcnq5 and Kcne2) were 
downregulated at both 15 days and 6 months. Genes belonging to this downregulated 
cluster also coded for proteins involved in the establishment and maintenance of the 
architecture of brain tissue. These included three collagen subunits (Col9a3, Col6a3 
and Col8a1), Claudin 1 and 2 and the protein Tjp3 which are involved in the formation 
of tight junctions (Eum, Andras et al. 2008; Van Itallie, Holmes et al. 2008; Xu, 
Kausalya et al. 2008). Downregulation of Claudin 8 during kindling has been 
described by Lamas et al (2002). The presence of these genes at the injection site 
suggests that after KA-treatment and neuronal death, the extracellular matrix 
undergoes long-term changes consistent with the formation of a glial scar. 
4. Genes differentially expressed only at 6 hours only in the contralateral ventral area. 
Our differential analysis of dorsal and ventral regions of both injected and 
contralateral hippocampi permitted identification of changes at different distances 
from the site of KA-injection. We noted a cluster of 178 genes selectively changed at  
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the contralateral ventral site at 6 hrs after injection. These genes were mostly 
moderately up-regulated with fold changes in the range -2 to +2.5. They included 
genes associated with transcription and protein synthesis (Pa2g4, Chd4 or Nr2c2) 
genes coding for regulators of chromatin assembly (Smarcc1 and Smarca) and four 
factors that initiate translation (Eif3s10, Eif4g1, Eif4a1 and Eif5b). Possibly these 
Fig. 7: CLUSTERS OF GENE EXPRESSION CHANGES. In the graphs are represented 5 
clusters of common patterns of expression including most of the changes we identified. For 
each time point and area (x; ID= ipsilateral dorsal, IV=ipsilateral ventral, CD= contralateral 
dorsal, CV=contralateral ventral) the Fold Change is plotted (y). Different lines and colors 
indicate different genes. One single condition per cluster was used to filter the genes. Cluster 1: 
genes upregulated just at 15 days. Cluster 2: genes upregulated at 15 days and at more time 
point. Cluster 3: genes downregulated at 6 months in ID. Cluster 4: genes differentially 
regulated only in CV at 6 hours. Cluster 5: genes differentially regulated only in ID at 6 hours 
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genes are induced by activity associated with the status epilepticus since the Fink-
Heimer silver stain revealed subsequent little cell death or fibre degeneration in this 
zone.   
5. Genes differentially regulated only at 6 hours only in the ipsilateral dorsal area. A 
smaller cluster consists of genes (n=45) with medium changes in expression limited to 
the injection site during status epilepticus.  These early responding genes included 
Fos, Jun and JunB as well as some Kruppel-like transcription factors (members 4, 6 
and 9). The Klf family is involved in multiple processes including lymphocyte 
proliferation and differentiation, as well as apoptosis (Good and Tangye 2007; 
Britschgi, Trinh et al. 2008; Pearson, Fleetwood et al. 2008). The presence of these 
genes, with Il6, a factor associated with the pathogenesis of neurodegeneration during 
the development of an epileptic phenotype (Fassbender, Rossol et al. 1994; De 
Simoni, Perego et al. 2000) as well as the chemokines Ccl7 and Ccl11 suggest that the 
KA-treatment induces a rapid proliferation and activation of glial and microglial cells.  
 
Analysis of Gene expression profiles: Neurotransmitter receptors and voltage-gated channels. 
 
Genes coding for membrane proteins associated with synaptic signalling and cellular 
excitability showed only moderate changes. Five GABA-receptor subunits were differentially 
regulated.  
• Gabrg1was downregulated (-1.2) and Gabrg2 upregulated (1.18). at 15 days in the 
injected site.   
• Gabra1 and Gabrb3 were moderately upregulated in the Contralateral Ventral area at 
6 months (fold-chages of 1.27 and 1.58 respectively).  
• Surprisingly, the subunit Gabra6, thought to be expressed only in the cerebellum 
(Kato 1990; Luddens, Pritchett et al. 1990) was detected at three different sites (ID, 
1.74; CD, 1.85; CV, 1.02) at 6 months after the injection.    
Expression changes were detected for four glutamate receptor subunits:  
• Gria3 was upregulated at 6 hours in the CV area (fold-change of 1.29)  
• Gria1, Grim1 and Grik1 were moderately downregulated at 15 days in close to the site 
of KA-injection. Possibly these changes resulted from a dilution effect related to 
neuronal loss in the area.   
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The polypeptide 1 of the alpha nicotinic receptor (Chrna1) was up-regulated at both 15 days 
and 6 months in the injected area.  
The strongest changes in genes coding for membrane channels controlling cellular excitability 
were observed for potassium channel subunits. Fig. 8 shows complex temporal and spatial 
patterns of up- and down regulation detected for genes of this family.  
• Five genes (Kcnk4, Kcnmb2, Kctd2, Kcnq2 and Kcnab2) were downregulated in the 
injected site of the dorsal hippocampous at 15 days.  
• Kcnq5 was down-regulated at 15 days in the injection site as well as in ipsilateral 
ventral and contralateral dorsal areas. At 6 months it was still downregulated in the 
ipsilateral dorsal site.  
• Kcne2 was downregulated at 15 days in both injected hippocampus and in 
contralateral ventral area with an increased down-regulation (fold-change of -4.65) at 
6 months in the ipsilateral dorsal hippocampus.  
• Kcne1l was the only K-channel subunit up-regulated at all four sites at 15 days 
especially (maximum fold-change of 4.67) in the ipsilateral dorsal where it also 
remained upregulated at 6 months.  
 
Analysis of gene expression profiles: Transcription Factors. 
 
A large number of differentially expressed genes were transcription factors. Expression 
changed significantly for 74 of them. Changes were detected at 6 hrs after KA-treatment for 
Jun, Fos and Fosb.  While these changes were not unexpected, the largest alterations were 
detected for the transcription factor Atf3 which is related to neuronal protection and known to 
be upregulated by KA-treatment (Francis, Dragunow et al. 2004). This transcription factor 
was upregulated at both 6 hrs and at 15 days. Stat3, a transcription factor involved in 
microglia activation (Fielding, McLoughlin et al. 2008; Huang, Ma et al. 2008), was 
upregulated at all time points in the injected area, underlying perhaps a persistent microglial 
activation to promote the inflammatory process. 
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Many of the changes in transcription factor expression detected at 15 days after KA-
treatments also seem likely to be involved in the orchestration of inflammatory responses.  
They include the interferon-related factors (Irf7 and Irf8), as well as Mef2c or Fli1. Other 
identified regulatory genes have been associated with cellular proliferation and 
differentiation. The transcription factor Satb2, involved in the specification of a neuronal 
phenotype (Szemes, Gyorgy et al. 2006; Alcamo, Chirivella et al. 2008) was strongly 
downregulated at 15 days in the injected area as was Lhx9 (Molle, Pere et al. 2004). 
Some others transcription factors with altered expression limited to the ipsilateral dorsal site 
of the hippocampus showed alteration at 15 days persistant at 6 months. They were typically 
downregulated,  including Dlx1 and Dlx5, which form part of a family of transcription factors 
associated with interneuronal differentiation and migration (Anderson, Eisenstat et al. 1997) 
via inhibitory actions on axonal and dendritic growth (Cobos, Borello et al. 2007). 
Fig. 8: TEMPORAL PATTERN OF DIFFERENTIAL EXPRESSION OF K CHANNELS. Fold 
Change of gene expression alteration expressed as a function of time points and areas (ID= 
ipsilateral dorsal, IV=ipsilateral ventral, CD= contralateral dorsal, CV=contralateral ventral) for 
subunits of K+ channels reported in the legend. 
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Suppression of Dlx1 results in a loss of interneurons and induces seizures (Cobos, 
Calcagnotto et al. 2005). 
 
Immuno-histochemical exploration of cell-type specificity of changes in selected genes.  
 
While micro-array data from brain homogenates obtained from KA-treated animals provide 
evidence that a number of identified transcripts are up- or down regulated, they did not allow 
identifying the cells in which gene expression was changed.  We therefore turned to 
immunohistochemistry to try to link gene profile data with cell types and their localisation 
within the hippocampus.  
 
Glial cell activation is a key process induced by KA-treatment (refs) as confirmed by our 
micro-array data.  We traced this process using antibodies that recognize vimentin and Glial 
Fibrillary Acidic Protein, two intermediate filament proteins expressed in astrocytes. Vimentin 
is expressed in both early and late developmental stages, but GFAP is only present in mature 
astrocytes (Eng 1988; Eliasson, Sahlgren et al. 1999). Both vimentin and GFAP are enhanced 
in reactive gliosis and after seizures (Lin and Cai 2004; Pekny and Nilsson 2005).  Our gene 
profile data revealed a major up-regulation of Vim and Gfap at 15 days in all areas which 
persisted at 6 months near the injection site. We also detected Vim up-regulation at 6 hrs in 
both dorsal and ventral injected hippocampus. Astrocyte, or radial glial cell, activation in the 
hippocampus also contributes to neurogenesis (Doetsch and Scharff 2001; Song, Stevens et al. 
2002; Doetsch 2003; Berninger, Costa et al. 2007) and synaptic activity (Porter and McCarthy 
1996; Porter and McCarthy 1997; Kang, Jiang et al. 1998; Araque, Martin et al. 2002). 
Fig. 9 shows immuno-staining experiments to explore the identity of elements expressing Vim 
and Gfap in hippocampal tissue from KA-treated animals at 15 days after injection. The neuronal 
marker NeuN let us identify changes in neuronal architecture including the loss of CA1 and 
hilar cells as well as the dispersion of dentate granule cells.  
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Fig. 9: IMMUNOSTAINING FOR PROTEINS ASSOCIATED WITH EARLY AND MATURE 
ASTROCYTES. A shows DAPI staining of both ipsilateral and contralateral hippocampi at 15 
days after KA-injection.  The injection site is shown and red squares indicate regions shown at 
greater magnification in B.  B, shows stains for NeuN (orange) to indicate neurons, Vim (green), 
and Gfap (red) and the final overlay column (Vim + Gfap) shows their co-expression.   The rows 
show tissue from the Ipsilateral Dorsal of NaCl-injected (first row) and KA-treated animals 
(second row) and from the contralateral site of the KA-treated animal (third row). 
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Immuno-staining for Vimentin and GFAP proteins revealed that KA-treatment induced a 
consistent increase in cells expressing Vim alone or both Vimentin and GFAP.  The increase 
was larger in injected than in contralateral site of the hippocampus. It was most evident in the 
dentate, but also in the stratum radiatum of the CA1 region.  Neither Vimentin nor GFAP 
staining was detected with NeuN in neuronal somatic layers. Comparison of dorsal and ventral 
regions of injected and contralateral hippocampus revealed differential staining patterns.  
 
 
 
 
 
 
 
The highest density of Vim+ cells was detected in the dentate region of ipsilateral dorsal 
hippocampus with a significant co-localization with Gfap+ elements. Staining levels were 
lowest in tissue from contralateral ventral hippocampus, but colocalization of Vim+ and 
Gfap+ elements was consistently higher in ventral rather than in dorsal regions.  
Fig. 10: VIM+ and GFAP+ CO-EXPRESSION IN THE DENTATE REGION OF KA-TREATED 
MICE. A shows immunofluorescence for Vimentin (green) and GFAP¨ (red) in the Dentate Gyrus 
at 15 days after KA-injection for tissue from ipsilateral dorsal, ID, contralateral dorsal, CD, 
ipsilateral ventral, IV and contralateral ventral CV regions. The granule cell layer is outlined with 
white dots. B shows log fold-changes from the array work for Vim and Gfap at 15 days. Red 
highlights the zone of maximal upregulation.  
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There was also a consistent difference in the localization of differentially immuno-positive 
elements (see Fig. 10). Vim+ cells were typically detected in the hilus, especially of dorsal 
injected hippocampus where most of them were Vim+/Gfap- while Vim+/Gfap+ elements 
tended to increase in ventral injected hippocampus.  In contralateral hippocampus however 
Vim+ cells were strictly confined to the granular and subgranular zones of the dentate gyrus, 
regions classically associated with neuronal progenitor cells.  
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Discussion 
 
The data on the identity of genes that change expression after KA-treatment shows some 
similarities to previous gene-chip work on epilepsy models. Our protocol based on intra-
hippocampal KA injection permitted comparison of tissue from both injected and non-
injected hippocampus. In this way we aimed to dissect relations between the genetic changes 
involved in epileptogenesis and the distinct stimuli, including the initial status epilepticus, cell 
death and the ensuing deafferentation as well as gliosis. Our data provided evidence for 
changes in a large number of genes (n=1563, see Figs 4 and Supplementary Table). The major 
classes of genes changed were involved in immune responses and inflammation, in cell death 
and cell growth. Many distinct spatio-temporal patterns of up- and down regulation were 
evident in our data, but a clear temporal sequence of changes in gene expression was evident: 
• Early changes, at 6hrs after KA-treatment, included several transcription and growth 
factors.  
• The largest numbers of altered genes involved with immune and inflammatory 
responses were detected at 15 days  
• There was a limited number of persistent changes in genes coding for proteins that 
control cellular excitability and neuronal communication. However, most persistent 
changes were limited to tissue near to the KA-injection site and also concerned genes 
linked to inflammatory and immune responses.   
 
Technical points:  
 
To perform our study we used a common, well annotated array (mouse 430A2.0 from 
Affymetrix) containing thousands of genes, although not the entire transcriptome. Analyses 
were performed separately on four different areas: dorsal and ventral regions of injected and 
contralateral hippocampus for three time points each.  
The number of animals used could have been larger, but we are encouraged that our results 
were similar to previous studies (Tang, Lu et al. 2002; Lukasiuk, Kontula et al. 2003; Gorter, 
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van Vliet et al. 2006). Furthermore, they were confirmed by measurements on some of the 
same genes using q-PCR (Fig. 5) and on their protein products using immunohistochemistry 
(Figs. 9 and 10).  EEG records made from a larger animal sample could also have permitted 
correlation of genetic changes with the time from the most recent seizure (Gorter, van Vliet et 
al. 2006). 
Our relatively large tissue samples yielded good quantities of genetic material but dictated a 
coarse spatial resolution. More detailed studies comparing tissue from smaller regions such as 
the sclerotic CA1 region and the non-sclerotic dentate gyrus should give more precise 
information. An increased number of time points might permit a better temporal mapping of 
genetic processes during the progression towards an epileptic brain. It would specifically 
permit verification of genes whose expression was altered at a single site and single time-
point (178 genes for contralateral ventral tissue at 6 hrs and 545 genes from ipsilateral dorsal 
tissue at 15 days). While our immunohistochemical work begins to link changed genes to 
specific cell types (Vim and Gfap in Figs. 9 and 10), micro-array analysis does not provide 
such data.  Cell specificity may be especially important in the epilepsies since neuronal death 
and glial proliferation implies that the cellular provenance of the material studied can change.  
The size of this shift in cell numbers has been derived from the CA1 region of patients with 
temporal lobe epilepsy (Lee, Dziema et al. 2007).  In sclerotic tissue 95% of CA1 cells were 
of glial origin, while only 56 % of CA1 cells were glial in non-sclerotic tissue.  Such a 
‘neuronal dilution’ effect might bias data towards an upregulation of genes associated with 
glial cells. Our data and other studies (Hendriksen, Datson et al. 2001; Tang, Lu et al. 2002; 
Lukasiuk, Kontula et al. 2003) report an upregulation of such genes, but we noted no 
systematic artefactual down-regulation of genes associated with neurons.   
 
Differential changes in gene expression resulting from focal KA-injection:  
 
We defined some of the stimuli contributing to the development of chronic epileptiform 
activities with EEG records and anatomy. All regions participated in the status epilepticus at 
the first 6 hr time point used in array analysis (Fig. 1). The strongest activity was recorded 
from ventral regions of contralateral and injected hippocampus. Slice work (Le Duigou, 
Wittner et al. 2005) suggests that at this time, some cells near the KA-injection site are 
depolarized to potentials where they no longer discharge.  Nissl and Fink Heimer stains made 
at 8 days after KA-injection (Fig. 3A) let us define the extent of cell death and fibre 
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degeneration before the second time point at 15 days.  Cell death was maximal in the 
ipsilateral dorsal region, moderate in ipsilateral ventral regions and effectively absent in 
contralateral hippocampus.  Fibre degeneration was detected in dorsal contralateral 
hippocampus as well as in both regions from the injected hippocampus.  Slice records from 
hippocampal tissue obtained from KA-treated animals at latencies corresponding to the 6 
month chronic time point reveal that interictal-like activity is preserved in vitro and occurs 
spontaneously in slices from both the ipsilateral and the controlateral side after KA-injection 
(Le Duigou, Bouilleret et al. 2008). Seizure-like activity could be induced by tetanic 
stimulation in both ipsilateral and contralateral hippocampus.  Spontaneous interictal activity 
was rarely detected and tetanic stimuli rarely induced seizures in the region of maximal 
sclerosis in dorsal ipsilateral hippocampus.   
 
There is a very good correlation between kainite-induced changes in gene expression and 
electrical and anatomical modifications. Genes up- and down-regulated in the ipsilateral 
dorsal cluster at 6 hours presumably correspond to those activated in early stages of neuronal 
death and to those involved in inflammatory and immune responses.  In contrast those genes 
changed in the contralateral ventral cluster at 6 hours (largely moderate changes) may 
correspond more closely to changes induced by the epileptiform activity and exclude genes 
involved in neuronal death.  The largest gene cluster centred on the ipsilateral dorsal 
hippocampus at the 15 day time point included those coding for proteins associated with the 
inflammatory and immune responses.  There was little evidence for a cluster centred on dorsal 
contralateral hippocampus at 15 days where relatively pure responses to de-afferentation 
might have been expected, however genes induced by de-afferentation seem likely to also 
have been strongly activated in ipsilateral hippocampus.  At this time point genes associated 
with the growth of neuronal processes and with neurogenesis were activated in tissue from 
both injected and non-injected hippocampus.  At six months a single gene cluster was 
apparent in dorsal injected hippocampus with a few isolated genes still active in other regions.  
This cluster, with a strong down-regulated component, consisted of genes that were also 
detected at earlier time points together with some novel transcripts. There was a significant 
contribution of genes related to inflammation as noted in previous gene profile analyses of the 
epilepsies (Lukasiuk, Kontula et al. 2003; de Lanerolle and Lee 2005; Hunsberger, Bennett et 
al. 2005; Gorter, van Vliet et al. 2006). These may be related to the persistence of a glial scar 
(Crespel, Coubes et al. 2002) as well as other secondary inflammatory responses.  
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Microglial activation and immune / inflammatory responses  
 
As already mentioned, the gene profile approach does not allow to link altered gene 
expressions with particular cell types. We are completing an immunohisto-chemical approach 
to this question as shown in Figs. 9 and 10 data on Vim and Gfap.  Even so, several of the 
processes that change according to Gene Ontology associations can be linked to specific cell 
types.  
Inflammatory processes and immune responses, are strongly upregulated in seizure-evoked 
animal models of hippocampal epilepsies as well as in epileptic patients, (Billiau, Wouters et 
al. 2005; Vezzani and Granata 2005; Gorter, van Vliet et al. 2006; van Gassen, de Wit et al. 
2008). They involve microglial cells.  After seizures these cells are activated which involves 
changes in cell number, morphology and gene expression (Niquet, Ben-Ari et al. 1994; 
Represa, Niquet et al. 1995). When activated, microglia secrete modulators of inflammation 
including cytokines and chemokines (Giulian 1993; Chao, Hu et al. 1995) which contribute to 
the induction of apoptosis (Margerison and Corsellis 1966; Magloczky and Freund 1993; 
Pollard, Charriaut-Marlangue et al. 1994; Fujikawa, Shinmei et al. 2000; Ben-Ari 2001).  
We obtained evidence for a global up-regulation of genes associated with microglial 
signalling in both injected and contralateral hippocampus during the latent period.  However 
at the time point corresponding to the emergence of chronic seizures, changes in expression of 
these genes became restricted to the injection site. This restriction may result from specific 
chemokines and trophic factors that maintain immune cells at this site in an active state. 
 
Astrocyte proliferation, neurogenesis and growth.  
 
Astrocytes are also activated in epileptic brain (Ernfors, Bengzon et al. 1991) and can be 
linked to a distinct set of Gene Ontology terms that we found were altered.  They are involved 
in precursor cell proliferation and differentiation and secrete trophic factors that encourage 
cell growth (Song, Stevens et al. 2002). We detected an upregulation of genes coding for 
markers of precursor and mature astrocytes (Vimentin and GFAP, Figs 9 and 10) as well as 
secreted growth factors including members of the Bdnf, Gmfa, Fgf and Tgf’s families. Some 
of these factors, including bdnf, are known to modify neuronal excitability (Bariohay, 
Tardivel et al. 2008). Astrocytes may act as a third modulatory element at synapses involving 
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several neuro-transmitters (Porter and McCarthy 1996; Porter and McCarthy 1997; Kang, 
Jiang et al. 1998; Araque, Martin et al. 2002) and can also themselves release 
neurotransmitters in some conditions (Bezzi, Carmignoto et al. 1998; Araque, Li et al. 2000; 
Pasti, Zonta et al. 2001; D'Ascenzo, Fellin et al. 2007; Fellin, D'Ascenzo et al. 2007). 
Our immunofluorescence data (Figs. 9 and 10) verified the Affymetrix data suggesting an 
upregulation of the genes Vim and Gfap also providing an insight into the cellular and 
regional specificity of their protein products.  Vimentin is a marker for precursor cells while 
mature astrocytes express both Vimentin and GFAP.  We found an increase in precursor 
radial glial-like elements (Gfap-/Vim+) in dorsal regions of both injected and contralateral 
hippocampus.  Contralaterally, Vim and Gfap were confined to the subgranular zone of the 
dentate region, the traditional site for neurogenesis, but in injected hippocampus these cells 
were much more widely expressed.  
The question of an increased neurogenesis in an epileptic brain remains controversial (Parent, 
Yu et al. 1997; Scharfman, Goodman et al. 2000; Fahrner, Kann et al. 2007). Our data suggest 
that hippocampal neuronal precursor cells receive distinct stimuli, but it remains unclear 
whether they favour production of stable new neurons. Some data suggests that newly 
generated elements mostly differentiate into astrocytes near the injection site but that the rate 
of neurogenesis is higher contralaterally (Kralic, Ledergerber et al. 2005; Ledergerber, 
Fritschy et al. 2006). Other work suggests daughter elements of radial glial cells can 
differentiate into neurons (Berninger, Costa et al. 2007).  Probably precise patterns of 
precursor production depend on distinct niche conditions and different stimuli operating in the 
various environments.  Our immuno-staining data supports this possibility suggesting that 
precursor proliferation and differentiation may even vary at distant sites of the same area in 
the same hippocampus.   
 
Comparison with gene profile studies on animal models and human epileptic tissue  
 
Genomic approaches based on a microarray analysis of epileptic tissue from MTLE patients 
are confined to the chronic phase of the pathology and often to sclerotic tissue (Becker, Chen 
et al. 2002; de Lanerolle and Lee 2005; Arion, Sabatini et al. 2006; Jamali, Bartolomei et al. 
2006; Ozbas-Gerceker, Redeker et al. 2006).  Several features of these results are consistent 
with our data. There is a consensus on changes in genes associated with glial cells, including 
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gfap, as well as inflammatory and immune responses, especially activation of the complement 
system and interleukins (de Lanerolle and Lee 2005; Jamali, Bartolomei et al. 2006). The 
predominance of changes in genes associated with glial cells led de Lanerolle and colleagues 
to emphasize an active astrocytic role in icto-genesis.  They suggested this might emerge from 
a loss of K+ buffering capacity due to down regulation of aquaporins. We found that Aq4 was 
downregulated at 6hrs and became progressively more so with time. Changes in expression of 
genes coding for receptor and voltage-operated channels tended to be related to GABAergic 
transmission and to K+ conductances (Arion, Sabatini et al. 2006; de Lanerolle and Lee 2005; 
Jamali, Bartolomei et al. 2006). We were also able to detect changes in K-channel subunits 
(Fig. 8) and a differential regulation, but in the opposite direction, of Gabrb3 and Gabrg2 
subunits as in sclerotic human temporal lobe (Arion, Sabatini et al. 2006). 
The use of animal models of epilepsy based either on convulsant treatment inducing a status 
epilepticus or on kindling stimulation has permitted to follow gene profile changes to the 
chronically epileptic state.  The first studies identified changes in genes coding for structural 
and especially inflammatory processes at early time points (Elliott, Khademi et al. 2001; 
Matzilevich, Rall et al. 2002; Tang, Lu et al. 2002; Long, Zou et al. 2003).  Elliott and 
colleagues focussing on transcription factors described a down-regulation of Hes5, a gene that 
we detected and that is involved in neurogenesis.   As in the present case, pooling data from 
ipsilateral and contralateral hippocampis, Lukasiuk and colleagues (Lukasiuk, Kontula et al. 
2003) provided evidence for activation of genes coding for transcription factors, cytokines 
structural proteins and immune processes. Gorter and colleagues (Gorter, van Vliet et al. 
2006) performed possibly the most complete gene expression study on a kindling model of 
epilepsy analyzing tissue from CA3 hippocampal region, entorhinal cortex and cerebellum at 
acute, latent and chronic phases of the progression of this model toward recurrent seizures.  
Our derivation of Gene Ontology terms associated with the three time points reveals several 
similarities, although our data describes a lower level of changes in voltage-gated channels 
during the chronic phase and we did not detect a down-regulation of terms associated with 
synaptic transmission during the acute phase.  
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Genes associated with chronic epileptiform activity. 
 
At six months after KA-injection, few genes were altered at sites distant from the original 
injection and few of them are involved in synaptic transmission or membrane excitability.  
The most intriguing of them was the GABA receptor subunit Gabra6 which was found to be 
upregulated exclusively at 6 months after KA-injection. Immunostaining is needed to 
determine which cells express this subunit which was previously thought to be present only in 
the cerebellum (Kato 1990; Luddens, Pritchett et al. 1990). 
What does our data mean for the contribution of long-term genetic alterations to the chronic 
epileptic state?  Possibly seizures are generated exclusively from the sclerotic region.  This 
seems to contradict our slice work suggesting that seizures could be initiated by tetanic 
stimuli applied to both ipsilateral and contralateral sites. Furthermore interictal-like activity 
was generated by slices from both injected and non-injected hippocampus.  Alternatively, 
changes in genes controlling neuronal electrical activity and synaptic transmission were 
diluted by tissue volume or glial proliferation to levels below our detection criteria.  Finally, it 
may be that the genetic changes needed to produce an epileptic brain are terminated at the 6 
month time point.  This could be the case, if for example, circuit reconfiguration that involves 
the establishment of aberrant synaptic connections depends on the activation of genetic 
pathways for axonal and dendritic growth and synapse formation during a limited period.  Our 
data show that genes associated with these processes were activated in regions other than 
dorsal ipsilateral hippocampus at the 15 day time point.   
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Conclusions and Perspectives  
 
 
In the work done for this thesis, I used a genomic approach consisting of expression profile 
analysis with microarray technology to study genetic differences between a defined set of 
hippocampal interneurons and CA1 pyramidal cells and also to examine the time course of 
genetic changes involved in the emergence of an epileptic brain after intra-hippocampal 
injection of the convulsant kainic acid.  
 
Gene profiling studies on interneuron diversity. 
 
A two channel microarray technology was used to examine gene expression of EGFP-positive 
hippocampal interneurons from the GIN strain of mice (Oliva, Jiang et al. 2000) which 
correspond to the O-LM inhibitory cells containing somatostatin and sending an axon to 
innervate distal dendrites of CA1 pyramidal cells.  We compare gene expression of EGFP-
positive cells and CA1 pyramidal cells after sorting using on the basis of fluorescence or of a 
modified fast-Nissl stain combined with laser capture technology.   
 
Comparison of expression levels for more than 10 000 transcripts represented on these arrays 
revealed specific differences between EGFP+ cells and pyramidal cells.  A group of 443 
transcripts was differentially expressed between the two different cell types; 260 of them at 
higher levels in the O-LM interneurons and 183 significantly more highly expressed in CA1 
pyramidal cells. The Gene Ontology notation suggested that many of the genes with 
differential expression were involved in the processes of signal transduction and transport. 
Some genes coding for neurotransmitter receptors and ion channels were also differentially 
expressed and these genes together with those involved in signal transduction and transport 
may contribute to the neurophysiological difference between these different cell types.  
 
Further experiments using qPCR experiments or immuno-histochemistry are needed to 
confirm the identity of differentially regulated transcripts. Either a conclusive identification of 
genes specific to this subset of Somatostatin-containing O-LM cells or just differentially 
expressed between hippocampal interneurons and pyramidal cells would be of interest.  A 
complete characterization of the genetic profile of different sets of hippocampal GABAergic 
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neurons will be extremely useful to progress with the question of the complexity and diversity 
of this cell population (Ascoli, Alonso-Nanclares et al. 2008).  
More precisely targeted experimental work would be useful to pursue the functional effects of 
some of the proteins found to be differentially expressed by SOM interneurons and CA1 
pyramidal cells.  For instance how does the differential expression of the Rab3b protein 
contribute to the differences in physiological properties of the two cell types?  One possibility 
would be to use selective intrabodies (Zita, Marchionni et al. 2007) as molecular tools to 
suppress function of this gene in vivo. Alternatively, Rab3b might be targeted with  RNA 
interference techniques (RNAi) at the level of mRNA degradation and subsequent inhibition 
of protein synthesis (Ramos, Bai et al. 2006). Further tests of electrical activity of perhaps and 
synaptic transmission may help identifying how Rab3b contributes to distinct functions of the 
two cell types.   
 
We also noted with interest that a number of transcription factors were differentially 
expressed in the two cell types.  None of these regulatory elements have previously been 
linked with specification of interneurons or pyramidal cells.  Possibly knock-out or RNAi 
experiments might help define a differential role for these molecules during neuronal 
development.   
 
A conclusive validation of the gene array technology might have been provided if it showed a 
differential expression of genes coding for proteins known to be differentially expressed by 
the two cell types.  Unfortunately neither the gene coding for somatostatin nor for the a splice 
variant of mGluR1 (Oliva, Jiang et al. 2000) were present in the arrays used in this work.  
However it seems clear that the combined use of laser capture technology and gene profile 
analysis can reveal sensitive differences in gene expression by distinct interneuron cell 
populations and principal cells of hippocampus and cortex (Sugino, Hempel et al. 2006).  
 
A necessary further step in this work will be to compare profiles of differentially expressed 
genes with anatomical, immunostaining and especially electrophysiological data.  It may even 
be possible eventually to perform expression profile experiments on single neurones 
(Subkhankulova and Livesey 2006; Yano, Subkhankulova et al. 2006), in conjunction with 
patch clamp recording. Such studies might provide data on the variability of genetic 
properties of different cells within an identified interneurone population. Physiological studies 
suggest that O-LM interneurons have diverse excitable properties (Minneci, Janahmadi et al. 
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2007). So are Somatostatin containing Interneurons part of a unique class? Single cell gene 
expression profiles from these cells could highlight differences and similarities between the 
neurons and clarify whether they form a genomically homogeneous population. 
 
Gene profiling studies on dynamic changes in a model of an epileptic syndrome.   
 
In the second part of the work, I used the well characterized Affymetrix GeneChip 
technology.(430A 2.0 chip, ~14 000 transcripts) to analyse gene expression changes occurring 
at 6 hours, 15 days and 6 months after KA-injection into the hippocampus.  These time points 
correspond to the initial status epilepticus, the latent phase, and the stable expression of 
spontaneous recurrent seizures in this mouse model of temporal lobe epilepsy. I identified 
large numbers of transcripts that were differentially regulated in a number of different 
patterns over the three different time points.  As expected, the profiles of differentially 
expressed genes suggested multiple processes were activated during the progression towards 
an epileptic brain including immune and inflammatory responses, as well as cell growth and 
neurogenesis were activated during the progression towards an epileptic brain. Changes 
detected with the array studies were concordant with controls using qPCR and 
immunohistochemistry to measure changes in expression of gene and of coded proteins.  
 
Inflammatory processes were still engaged, exclusively at sites near KA-injection, even after 
a delay of six months.  The role of these persistent changes remains unclear but they are 
consistent with recent findings in both animal models of epilepsy and in tissue obtained from 
epileptic patients (de Lanerolle and Lee 2005; Ozbas-Gerceker, Redeker et al. 2006; Aronica 
and Gorter 2007).  Further studies are needed to ask whether this persistent inflammation is an 
epi-phenomenon related to the cell death of hippocampal sclerosis, or a crucial factor in the 
emergence of recurrent seizures. Interestingly, inflammation-associated genes are activated 
after convulsant-induced status epilepticus and ischemia-induced neuronal loss (Simon, Cho 
et al. 1991; Stoll, Jander et al. 1998; Lee, Grabb et al. 2000) which may not lead to an 
epileptic brain. A careful comparison of gene expression changes in epileptic and ischemic 
tissue may permit identification of similarities and difference in the activation of the immune 
system by the two stimuli.   
 
It would be especially useful to compare in ischemic and epileptic animals the degree of 
activation of the complement cascade (Jamali, Bartolomei et al. 2006; Aronica, Boer et al. 
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2007). Furthermore, injection of complement factors induces cell death and seizures in the rat 
(Xiong, Qian et al. 2003). Further studies using KO or RNAi techniques may help identifying 
the roles of specific components of the immune system in the generation of the epileptic 
network (Einav, Pozdnyakova et al. 2002). 
 
My gene array analysis identified many transcripts associated with microglia and astrocytes as 
well as large numbers of genes that could not be definitively attributed to a specific cell type.  
Immunostaining work (i.e. for Vimentin and GFAP) may help clarify the cell-type and 
regional distribution of gene changes. An alternative approach to this question might be to 
pursue gene profile studies on purified cell populations obtained from epileptic animals at 
different time points.  In this sense the FACS technology used to separate EGFP+ 
hippocampal interneurons, together with astrocyte or microglial-specific fluorescent markers 
could prove useful.  It might permit to detect neuron-specific changes more sensitively than 
from whole-tissue homogenates by avoiding fractional changes in cell types resulting from 
‘glial dilution’.   
 
The effects of KA-injection on gene expression by EGFP+ neurons from GIN mice could be 
followed with this technique. In fact this cell group seems to be particularly vulnerable to 
excitotoxic insults (Oliva, Lam et al. 2002) and they are among the first cells to die during the 
development of the epileptic network (Dinocourt, Petanjek et al. 2003). Studies on EGFP+ 
cells may permit a clarification of genes and pathways activated in KA-induced cell death.   
 
Epilepsy is a disease of aberrant and hypersynchronous neuronal electrical activity. I 
identified a set of genes, in the contralateral ventral region, that were probably activated by 
epileptiform activity during the status epilepticus and were not related to neuronal death.  At 
the 15 days time point, changes were detected in many transcripts related to glial cell 
activation. During the persistent phase of recurrent seizure expression, there were few 
changes in neuron-associated genes outside the initial injection site. Are seizures initiated 
exclusively from sites of profound neuronal death?  Or might seizures arise from changes in 
neuronal connectivity due to genes controlling growth processes activated at the intermediate 
time point?  Gene profile analysis at more intermediate time points might better define growth 
processes. Further EEG studies on sites for seizure initiation would also be useful to define 
sites for a more precise gene profile analysis to improve understanding on the links between 
changes at these sites and the initiation of recurrent seizures.   
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o
n
e) 1
 alph
a
 sub
co
m
plex
 11
 
1
.372
 
0
.04063
 
2310003H
01Rik
 
R
IK
EN
 cD
N
A
 2310003H
01
 g
en
e
 
1
.367
 
0
.00732
 
T
rapp
c4
 
T
rafficking
 p
rotein
 p
article
 co
m
plex
 4
 
1
.367
 
0
.00001
 
P
u
ra
 
P
u
rin
e
 rich
 elem
ent
 binding
 p
rotein
 A
 
1
.361
 
0
.02605
 
C
end1
 
C
ell
 cy
cle
 e
xit
 and
 n
eu
ro
n
al
 differentiatio
n
 1
 
1
.353
 
0
.04658
 
Y
ipf1
 
Y
ip1
 d
o
m
ain
 fam
ily
,
 m
em
b
er 1
 
1
.351
 
0
.00355
 
1500005A
01Rik
 
R
IK
EN
 cD
N
A
 1500005A
01
 g
en
e
 
1
.348
 
0
.00012
 
3321401G
04Rik
 
R
IK
EN
 cD
N
A
 3321401G
04
 g
en
e
 
1
.348
 
0
.00179
 
N
sg2
 
N
eu
ro
n
 sp
ecific
 g
en
e
 fam
ily
 m
em
b
er 2
 
1
.345
 
0
.00095
 
Plxd
c2
 
Plexin
 d
o
m
ain
 co
ntaining
 2
 
1
.344
 
0
.00447
 
N
ell2
 
N
EL
-lik
e
 2
 (chick
en) 
1
.342
 
0
.01998
 
BC003267
 
C
D
N
A
 seq
u
en
ce
 BC003267
 
1
.340
 
0
.03731
 
R
m
nd1
 
R
eq
uired
 fo
r m
eiotic
 n
u
clear divisio
n
 1
 h
o
m
olog
 (S
.
 cerevisiae) 
1
.339
 
0
.01424
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2310014G
06Rik
 
R
IK
EN
 cD
N
A
 2310014G
06
 g
en
e
 
1
.330
 
0
.02515
 
A
csbg1
 
A
cyl
-C
oA
 sy
nth
etase
 b
ubbleg
u
m
 fam
ily
 m
em
b
er 1
 
1
.325
 
0
.00038
 
Fto
 
F
at
 m
ass
 and
 ob
esity
 asso
ciated
 
1
.313
 
0
.00026
 
1700016H
13Rik
 
R
IK
EN
 cD
N
A
 1700016H
13
 g
en
e
 
1
.309
 
0
.01334
 
N
sbp1
 
N
u
cleo
so
m
e
 binding
 p
rotein
 1
 
1
.306
 
0
.00847
 
D
d
x24
 
D
EA
D
 (A
sp
-G
lu
-A
la
-A
sp) b
o
x
 p
olyp
eptid
e
 24
 
1
.305
 
0
.00008
 
M
tdh
 
M
etadh
erin
 
1
.304
 
0
.00692
 
G
6p
c3
 
G
lu
co
se
 6
 ph
o
sph
atase
,
 catalytic
,
 3
 
1
.301
 
0
.00921
 
Sdhb
 
S
u
ccin
ate
 d
ehyd
rog
en
ase
 co
m
ple
x
,
 sub
u
nit
 B
,
 iro
n
 sulfu
r (Ip) 
1
.300
 
0
.01527
 
S
n
rp
n
 
S
m
all
 n
u
clear rib
o
n
u
cleop
rotein
 N
 
1
.300
 
0
.00293
 
H
o
ok2
 
H
o
ok
 h
o
m
olog
 2
 (D
ro
sophila) 
1
.299
 
0
.01960
 
C330019L16Rik
 
R
IK
EN
 cD
N
A
 C330019L16
 g
en
e
 
1
.295
 
0
.04531
 
2810468N
07Rik
 
R
IK
EN
 cD
N
A
 2810468N
07
 g
en
e
 
1
.291
 
0
.00360
 
Eg
r1
 
E
arly
 g
ro
w
th
 resp
o
n
se
 1
 
1
.291
 
0
.01541
 
N
d
ufb5
 
N
A
D
H
 d
ehyd
rog
en
ase
 (ubiq
uin
o
n
e) 1
 b
eta
 sub
co
m
plex
,
 5
 
1
.288
 
0
.04489
 
R
tcd1
 
RN
A
 term
in
al
 ph
o
sph
ate
 cy
clase
 d
o
m
ain
 1
 
1
.288
 
0
.00160
 
T
m
2d2
 
TM
2
 d
o
m
ain
 co
ntaining
 2
 
1
.286
 
0
.00177
 
Ppp1
r11
 
P
rotein
 ph
o
sph
atase
 1
,
 reg
ulato
ry
 (inhibito
r) sub
u
nit
 11
 
1
.284
 
0
.02206
 
N
eu
rl2
 
N
eu
ralized
-lik
e
 2
 (D
ro
sophila) 
1
.278
 
0
.03273
 
1810021J13Rik
 
R
IK
EN
 cD
N
A
 1810021J13
 g
en
e
 
1
.273
 
0
.03201
 
G
tpbp1
 
G
TP
 binding
 p
rotein
 1
 
1
.262
 
0
.03275
 
Rp
s11
 
Rib
o
so
m
al
 p
rotein
 S11
 
1
.262
 
0
.01445
 
V
am
p8
 
V
esicle
-asso
ciated
 m
em
b
ran
e
 p
rotein
 8
 
1
.260
 
0
.01685
 
M
el13
 
M
elan
o
m
a
 n
u
clear p
rotein
 13
 
1
.256
 
0
.04574
 
P
olr2f
 
P
oly
m
erase
 (RN
A) II (D
N
A
 directed) p
olyp
eptid
e
 F
 
1
.253
 
0
.01969
 
Sfx
n5
 
Sid
eroflexin
 5
 
1
.247
 
0
.01497
 
M
ea1
 
M
ale
 enh
an
ced
 antig
en
 1
 
1
.244
 
0
.00732
 
S
elm
 
S
elen
op
rotein
 M
 
1
.244
 
0
.02996
 
Tim
p4
 
Tissu
e
 inhibito
r of
 m
etallop
rotein
ase
 4
 
1
.239
 
0
.02806
 
Rg
s16
 
R
eg
ulato
r of
 G
-p
rotein
 sig
n
aling
 16
 
1
.237
 
0
.02432
 
A
930017N
06Rik
 
R
IK
EN
 cD
N
A
 A
930017N
06
 g
en
e
 
1
.235
 
0
.01317
 
BC049635
 
C
D
N
A
 seq
u
en
ce
 BC049635
 
1
.230
 
0
.00882
 
Sdh
a
 
S
u
ccin
ate
 d
ehyd
rog
en
ase
 co
m
ple
x
,
 sub
u
nit
 A
,
 flav
op
rotein
 (Fp) 
1
.229
 
0
.00347
 
M
g
at5b
 
M
an
n
o
sid
e
 acetylglu
co
sam
inyltran
sferase
 5
,
 iso
en
zy
m
e
 B
 
1
.228
 
0
.01926
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BC003266
 
C
D
N
A
 seq
u
en
ce
 BC003266
 
1
.227
 
0
.00357
 
O
TTM
U
SG
00000007209
 
P
redicted
 g
en
e
,
 O
TTM
U
SG
00000007209
 
1
.225
 
0
.00329
 
M
obkl1b
 
M
O
B1
,
 M
p
s
 O
n
e
 Bind
er kin
ase
 activ
ato
r-lik
e
 1B
 (y
east) 
1
.224
 
0
.00263
 
V
cp
 
V
alo
sin
 co
ntaining
 p
rotein
 
1
.223
 
0
.00904
 
O
rc5l
 
O
rigin
 recog
nitio
n
 co
m
plex
,
 sub
u
nit
 5
-lik
e
 (S
.
 cerevisiae) 
1
.220
 
0
.00626
 
Tp
o
 
Thy
roid
 p
ero
xid
ase
 
1
.210
 
0
.00511
 
D
olk
 
D
olich
ol
 kin
ase
 
1
.207
 
0
.00038
 
G
ab
ra4
 
G
am
m
a
-am
in
ob
uty
ric
 acid
 (G
A
B
A
-A) recepto
r,
 sub
u
nit
 alph
a
 4
 
1
.204
 
0
.04632
 
U
b
xd2
 
U
B
X
 d
o
m
ain
 co
ntaining
 2
 
1
.204
 
0
.00329
 
S
ap18
 
Sin3
-asso
ciated
 p
olyp
eptid
e
 18
 
1
.203
 
0
.01974
 
4930520K
10Rik
 
R
IK
EN
 cD
N
A
 4930520K
10
 g
en
e
 
1
.197
 
0
.01876
 
Rb
m
x2
 
RN
A
 binding
 m
otif
 p
rotein
,
 X
-link
ed
 2
 
1
.196
 
0
.02084
 
B
nip2
 
BC
L2/ad
en
o
viru
s
 E1B
 interacting
 p
rotein
 1
,
 N
IP2
 
1
.195
 
0
.00606
 
R
n
aseh2
c
 
Rib
o
n
u
clease
 H
2
,
 sub
u
nit
 C
 
1
.189
 
0
.00904
 
A
dpgk
 
A
D
P
-d
ep
end
ent
 glu
cokin
ase
 
1
.185
 
0
.00256
 
T
af9
 
TA
F9
 RN
A
 p
oly
m
erase
 II,
 TA
TA
 b
o
x
 binding
 p
rotein
 (TB
P)-asso
ciated
 facto
r 
1
.185
 
0
.00026
 
Cld
n5
 
Claudin
 5
 
1
.184
 
0
.02873
 
2310004L02Rik
 
R
IK
EN
 cD
N
A
 2310004L02
 g
en
e
 
1
.183
 
0
.03770
 
Ptp
rk
 
P
rotein
 ty
ro
sin
e
 ph
o
sph
atase
,
 recepto
r typ
e
,
 K
 
1
.178
 
0
.00662
 
A
230065H
16Rik
 
R
IK
EN
 cD
N
A
 A
230065H
16
 g
en
e
 
1
.177
 
0
.01060
 
K
lhl22
 
K
elch
-lik
e
 22
 (D
ro
sophila) 
1
.176
 
0
.02382
 
M
ark2
 
M
A
P/m
icrotub
ule
 affinity
-reg
ulating
 kin
ase
 2
 
1
.174
 
0
.00727
 
Stt3b
 
STT3
,
 sub
u
nit
 of
 th
e
 olig
o
sacch
aryltran
sferase
 co
m
plex
,
 h
o
m
olog
 B
 (S
.
 cerevisiae) 
1
.170
 
0
.00607
 
T
m
em
176b
 
T
ran
sm
em
b
ran
e
 p
rotein
 176B
 
1
.170
 
0
.01497
 
A
rl4d
 
A
D
P
-rib
o
sylatio
n
 facto
r-lik
e
 4D
 
1
.168
 
0
.02515
 
D
d
x54
 
D
EA
D
 (A
sp
-G
lu
-A
la
-A
sp) b
o
x
 p
olyp
eptid
e
 54
 
1
.165
 
0
.01455
 
A
ctr10
 
A
R
P10
 actin
-related
 p
rotein
 10
 h
o
m
olog
 (S
.
 cerevisiae) 
1
.155
 
0
.00665
 
Edf1
 
E
nd
oth
elial
 differentiatio
n
-related
 facto
r 1
 
1
.155
 
0
.01651
 
M
ir16
 
M
em
b
ran
e
 interacting
 p
rotein
 of
 RG
S16
 
1
.155
 
0
.00447
 
P
olr2k
 
P
oly
m
erase
 (RN
A) II (D
N
A
 directed) p
olyp
eptid
e
 K
 
1
.155
 
0
.00170
 
P
cbd1
 
Pterin
 4
 alph
a
 carbin
olam
in
e
 d
ehyd
ratase/dim
erizatio
n
 cofacto
r of
 h
ep
ato
cyte
 n
u
clear facto
r 1
 alph
a
 (TC
F1) 1
 
1
.152
 
0
.03875
 
T
o
r2
a
 
T
o
rsin
 fam
ily
 2
,
 m
em
b
er A
 
1
.150
 
0
.00360
 
M
ed11
 
M
ediato
r of
 RN
A
 p
oly
m
erase
 II tran
scriptio
n
,
 sub
u
nit
 11
 h
o
m
olog
 (S
.
 cerevisiae) 
1
.148
 
0
.02504
 
G
clm
 
G
lutam
ate
-cy
stein
e
 lig
ase
 
,
 m
odifier sub
u
nit
 
1
.143
 
0
.01424
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Sbd
s
 
Sh
w
ach
m
an
-B
odian
-D
iam
o
nd
 sy
nd
ro
m
e
 h
o
m
olog
 (h
u
m
an) 
1
.142
 
0
.01317
 
2610204K
14Rik
 
R
IK
EN
 cD
N
A
 2610204K
14
 g
en
e
 
1
.141
 
0
.01334
 
M
y
o18b
 
M
y
o
sin
 X
V
IIIb
 
1
.140
 
0
.02101
 
U
xt
 
U
biq
uito
u
sly
 exp
ressed
 tran
script
 
1
.140
 
0
.01186
 
H
sp
a4
 
H
eat
 sh
o
ck
 p
rotein
 4
 
1
.135
 
0
.00923
 
Itm
2b
 
Integ
ral
 m
em
b
ran
e
 p
rotein
 2B
 
1
.135
 
0
.02382
 
A
lkbh2
 
A
lkB
,
 alkylatio
n
 rep
air h
o
m
olog
 2
 (E
.
 coli) 
1
.134
 
0
.01880
 
T
m
em
79
 
T
ran
sm
em
b
ran
e
 p
rotein
 79
 
1
.134
 
0
.01614
 
Rb1
 
R
etin
oblasto
m
a
 1
 
1
.132
 
0
.03985
 
Sh
m
t1
 
S
erin
e
 hyd
ro
xy
m
ethyltran
sferase
 1
 (soluble) 
1
.125
 
0
.00268
 
8430415E04Rik
 
R
IK
EN
 cD
N
A
 8430415E04
 g
en
e
 
1
.124
 
0
.01960
 
A
tp6
v1
c1
 
N
A
 
1
.120
 
0
.01614
 
0610007L01Rik
 
R
IK
EN
 cD
N
A
 0610007L01
 g
en
e
 
1
.118
 
0
.01614
 
G
stm
4
 
G
lutathio
n
e
 S
-tran
sferase
,
 m
u
 4
 
1
.115
 
0
.01444
 
Rb
m
16
 
RN
A
 binding
 m
otif
 p
rotein
 16
 
1
.115
 
0
.00171
 
R
tn3
 
R
eticulo
n
 3
 
1
.114
 
0
.01250
 
S
erpinb12
 
S
erin
e
 (o
r cy
stein
e) p
eptid
ase
 inhibito
r
,
 clad
e
 B
 (o
v
alb
u
m
in),
 m
em
b
er 12
 
1
.114
 
0
.03623
 
A
230056P14Rik
 
R
IK
EN
 cD
N
A
 A
230056P14
 g
en
e
 
1
.112
 
0
.03229
 
P
sm
d11
 
P
roteaso
m
e
 (p
ro
so
m
e
,
 m
acrop
ain) 26S
 sub
u
nit
,
 n
o
n
-A
TP
ase
,
 11
 
1
.108
 
0
.02625
 
N
at2
 
N
-acetyltran
sferase
 2
 (arylam
in
e
 N
-acetyltran
sferase) 
1
.103
 
0
.01674
 
K
in
 
A
ntig
enic
 d
eterm
in
ant
 of
 rec
-A
 p
rotein
 
1
.098
 
0
.00906
 
N
cam
1
 
N
eu
ral
 cell
 adh
esio
n
 m
olecule
 1
 
1
.098
 
0
.01681
 
A
dip
o
r1
 
A
dip
o
n
ectin
 recepto
r 1
 
1
.095
 
0
.02402
 
1300010M
03Rik
 
R
IK
EN
 cD
N
A
 1300010M
03
 g
en
e
 
1
.093
 
0
.02382
 
K
lf15
 
K
rupp
el
-lik
e
 facto
r 15
 
1
.087
 
0
.02405
 
Rh
oj
 
R
as
 h
o
m
olog
 g
en
e
 fam
ily
,
 m
em
b
er J
 
1
.087
 
0
.00102
 
A
W
209491
 
E
xp
ressed
 seq
u
en
ce
 A
W
209491
 
1
.084
 
0
.02630
 
EN
SM
U
SG
00000053412
 
P
redicted
 g
en
e
,
 EN
SM
U
SG
00000053412
 
1
.084
 
0
.04715
 
C
o
rt
 
C
o
rtistatin
 
1
.083
 
0
.02651
 
1810029B16Rik
 
R
IK
EN
 cD
N
A
 1810029B16
 g
en
e
 
1
.082
 
0
.03273
 
2700078K
21Rik
 
R
IK
EN
 cD
N
A
 2700078K
21
 g
en
e
 
1
.080
 
0
.02013
 
U
b
e2
z
 
U
biq
uitin
-co
njug
ating
 en
zy
m
e
 E2Z
 (p
utativ
e) 
1
.079
 
0
.03996
 
M
rpl14
 
M
ito
ch
o
nd
rial
 rib
o
so
m
al
 p
rotein
 L14
 
1
.075
 
0
.02686
 
5430433E21Rik
 
R
IK
EN
 cD
N
A
 5430433E21
 g
en
e
 
1
.074
 
0
.00662
 
1 6 1
Bicd1
 
Bicaud
al
 D
 h
o
m
olog
 1
 (D
ro
sophila) 
1
.072
 
0
.01873
 
S
su72
 
S
su72
 RN
A
 p
oly
m
erase
 II C
TD
 ph
o
sph
atase
 h
o
m
olog
 (y
east) 
1
.071
 
0
.00662
 
G
ab
arapl1
 
G
am
m
a
-am
in
ob
uty
ric
 acid
 (G
A
B
A(A)) recepto
r-asso
ciated
 p
rotein
-lik
e
 1
 
1
.070
 
0
.00713
 
E
npp2
 
E
cto
n
u
cleotid
e
 py
roph
o
sph
atase/ph
o
sph
odiesterase
 2
 
1
.064
 
0
.04117
 
2410002F23Rik
 
R
IK
EN
 cD
N
A
 2410002F23
 g
en
e
 
1
.058
 
0
.02010
 
M
ed28
 
M
ediato
r of
 RN
A
 p
oly
m
erase
 II tran
scriptio
n
,
 sub
u
nit
 28
 h
o
m
olog
 (y
east) 
1
.046
 
0
.00647
 
R
ufy3
 
RU
N
 and
 FY
V
E
 d
o
m
ain
 co
ntaining
 3
 
1
.044
 
0
.02286
 
1110034G
24Rik
 
R
IK
EN
 cD
N
A
 1110034G
24
 g
en
e
 
1
.040
 
0
.02126
 
5830471E12Rik
 
R
IK
EN
 cD
N
A
 5830471E12
 g
en
e
 
1
.040
 
0
.00330
 
A
ktip
 
Thy
m
o
m
a
 viral
 p
roto
-o
n
cog
en
e
 1
 interacting
 p
rotein
 
1
.040
 
0
.02120
 
E
rgic2
 
ERG
IC
 and
 g
olgi
 2
 
1
.037
 
0
.00331
 
C
o
x11
 
CO
X
11
 h
o
m
olog
,
 cyto
ch
ro
m
e
 c
 o
xid
ase
 assem
bly
 p
rotein
 (y
east) 
1
.036
 
0
.02126
 
T
m
em
119
 
T
ran
sm
em
b
ran
e
 p
rotein
 119
 
1
.035
 
0
.01685
 
Im
m
t
 
In
n
er m
em
b
ran
e
 p
rotein
,
 m
ito
ch
o
nd
rial
 
1
.029
 
0
.02286
 
C230093N
12Rik
 
R
IK
EN
 cD
N
A
 C230093N
12
 g
en
e
 
1
.024
 
0
.02155
 
B
ru
n
ol4
 
B
ru
n
o
-lik
e
 4
,
 RN
A
 binding
 p
rotein
 (D
ro
sophila) 
1
.021
 
0
.00287
 
C
reb3
 
CA
M
P
 resp
o
n
siv
e
 elem
ent
 binding
 p
rotein
 3
 
1
.021
 
0
.03996
 
Pigy
 
Ph
o
sph
atidylin
o
sitol
 gly
can
 an
ch
o
r bio
sy
nth
esis
,
 class
 Y
 
1
.021
 
0
.00643
 
S
eph
s1
 
S
elen
oph
o
sph
ate
 sy
nth
etase
 1
 
1
.021
 
0
.01042
 
Sdk1
 
Sid
ekick
 h
o
m
olog
 1
 (chick
en) 
1
.019
 
0
.04794
 
Slc2
a5
 
S
olute
 carrier fam
ily
 2
 (facilitated
 glu
co
se
 tran
sp
o
rter),
 m
em
b
er 5
 
1
.019
 
0
.02534
 
Th
u
m
pd2
 
TH
U
M
P
 d
o
m
ain
 co
ntaining
 2
 
1
.019
 
0
.03388
 
G
abpb2
 
G
A
 rep
eat
 binding
 p
rotein
,
 b
eta
 2
 
1
.018
 
0
.03717
 
Cd
c123
 
C
ell
 divisio
n
 cy
cle
 123
 h
o
m
olog
 (S
.
 cerevisiae) 
1
.017
 
0
.04051
 
S
o
x8
 
SR
Y
-b
o
x
 co
ntaining
 g
en
e
 8
 
1
.016
 
0
.01630
 
M
cts2
 
M
alig
n
ant
 T
 cell
 am
plified
 seq
u
en
ce
 2
 
1
.013
 
0
.00662
 
G
p
r83
 
G
 p
rotein
-co
upled
 recepto
r 83
 
1
.010
 
0
.02387
 
U
sp4
 
U
biq
uitin
 sp
ecific
 p
eptid
ase
 4
 (p
roto
-o
n
cog
en
e) 
1
.010
 
0
.01317
 
N
t5
c3l
 
5
'
-n
u
cleotid
ase
,
 cyto
solic
 III-lik
e
 
1
.008
 
0
.02899
 
K
el
 
K
ell
 blo
od
 g
ro
up
 
1
.002
 
0
.00500
 
Sto
m
 
Sto
m
atin
 
-1
.004
 
0
.01251
 
Clrn1
 
Clarin
 1
 
-1
.006
 
0
.01725
 
Slc6
a19
 
S
olute
 carrier fam
ily
 6
 (n
eu
rotran
sm
itter tran
sp
o
rter),
 m
em
b
er 19
 
-1
.006
 
0
.01732
 
C030048H
21Rik
 
R
IK
EN
 cD
N
A
 C030048H
21
 g
en
e
 
-1
.010
 
0
.03024
 
1 6 2
S
ap
s2
 
SA
PS
 d
o
m
ain
 fam
ily
,
 m
em
b
er 2
 
-1
.012
 
0
.02510
 
EN
SM
U
SG
00000051848
 
P
redicted
 g
en
e
,
 EN
SM
U
SG
00000051848
 
-1
.027
 
0
.01012
 
W
d
r89
 
W
D
 rep
eat
 d
o
m
ain
 89
 
-1
.027
 
0
.00529
 
C
rk
rs
 
Cd
c2
-related
 kin
ase
,
 arginin
e/serin
e
-rich
 
-1
.029
 
0
.03024
 
Eif4h
 
E
uk
ary
otic
 tran
slatio
n
 initiatio
n
 facto
r 4H
 
-1
.038
 
0
.01275
 
C330006K
01Rik
 
R
IK
EN
 cD
N
A
 C330006K
01
 g
en
e
 
-1
.039
 
0
.00355
 
E130116L18Rik
 
R
IK
EN
 cD
N
A
 E130116L18
 g
en
e
 
-1
.041
 
0
.00505
 
Ikbkg
 
Inhibito
r of
 k
app
aB
 kin
ase
 g
am
m
a
 
-1
.043
 
0
.02899
 
L
ass4
 
L
o
ng
evity
 assu
ran
ce
 h
o
m
olog
 4
 (S
.
 cerevisiae) 
-1
.044
 
0
.04880
 
D
d
x21
 
D
EA
D
 (A
sp
-G
lu
-A
la
-A
sp) b
o
x
 p
olyp
eptid
e
 21
 
-1
.045
 
0
.04629
 
A
nk
rd13
a
 
A
nky
rin
 rep
eat
 d
o
m
ain
 13
a
 
-1
.047
 
0
.01651
 
Ck
ap5
 
C
yto
sk
eleto
n
 asso
ciated
 p
rotein
 5
 
-1
.050
 
0
.04593
 
F
zd2
 
F
rizzled
 h
o
m
olog
 2
 (D
ro
sophila)
 
-1
.050
 
0
.01831
 
P4h
a1
 
P
ro
collag
en
-p
rolin
e
,
 2
-o
x
oglutarate
 4
-dio
xyg
en
ase
 (p
rolin
e
 4
-hyd
ro
xylase),
 alph
a
 1
 p
olyp
eptid
e
 
-1
.053
 
0
.00578
 
Fln
c
 
Filam
in
 C
,
 g
am
m
a
 (actin
 binding
 p
rotein
 280) 
-1
.054
 
0
.03985
 
L
am
p2
 
Ly
so
so
m
al
-asso
ciated
 m
em
b
ran
e
 p
rotein
 2
 
-1
.057
 
0
.01359
 
B
B031773
 
E
xp
ressed
 seq
u
en
ce
 B
B031773
 
-1
.060
 
0
.04084
 
Cd44
 
C
D
44
 antig
en
 
-1
.062
 
0
.01399
 
A
d
am
23
 
A
 disinteg
rin
 and
 m
etallop
eptid
ase
 d
o
m
ain
 23
 
-1
.065
 
0
.01998
 
C
n
ot1
 
CC
R4
-N
O
T
 tran
scriptio
n
 co
m
plex
,
 sub
u
nit
 1
 
-1
.071
 
0
.00278
 
Pik3
cd
 
Ph
o
sph
atidylin
o
sitol
 3
-kin
ase
 catalytic
 d
elta
 p
olyp
eptid
e
 
-1
.073
 
0
.04113
 
2810408A
11Rik
 
R
IK
EN
 cD
N
A
 2810408A
11
 g
en
e
 
-1
.084
 
0
.04084
 
B
at1
a
 
H
LA
-B
-asso
ciated
 tran
script
 1A
 
-1
.086
 
0
.02382
 
D
tl
 
D
enticleless
 h
o
m
olog
 (D
ro
sophila) 
-1
.088
 
0
.02013
 
BC005537
 
C
D
N
A
 seq
u
en
ce
 BC005537
 
-1
.093
 
0
.03090
 
M
m
p19
 
M
atrix
 m
etallop
eptid
ase
 19
 
-1
.098
 
0
.02886
 
T
sp
an31
 
T
etrasp
anin
 31
 
-1
.098
 
0
.01501
 
D
d
x6
 
D
EA
D
 (A
sp
-G
lu
-A
la
-A
sp) b
o
x
 p
olyp
eptid
e
 6
 
-1
.102
 
0
.04632
 
U
sp7
 
U
biq
uitin
 sp
ecific
 p
eptid
ase
 7
 
-1
.104
 
0
.00826
 
W
d
r82
 
W
D
 rep
eat
 d
o
m
ain
 co
ntaining
 82
 
-1
.106
 
0
.00009
 
C
cr9
 
Ch
em
okin
e
 (C
-C
 m
otif) recepto
r 9
 
-1
.110
 
0
.01361
 
T
radd
 
TN
FRSF1A
-asso
ciated
 via
 d
eath
 d
o
m
ain
 
-1
.113
 
0
.02496
 
2210038L17Rik
 
R
IK
EN
 cD
N
A
 2210038L17
 g
en
e
 
-1
.114
 
0
.03514
 
Fbln2
 
Fib
ulin
 2
 
-1
.115
 
0
.02376
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A
k
ap8
 
A
 kin
ase
 (PR
K
A) an
ch
o
r p
rotein
 8
 
-1
.117
 
0
.02758
 
Sd
ccag3
 
S
erologically
 d
efin
ed
 colo
n
 can
cer antig
en
 3
 
-1
.117
 
0
.03486
 
C
ct7
 
Ch
ap
ero
nin
 sub
u
nit
 7
 (eta) 
-1
.125
 
0
.01764
 
P
olb
 
P
oly
m
erase
 (D
N
A
 directed),
 b
eta
 
-1
.129
 
0
.00594
 
S
cd2
 
Stearoyl
-C
o
en
zy
m
e
 A
 d
esatu
rase
 2
 
-1
.130
 
0
.01974
 
T
rp
c4
ap
 
T
ran
sient
 recepto
r p
otential
 catio
n
 ch
an
n
el
,
 subfam
ily
 C
,
 m
em
b
er 4
 asso
ciated
 p
rotein
 
-1
.142
 
0
.00076
 
A
b
cc9
 
A
TP
-binding
 cassette
,
 sub
-fam
ily
 C
 (C
FTR/M
RP),
 m
em
b
er 9
 
-1
.143
 
0
.01651
 
U
b
e2
c
 
U
biq
uitin
-co
njug
ating
 en
zy
m
e
 E2C
 
-1
.145
 
0
.01518
 
A
m
pd2
 
A
d
en
o
sin
e
 m
o
n
oph
o
sph
ate
 d
eam
in
ase
 2
 (isofo
rm
 L) 
-1
.151
 
0
.02571
 
Ch
rn
a1
 
Ch
olin
ergic
 recepto
r,
 nicotinic
,
 alph
a
 p
olyp
eptid
e
 1
 (m
u
scle) 
-1
.153
 
0
.04872
 
2900005J15Rik
 
R
IK
EN
 cD
N
A
 2900005J15
 g
en
e
 
-1
.154
 
0
.03388
 
G
tpbp4
 
G
TP
 binding
 p
rotein
 4
 
-1
.156
 
0
.01329
 
Pd
e4dip
 
Ph
o
sph
odiesterase
 4D
 interacting
 p
rotein
 (m
y
o
m
eg
alin) 
-1
.157
 
0
.01317
 
L
o
xl2
 
Ly
syl
 o
xid
ase
-lik
e
 2
 
-1
.158
 
0
.01361
 
F
asn
 
F
atty
 acid
 sy
nth
ase
 
-1
.167
 
0
.00768
 
S
nd1
 
Staphylo
co
ccal
 n
u
clease
 and
 tud
o
r d
o
m
ain
 co
ntaining
 1
 
-1
.174
 
0
.03875
 
D
cakd
 
D
eph
o
sph
o
-C
oA
 kin
ase
 d
o
m
ain
 co
ntaining
 
-1
.176
 
0
.02084
 
Sh
ro
o
m
2
 
Sh
ro
o
m
 fam
ily
 m
em
b
er 2
 
-1
.188
 
0
.01488
 
4930423O
20Rik
 
R
IK
EN
 cD
N
A
 4930423O
20
 g
en
e
 
-1
.189
 
0
.00307
 
A
630033H
20Rik
 
R
IK
EN
 cD
N
A
 A
630033H
20
 g
en
e
 
-1
.190
 
0
.04172
 
Cdk9
 
C
y
clin
-d
ep
end
ent
 kin
ase
 9
 (C
D
C2
-related
 kin
ase) 
-1
.191
 
0
.00854
 
E
ed
 
E
m
b
ry
o
nic
 ectod
erm
 d
ev
elop
m
ent
 
-1
.196
 
0
.02126
 
A
m
m
ecr1
 
A
lp
o
rt
 sy
nd
ro
m
e
,
 m
ental
 retard
atio
n
,
 m
idface
 hyp
oplasia
 and
 ellipto
cyto
sis
 ch
ro
m
o
so
m
al
 regio
n
 g
en
e
 1
 h
o
m
olog
 (h
u
m
an) 
-1
.197
 
0
.00164
 
L
rrc40
 
L
eu
cin
e
 rich
 rep
eat
 co
ntaining
 40
 
-1
.197
 
0
.00854
 
D
y
n
c1i2
 
D
y
n
ein
 cytoplasm
ic
 1
 interm
ediate
 ch
ain
 2
 
-1
.199
 
0
.02390
 
A
I847670
 
E
xp
ressed
 seq
u
en
ce
 A
I847670
 
-1
.203
 
0
.04627
 
F
at1
 
FA
T
 tu
m
o
r supp
resso
r h
o
m
olog
 1
 (D
ro
sophila) 
-1
.204
 
0
.01680
 
M
asp1
 
M
an
n
an
-binding
 lectin
 serin
e
 p
eptid
ase
 1
 
-1
.204
 
0
.04758
 
R
rm
2
 
Rib
o
n
u
cleotid
e
 red
u
ctase
 M
2
 
-1
.204
 
0
.02084
 
A
d
sl
 
A
d
enylo
su
ccin
ate
 ly
ase
 1
 
-1
.206
 
0
.00751
 
T
raf2
 
T
nf
 recepto
r-asso
ciated
 facto
r 2
 
-1
.209
 
0
.01361
 
S
ec16
a
 
SEC16
 h
o
m
olog
 A
 (S
.
 cerevisiae)
 
-1
.217
 
0
.01003
 
H
igd2
a
 
H
IG
1
 d
o
m
ain
 fam
ily
,
 m
em
b
er 2A
 
-1
.218
 
0
.02449
 
Sh
m
t2
 
S
erin
e
 hyd
ro
xy
m
ethyltran
sferase
 2
 (m
ito
ch
o
nd
rial) 
-1
.219
 
0
.00847
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X
cr1
 
Ch
em
okin
e
 (C
 m
otif) recepto
r 1
 
-1
.219
 
0
.00505
 
S
upt7l
 
S
upp
resso
r of
 Ty
 7
 (S
.
 cerevisiae)
-lik
e
 
-1
.220
 
0
.02191
 
P
o
u2
af1
 
PO
U
 d
o
m
ain
,
 class
 2
,
 asso
ciating
 facto
r 1
 
-1
.222
 
0
.02913
 
Thtp
a
 
Thiam
in
e
 triph
o
sph
atase
 
-1
.226
 
0
.01596
 
2600001M
11Rik
 
R
IK
EN
 cD
N
A
 2600001M
11
 g
en
e
 
-1
.227
 
0
.00258
 
C
ttn
 
C
o
rtactin
 
-1
.242
 
0
.00320
 
A
rm
c7
 
A
rm
adillo
 rep
eat
 co
ntaining
 7
 
-1
.247
 
0
.00447
 
Ptp
n7
 
P
rotein
 ty
ro
sin
e
 ph
o
sph
atase
,
 n
o
n
-recepto
r typ
e
 7
 
-1
.253
 
0
.02126
 
N
m
ral1
 
N
m
rA
-lik
e
 fam
ily
 d
o
m
ain
 co
ntaining
 1
 
-1
.256
 
0
.02730
 
T
cfcp2
 
T
ran
scriptio
n
 facto
r CP2
 
-1
.256
 
0
.00512
 
E
rcc6
 
E
x
cisio
n
 rep
air cro
ss
-co
m
plem
enting
 rod
ent
 rep
air
 d
eficien
cy
,
 co
m
plem
entatio
n
 g
ro
up
 6
 
-1
.265
 
0
.04062
 
LO
C100039419
 
Sim
ilar to
 tran
slatio
n
 initiatio
n
 facto
r eIF
-2
 g
am
m
a
 sub
u
nit
 
-1
.265
 
0
.02651
 
P
ole
 
P
oly
m
erase
 (D
N
A
 directed),
 ep
silo
n
 
-1
.266
 
0
.00683
 
T
rim
2
 
T
rip
artite
 m
otif
 p
rotein
 2
 
-1
.278
 
0
.01152
 
2010003O
18Rik
 
R
IK
EN
 cD
N
A
 2010003O
18
 g
en
e
 
-1
.279
 
0
.03655
 
C230021P08Rik
 
Rik
en
 cD
N
A
 C230021P08
 g
en
e
 
-1
.280
 
0
.02387
 
4930550G
17Rik
 
R
IK
EN
 cD
N
A
 4930550G
17
 g
en
e
 
-1
.281
 
0
.00472
 
Lb
r 
L
am
in
 B
 recepto
r 
-1
.282
 
0
.01547
 
Ift172
 
Intraflag
ellar tran
sp
o
rt
 172
 h
o
m
olog
 (Chlam
yd
o
m
o
n
as) 
-1
.284
 
0
.02158
 
Rint1
 
RA
D
50
 interacto
r 1
 
-1
.287
 
0
.00727
 
1200009F10Rik
 
R
IK
EN
 cD
N
A
 1200009F10
 g
en
e
 
-1
.294
 
0
.00662
 
Pisd
 
Ph
o
sph
atidylserin
e
 d
ecarb
o
xylase
 
-1
.305
 
0
.01630
 
EG
433144
 
P
redicted
 g
en
e
,
 EG
433144
 
-1
.306
 
0
.04157
 
A
ctn4
 
A
ctinin
 alph
a
 4
 
-1
.307
 
0
.02842
 
Spint1
 
S
erin
e
 p
rotease
 inhibito
r,
 K
u
nitz
 typ
e
 1
 
-1
.310
 
0
.00015
 
A
930005I04Rik
 
R
IK
EN
 cD
N
A
 A
930005I04
 g
en
e
 
-1
.311
 
0
.00505
 
R
abl2
a
 
RA
B
,
 m
em
b
er of
 R
A
S
 o
n
cog
en
e
 fam
ily
-lik
e
 2A
 
-1
.314
 
0
.02515
 
4833442J19Rik
 
R
IK
EN
 cD
N
A
 4833442J19
 g
en
e
 
-1
.315
 
0
.04489
 
B3g
ntl1
 
U
D
P
-G
lcN
A
c:b
etaG
al
 b
eta
-1
,3
-N
-acetylglu
co
sam
inyltran
sferase
-lik
e
 1
 
-1
.315
 
0
.00842
 
P
n
n
 
Pinin
 
-1
.315
 
0
.00330
 
H
p
x
 
H
em
op
exin
 
-1
.331
 
0
.01619
 
Ptbp1
 
P
olypy
rim
idin
e
 tract
 binding
 p
rotein
 1
 
-1
.332
 
0
.02899
 
D
330001F17Rik
 
R
IK
EN
 cD
N
A
 D
330001F17
 g
en
e
 
-1
.335
 
0
.02382
 
P2
ry4
 
Py
rim
idin
ergic
 recepto
r P2Y
,
 G
-p
rotein
 co
upled
,
 4
 
-1
.338
 
0
.00076
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Cd300
a
 
C
D
300A
 antig
en
 
-1
.344
 
0
.02473
 
Rg
s11
 
R
eg
ulato
r of
 G
-p
rotein
 sig
n
aling
 11
 
-1
.347
 
0
.01441
 
F
er1l3
 
F
er-1
-lik
e
 3
,
 m
y
oferlin
 (C
.
 eleg
an
s) 
-1
.358
 
0
.00337
 
Slit3
 
Slit
 h
o
m
olog
 3
 (D
ro
sophila) 
-1
.366
 
0
.00443
 
C
cr4
 
Ch
em
okin
e
 (C
-C
 m
otif) recepto
r 4
 
-1
.370
 
0
.01314
 
H
2
-Bl
 
H
isto
co
m
p
atibility
 2
,
 blasto
cy
st
 
-1
.375
 
0
.00529
 
A
dh4
 
A
lcoh
ol
 d
ehyd
rog
en
ase
 4
 (class
 II),
 pi
 p
olyp
eptid
e
 
-1
.376
 
0
.04734
 
B230340J04Rik
 
R
IK
EN
 cD
N
A
 B230340J04
 g
en
e
 
-1
.388
 
0
.00305
 
N
py2
r 
N
eu
rop
eptid
e
 Y
 recepto
r
 Y
2
 
-1
.401
 
0
.01894
 
G
nl2
 
G
u
anin
e
 n
u
cleotid
e
 binding
 p
rotein
-lik
e
 2
 (n
u
cleolar) 
-1
.422
 
0
.00061
 
M
tr 
5
-m
ethyltetrahyd
rofolate
-h
o
m
o
cy
stein
e
 m
ethyltran
sferase
 
-1
.433
 
0
.00007
 
2210010N
04Rik
 
R
IK
EN
 cD
N
A
 2210010N
04
 g
en
e
 
-1
.436
 
0
.00447
 
A
b
cb6
 
A
TP
-binding
 cassette
,
 sub
-fam
ily
 B
 (M
D
R/TA
P),
 m
em
b
er 6
 
-1
.451
 
0
.01359
 
Rbpj
 
R
eco
m
bin
atio
n
 sig
n
al
 binding
 p
rotein
 fo
r im
m
u
n
oglob
ulin
 k
app
a
 J
 regio
n
 
-1
.452
 
0
.04573
 
T
m
em
16f
 
T
ran
sm
em
b
ran
e
 p
rotein
 16F
 
-1
.452
 
0
.01596
 
Th
n
sl1
 
Th
reo
nin
e
 sy
nth
ase
-lik
e
 1
 (b
acterial) 
-1
.472
 
0
.01567
 
L
ss
 
L
an
o
sterol
 sy
nth
ase
 
-1
.487
 
0
.02787
 
C
ep135
 
C
entro
so
m
al
 p
rotein
 135
 
-1
.491
 
0
.00284
 
LO
C100043000
 
Sim
ilar to
 rib
o
so
m
al
 p
rotein
 L3
 
-1
.510
 
0
.04673
 
A
d
ss
 
A
d
enylo
su
ccin
ate
 sy
nth
etase
,
 n
o
n
 m
u
scle
 
-1
.515
 
0
.03760
 
Efh
a1
 
EF
 h
and
 d
o
m
ain
 fam
ily
 A
1
 
-1
.520
 
0
.00491
 
EN
SM
U
SG
00000051848
 
P
redicted
 g
en
e
,
 EN
SM
U
SG
00000051848
 
-1
.525
 
0
.02144
 
G
ulp1
 
G
U
LP
,
 eng
ulfm
ent
 ad
apto
r
 PTB
 d
o
m
ain
 co
ntaining
 1
 
-1
.536
 
0
.00152
 
Cd
c37
 
C
ell
 divisio
n
 cy
cle
 37
 h
o
m
olog
 (S
.
 cerevisiae) 
-1
.537
 
0
.00936
 
G
ab
rq
 
G
am
m
a
-am
in
ob
uty
ric
 acid
 (G
A
B
A
-A) recepto
r,
 sub
u
nit
 th
eta
 
-1
.540
 
0
.01361
 
T
ad
a3l
 
T
ran
scriptio
n
al
 ad
apto
r 3
 (N
G
G
1
 h
o
m
olog
,
 y
east)-lik
e
 
-1
.552
 
0
.00027
 
A
430005L14Rik
 
R
IK
EN
 cD
N
A
 A
430005L14
 g
en
e
 
-1
.553
 
0
.04798
 
M
y
c
 
M
y
elo
cyto
m
ato
sis
 o
n
cog
en
e
 
-1
.573
 
0
.03436
 
4632417N
05Rik
 
R
IK
EN
 cD
N
A
 4632417N
05
 g
en
e
 
-1
.574
 
0
.02198
 
2900046G
09Rik
 
R
IK
EN
 cD
N
A
 2900046G
09
 g
en
e
 
-1
.594
 
0
.00028
 
2200002D
01Rik
 
R
IK
EN
 cD
N
A
 2200002D
01
 g
en
e
 
-1
.599
 
0
.02913
 
Lg
als3
 
L
ectin
,
 g
alacto
se
 binding
,
 soluble
 3
 
-1
.601
 
0
.01411
 
Rp
s6kb2
 
Rib
o
so
m
al
 p
rotein
 S6
 kin
ase
,
 p
olyp
eptid
e
 2
 
-1
.603
 
0
.00041
 
D
d
x46
 
D
EA
D
 (A
sp
-G
lu
-A
la
-A
sp) b
o
x
 p
olyp
eptid
e
 46
 
-1
.610
 
0
.00034
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A
sah3
 
N
-acylsphing
o
sin
e
 am
id
ohyd
rolase
 (alk
alin
e
 ceram
id
ase) 3
 
-1
.619
 
0
.00015
 
Tb
c1d5
 
TBC1
 d
o
m
ain
 fam
ily
,
 m
em
b
er 5
 
-1
.628
 
0
.02651
 
Cd
ca8
 
C
ell
 divisio
n
 cy
cle
 asso
ciated
 8
 
-1
.639
 
0
.01541
 
Pfn4
 
P
rofilin
 fam
ily
,
 m
em
b
er 4
 
-1
.645
 
0
.00031
 
6030405A
18Rik
 
R
IK
EN
 cD
N
A
 6030405A
18
 g
en
e
 
-1
.660
 
0
.00031
 
Ppp2
r3
a
 
P
rotein
 ph
o
sph
atase
 2
 (fo
rm
erly
 2A),
 reg
ulato
ry
 sub
u
nit
 B
'',
 alph
a
 
-1
.665
 
0
.04658
 
9
.13E
+15
 
H
yp
oth
etical
 9130022E09
 
-1
.672
 
0
.00031
 
Rp
sa
 
Rib
o
so
m
al
 p
rotein
 SA
 
-1
.687
 
0
.00491
 
D
ctn2
 
D
y
n
actin
 2
 
-1
.709
 
0
.02013
 
Rq
cd1
 
R
cd1
 (req
uired
 fo
r cell
 differentiatio
n)
 h
o
m
olog
 1
 (S
.
 p
o
m
b
e) 
-1
.711
 
0
.01614
 
Sdf2
 
Stro
m
al
 cell
 d
eriv
ed
 facto
r 2
 
-1
.723
 
0
.01366
 
Spire1
 
Spire
 h
o
m
olog
 1
 (D
ro
sophila) 
-1
.786
 
0
.01250
 
A
cp6
 
A
cid
 ph
o
sph
atase
 6
,
 ly
soph
o
sph
atidic
 
-1
.794
 
0
.00029
 
Ly6
e
 
Ly
m
ph
o
cyte
 antig
en
 6
 co
m
plex
,
 lo
cu
s
 E
 
-1
.797
 
0
.03775
 
Th
ap6
 
TH
A
P
 d
o
m
ain
 co
ntaining
 6
 
-1
.803
 
0
.01317
 
L
am
b1
-1
 
L
am
inin
 B1
 sub
u
nit
 1
 
-1
.805
 
0
.00330
 
T
an
c1
 
T
etratricop
eptid
e
 rep
eat
,
 anky
rin
 rep
eat
 and
 coiled
-coil
 co
ntaining
 1
 
-1
.809
 
0
.00004
 
S
erin
c3
 
S
erin
e
 in
co
rp
o
rato
r 3
 
-1
.817
 
0
.00375
 
S
o
at1
 
Sterol
 O
-acyltran
sferase
 1
 
-1
.818
 
0
.00692
 
4930435E12Rik
 
R
IK
EN
 cD
N
A
 4930435E12
 g
en
e
 
-1
.901
 
0
.01685
 
Tb
ce
 
T
ub
ulin
-sp
ecific
 ch
ap
ero
n
e
 e
 
-1
.922
 
0
.00022
 
U
b
xd5
 
U
B
X
 d
o
m
ain
 co
ntaining
 5
 
-1
.953
 
0
.00665
 
9130016M
20Rik
 
R
IK
EN
 cD
N
A
 9130016M
20
 g
en
e
 
-1
.964
 
0
.00243
 
C030019F02Rik
 
R
IK
EN
 cD
N
A
 C030019F02
 g
en
e
 
-1
.984
 
0
.00364
 
A
las2
 
A
m
in
olev
ulinic
 acid
 sy
nth
ase
 2
,
 eryth
roid
 
-1
.997
 
0
.01301
 
Jazf1
 
JA
ZF
 zin
c
 fing
er 1
 
-1
.997
 
0
.00712
 
Y
w
h
ah
 
Ty
ro
sin
e
 3
-m
o
n
o
o
xyg
en
ase/tryptoph
an
 5
-m
o
n
o
o
xyg
en
ase
 activ
atio
n
 p
rotein
,
 eta
 p
olyp
eptid
e
 
-2
.005
 
0
.01187
 
Pfas
 
Ph
o
sph
o
rib
o
sylfo
rm
ylgly
cin
am
idin
e
 sy
nth
ase
 (FG
A
R
 am
id
otran
sferase) 
-2
.071
 
0
.00411
 
P
olr2
e
 
P
oly
m
erase
 (RN
A) II (D
N
A
 directed) p
olyp
eptid
e
 E
 
-2
.096
 
0
.01588
 
C
yb5
r1
 
C
yto
ch
ro
m
e
 b5
 red
u
ctase
 1
 
-2
.131
 
0
.00360
 
Rb
m
10
 
RN
A
 binding
 m
otif
 p
rotein
 10
 
-2
.215
 
0
.01685
 
Ftsj3
 
FtsJ
 h
o
m
olog
 3
 (E
.
 coli) 
-2
.228
 
0
.00002
 
Stac3
 
SH
3
 and
 cy
stein
e
 rich
 d
o
m
ain
 3
 
-2
.311
 
0
.00000
 
N
cl
 
N
u
cleolin
 
-2
.398
 
0
.00026
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Il13
ra2
 
Interleukin
 13
 recepto
r,
 alph
a
 2
 
-2
.560
 
0
.00000
 
Sgta
 
S
m
all
 glutam
in
e
-rich
 tetratricop
eptid
e
 rep
eat
 (TPR)-co
ntaining
,
 alph
a
 
-2
.580
 
0
.00002
 
T
m
ed9
 
T
ran
sm
em
b
ran
e
 em
p24
 p
rotein
 tran
sp
o
rt
 d
o
m
ain
 co
ntaining
 9
 
-2
.614
 
0
.00038
 
Slc38
a6
 
S
olute
 carrier fam
ily
 38
,
 m
em
b
er 6
 
-2
.739
 
0
.00078
 
A
930016O
22Rik
 
R
IK
EN
 cD
N
A
 A
930016O
22
 g
en
e
 
-2
.790
 
0
.00066
 
A
I118078
 
E
xp
ressed
 seq
u
en
ce
 A
I118078
 
-2
.912
 
0
.00239
 
K
cn
ab1
 
P
otassiu
m
 v
oltag
e
-g
ated
 ch
an
n
el
,
 sh
ak
er-related
 subfam
ily
,
 b
eta
 m
em
b
er 1
 
-2
.929
 
0
.00240
 
A
830053O
21Rik
 
R
IK
EN
 cD
N
A
 A
830053O
21
 g
en
e
 
-3
.009
 
0
.00000
 
E430029J22Rik
 
R
IK
EN
 cD
N
A
 E430029J22
 g
en
e
 
-3
.245
 
0
.00000
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        Aff
 ID
 
G
e
n
e
 
 
G
e
n
e
 n
a
m
e
 
ID
 
6h
 
IV
 
 
6h
 
CD 
6h
 
CV
 
6h
 
ID
 
15d
 
IV
 
15d
 
CD 
15d
 
CV
 
15d
 
ID
 
6
m
 
IV
 
6
m
 
CD 
6
m
 
CV
 
6
m
 
1434719
_
at
 
A
2
m
 
alph
a
-2
-m
acroglob
ulin
 
-
 
-
 
-
 
-
 
3
.17
 
2
.31
 
1
.55
 
-
 
1
.59
 
-
 
-
 
-
 
1421839
_
at
 
A
b
ca1
 
A
TP
-binding
 cassette
,
 sub
-fam
ily
 A
 (A
BC1),
 m
em
b
er 1
 
-
 
-
 
-
 
-
 
1
.90
 
1
.2
 
-
 
1
.17
 
-
 
-
 
-
 
-
 
1449588
_
at
 
A
b
ca4
 
A
TP
-binding
 cassette
,
 sub
-fam
ily
 A
 (A
BC1),
 m
em
b
er 4
 
-
 
-
 
-
 
-
 
-1
.5
 
-
 
-
 
-
 
-2
.7
 
-
 
-
 
-
 
14164
-3
_
at
 
A
b
cb1
-
 
A
TP
-binding
 cassette
,
 sub
-fam
ily
 B
 (M
D
R/TA
P),
 m
em
b
er 1
-
 
-
 
-
 
-
 
1
.11
 
-
 
-
 
-
 
1
.08
 
-
 
-
 
-
 
-
 
1419759
_
at
 
A
b
cb1
a
 
A
TP
-binding
 cassette
,
 sub
-fam
ily
 B
 (M
D
R/TA
P),
 m
em
b
er 1A
 
-
 
-1
.2
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1418872
_
at
 
A
b
cb1b
 
A
TP
-binding
 cassette
,
 sub
-fam
ily
 B
 (M
D
R/TA
P),
 m
em
b
er 1B
 
-
 
-
 
-
 
-
 
1
.50
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1449818
_
at
 
A
b
cb4
 
A
TP
-binding
 cassette
,
 sub
-fam
ily
 B
 (M
D
R/TA
P),
 m
em
b
er 4
 
-
 
-
 
-
 
-
 
1
.28
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1428988
_
at
 
A
b
cc3
 
A
TP
-binding
 cassette
,
 sub
-fam
ily
 C
 (C
FTR/M
RP),
 m
em
b
er 3
 
-
 
-
 
-
 
-
 
1
.95
 
1
.4
 
1
.01
 
-
 
-
 
-
 
-
 
-
 
1419748
_
at
 
A
b
cd2
 
A
TP
-binding
 cassette
,
 sub
-fam
ily
 D
 (A
LD),
 m
em
b
er 2
 
-
 
-
 
-
 
-
 
1
.53
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1416315
_
at
 
A
bhd4
 
abhyd
rolase
 d
o
m
ain
 co
ntaining
 4
 
-
 
-
 
-
 
-
 
1
.00
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1416863
_
at
 
A
bhd8
 
abhyd
rolase
 d
o
m
ain
 co
ntaining
 8
 
-
 
-
 
-
 
-
 
1
.27
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1428146
_
s
_
at
 A
caa2
 
acetyl
-C
o
en
zy
m
e
 A
 acyltran
sferase
 2
 (m
ito
ch
o
nd
rial
 3
-o
x
o
acyl
-C
o
en
zy
m
e
 A
 
thiolase) 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-1
.5
 
-
 
-
 
-
 
1449827
_
at
 
A
can
 
agg
recan
 
-
 
-
 
-
 
-
 
3
.06
 
-
 
-
 
-
 
1
.41
 
-
 
-
 
-
 
1417994
_
a
_
at
 A
ccn1
 
am
ilo
rid
e
-sen
sitiv
e
 catio
n
 ch
an
n
el
 1
,
 n
eu
ro
n
al
 (d
eg
en
erin) 
-
 
-
 
-
 
-
 
1
.25
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1427
-34
_
at
 
A
ce
 
angioten
sin
 I
 co
n
v
erting
 en
zy
m
e
 (p
eptidyl
-dip
eptid
ase
 A) 1
 
-
 
-
 
-
 
-
 
-1
.1
 
-
 
-
 
-
 
-1
.5
 
-
 
-
 
-
 
1422715
_
s
_
at
 A
cp1
 
acid
 ph
o
sph
atase
 1
,
 soluble
 
-
 
-
 
-
 
1
.14
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1451828
_
a
_
at
 A
csl4
 
acyl
-C
oA
 sy
nth
etase
 lo
ng
-ch
ain
 fam
ily
 m
em
b
er 4
 
1
.2
 
-
 
-
 
1
.02
 
1
.58
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1416871
_
at
 
A
d
am
8
 
a
 disinteg
rin
 and
 m
etallop
eptid
ase
 d
o
m
ain
 8
 
1
.89
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
145
-716
_
at
 
A
d
am
ts1
 
a
 disinteg
rin
-lik
e
 and
 m
etallop
eptid
ase
 (rep
roly
sin
 typ
e) w
ith
 
th
ro
m
b
o
sp
o
ndin
 typ
e
 1
 m
otif
,
 1
 
1
.09
 
-
 
-
 
-
 
1
.42
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1451932
_
a
_
at
 A
d
am
tsl4
 
A
D
A
M
TS
-lik
e
 4
 
-
 
-
 
-
 
-
 
1
.28
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1455462
_
at
 
A
d
cy2
 
ad
enylate
 cy
clase
 2
 
-
 
-
 
-
 
-
 
-1
.01
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
14563
-7
_
s
_
at
 A
d
cy7
 
ad
enylate
 cy
clase
 7
 
-
 
-
 
-1
.1
 
-
 
2
.42
 
1
.5
-5
 
1
.26
 
-
 
-
 
-
 
-
 
-
 
1423427
_
at
 
A
d
cy
ap1
 
ad
enylate
 cy
clase
 activ
ating
 p
olyp
eptid
e
 1
 
-
 
-
 
-
 
-
 
1
.89
 
-
 
-
 
-
 
1
.67
 
-
 
-
 
-
 
1451914
_
a
_
at
 A
dd2
 
add
u
cin
 2
 (b
eta) 
-
 
-
 
-
 
1
.37
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
T
ab
.2 :
 D
ifferentially exp
ressed
 gen
es
 in
 m
o
u
se
 hipp
o
ca
m
p
u
s
 after
 fo
cal
 injectio
n
 of
 k
ainic
 a
cid
.
 In
 th
e
 12 colu
m
n
s
 o
n
 th
e
 right
 a
re
 rep
o
rted
 
th
e
 fold
 ch
a
nges
 fo
r
 ea
ch
 a
rea
 a
nd
 tim
e
 p
oint
.
 F
old
 C
h
a
nges
 a
re
 in
 log
a
rith
m
ic
 scale
 (b
a
se
 2)
.
 ID
=
 Ip
silateral
 D
o
rsal, IV
=
 Ip
silateral
 V
entral, 
C
D
=
 C
o
ntralateral
 D
o
rsal, C
V
=
 C
o
ntralateral
 V
entral
.
 6h
=
 6 h
o
u
rs
 after
 th
e
 injectio
n
, 15d
=
 15 d
ays
 after
 th
e
 injectio
n
, 6m
=
 6 m
o
nth
s
 after
 
th
e
 injectio
n
.
 Th
e
 “
-“
 sym
b
ol
 m
ea
n
s
 th
at
 fo
r
 th
at
 a
rea
 at
 th
at
 tim
e
 p
oint
 th
e
 sp
ecific
 gen
e
 is
 n
ot
 sh
o
w
ing sig
nifica
nt
 ch
a
nge
 o
r
 th
at
 ch
a
nge
 is
 
p
resent
 also
 in
 th
e
 N
aC
l
 injected
 co
ntrols
, th
erefo
re
 it
 w
a
s
 n
ot
 co
n
sid
ered
 in
 fu
rth
er
 a
n
alysis
.
 G
en
es
 a
re
 listed
 in
 alph
ab
etical
 o
rd
er
.
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1426574
_
a
_
at
 A
dd3
 
add
u
cin
 3
 (g
am
m
a) 
-
 
-
 
-
 
1
.09
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1448318
_
at
 
A
dfp
 
adip
o
se
 differentiatio
n
 related
 p
rotein
 
-
 
-
 
-
 
-
 
-
 
1
.07
 
-
 
-
 
-
 
-
 
-
 
-
 
145
-214
_
at
 
A
d
o
ra2b
 
ad
en
o
sin
e
 A
2b
 recepto
r 
-
 
-
 
-
 
-
 
-0
.98
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1422335
_
at
 
A
d
ra2
c
 
ad
ren
ergic
 recepto
r,
 alph
a
 2
c
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1
.01
 
-
 
-
 
-
 
-
 
1416645
_
a
_
at
 A
fp
 
alph
a
 fetop
rotein
 
1
.08
 
-
 
-
 
-
 
3
.75
 
1
.69
 
1
.47
 
-
 
-
 
-
 
-
 
-
 
1438651
_
a
_
at
 A
gtrl1
 
angioten
sin
 recepto
r-lik
e
 1
 
-
 
-
 
-
 
-
 
1
.71
 
1
.02
 
-
 
-
 
-
 
-
 
-
 
-
 
1425576
_
at
 
A
h
cyl1
 
S
-ad
en
o
sylh
o
m
o
cy
stein
e
 hyd
rolase
-lik
e
 1
 
-
 
-
 
-
 
1
.37
 
-
 
-
 
-
 
1
.54
 
-
 
-
 
-
 
-
 
1452217
_
at
 
A
h
n
ak
 
A
H
N
A
K
 n
u
cleop
rotein
 (d
esm
oy
okin) 
-
 
-
 
-
 
-
 
1
.04
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
14182
-4
_
s
_
at
 A
if1
 
allog
raft
 inflam
m
ato
ry
 facto
r 1
 
-
 
-
 
-
 
-
 
3
.08
 
2
.28
 
1
.64
 
-
 
-
 
-
 
-
 
-
 
14197
-6
_
a
_
at
 A
k
ap12
 
A
 kin
ase
 (PR
K
A) an
ch
o
r p
rotein
 (g
ravin) 12
 
1
.73
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1455151
_
at
 
A
k
ap9
 
A
 kin
ase
 (PR
K
A) an
ch
o
r p
rotein
 (y
otiao) 9
 
-
 
-
 
-
 
1
.15
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1448894
_
at
 
A
k
r1b8
 
ald
o
-k
eto
 red
u
ctase
 fam
ily
 1
,
 m
em
b
er B8
 
-
 
-
 
-
 
-
 
2
.07
 
1
.06
 
-
 
-
 
1
.38
 
-
 
-
 
-
 
1419136
_
at
 
A
k
r1
c18
 
ald
o
-k
eto
 red
u
ctase
 fam
ily
 1
,
 m
em
b
er C18
 
-
 
-
 
-
 
-
 
-1
.86
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1448789
_
at
 
A
ldh1
a3
 
ald
ehyd
e
 d
ehyd
rog
en
ase
 fam
ily
 1
,
 subfam
ily
 A
3
 
-
 
1
.09
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1434987
_
at
 
A
ldh2
 
ald
ehyd
e
 d
ehyd
rog
en
ase
 2
,
 m
ito
ch
o
nd
rial
 
-
 
-1
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1419115
_
at
 
A
lg14
 
asp
aragin
e
-link
ed
 gly
co
sylatio
n
 14
 h
o
m
olog
 (y
east) 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-1
.6
 
1437728
_
at
 
A
lkbh5
 
alkB
,
 alkylatio
n
 rep
air h
o
m
olog
 5
 (E
.
 coli) 
-
 
-
 
-
 
1
.76
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1418266
_
at
 
A
lo
x12b
 
arachid
o
n
ate
 12
-lip
o
xyg
en
ase
,
 12R
 typ
e
 
-
 
-
 
-
 
-
 
-1
.70
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1452
-16
_
at
 
A
lo
x5
ap
 
arachid
o
n
ate
 5
-lip
o
xyg
en
ase
 activ
ating
 p
rotein
 
-
 
-
 
-
 
-
 
1
.58
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1416835
_
s
_
at
 A
m
d1
 
S
-ad
en
o
sylm
ethio
nin
e
 d
ecarb
o
xylase
 1
 
-
 
-
 
-
 
1
.07
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1422573
_
at
 
A
m
pd3
 
A
M
P
 d
eam
in
ase
 3
 
-
 
-
 
-
 
-
 
1
.25
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1427
-44
_
a
_
at
 A
m
ph
 
am
phiphy
sin
 
-
 
-
 
-
 
-
 
-1
.29
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
145
-717
_
at
 
A
ng
 
angiog
enin
,
 rib
o
n
u
clease
,
 RN
ase
 A
 fam
ily
,
 5
 
-
 
-
 
-
 
-
 
1
.69
 
1
.35
 
-
 
-
 
-
 
-
 
-
 
-
 
141713
-
_
s
_
at
 A
ngptl4
 
angiop
oietin
-lik
e
 4
 
2
.78
 
2
.55
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1419421
_
at
 
A
nk1
 
anky
rin
 1
,
 eryth
roid
 
-
 
-
 
-
 
-
 
-1
.83
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1436998
_
at
 
A
nk
rd43
 
anky
rin
 rep
eat
 d
o
m
ain
 43
 
-
 
-
 
-
 
-
 
-2
.02
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1454736
_
at
 
A
nk
rd57
 
anky
rin
 rep
eat
 d
o
m
ain
 57
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-1
.2
 
-
 
-
 
-
 
1419
-91
_
a
_
at
 A
n
x
a2
 
an
n
exin
 A
2
 
-
 
1
.03
 
-
 
-
 
1
.58
 
1
.03
 
-
 
-
 
1
.05
 
-
 
-
 
-
 
146
-33
-
_
at
 
A
n
x
a3
 
an
n
exin
 A
3
 
-
 
-
 
-
 
-
 
2
.42
 
1
.65
 
1
.29
 
-
 
-
 
-
 
-
 
-
 
1424176
_
a
_
at
 A
n
x
a4
 
an
n
exin
 A
4
 
-
 
-
 
-
 
-
 
1
.79
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1425567
_
a
_
at
 A
n
x
a5
 
an
n
exin
 A
5
 
-
 
-
 
-
 
-
 
1
.26
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
145
-915
_
at
 
A
p3b1
 
ad
apto
r-related
 p
rotein
 co
m
plex
 3
,
 b
eta
 1
 sub
u
nit
 
-
 
-
 
-
 
1
.63
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1431946
_
a
_
at
 A
pb
a2bp
 
am
yloid
 b
eta
 (A
4) p
recu
rso
r p
rotein
-binding
,
 fam
ily
 A
,
 m
em
b
er 2
 binding
 
p
rotein
 
-
 
-
 
-
 
-
 
1
.41
 
-
 
-
 
-
 
1
.3
 
-
 
-
 
-
 
1 7 0
14218
-3
_
at
 
A
pbh
 
and
rog
en
-binding
 p
rotein
 eta
 
-1
.5
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
142
-957
_
at
 
A
p
c
 
ad
en
o
m
ato
sis
 p
olyp
o
sis
 coli
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1
.23
 
-
 
1439214
_
a
_
at
 A
pi5
 
ap
opto
sis
 inhibito
r 5
 
-
 
-
 
-
 
1
.18
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
142
-382
_
at
 
A
p
ob48
r 
ap
olip
op
rotein
 B48
 recepto
r 
-
 
-
 
-
 
-
 
1
.32
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1451755
_
a
_
at
 A
p
ob
ec1
 
ap
olip
op
rotein
 B
 editing
 co
m
plex
 1
 
-
 
-
 
-
 
-
 
1
.93
 
1
.25
 
-
 
-
 
-
 
-
 
-
 
-
 
141747
-
_
at
 
A
p
ob
ec3
 
ap
olip
op
rotein
 B
 editing
 co
m
plex
 3
 
-
 
-
 
-
 
-
 
1
.14
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1417561
_
at
 
A
p
o
c1
 
ap
olip
op
rotein
 C
-I 
-
 
-
 
-
 
-
 
1
.23
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1418
-69
_
at
 
A
p
o
c2
 
ap
olip
op
rotein
 C
-II 
-
 
-
 
-
 
-
 
1
.95
 
1
.34
 
-
 
-
 
-
 
-
 
-
 
-
 
14162
-3
_
at
 
A
qp1
 
aq
u
ap
o
rin
 1
 
-1
.6
 
-
 
-
 
-
 
-2
.3
 
-1
.6
 
-
 
-1
.6
 
-3
.5
 
-
 
-
 
-
 
1425382
_
a
_
at
 A
qp4
 
aq
u
ap
o
rin
 4
 
-
 
-
 
-
 
-
 
2
.51
 
1
.36
 
1
.34
 
1
.34
 
1
.6
 
-
 
-
 
-
 
1418687
_
at
 
A
rc
 
activity
 reg
ulated
 cyto
sk
eletal
-asso
ciated
 p
rotein
 
1
.64
 
-
 
-
 
-
 
-
 
-1
 
-
 
-1
.4
 
-
 
-
 
-
 
-
 
1423743
_
at
 
A
rcn1
 
arch
ain
 1
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-1
 
-
 
-
 
-
 
-
 
1421134
_
at
 
A
reg
 
am
phireg
ulin
 
1
.83
 
-
 
-
 
-
 
1
.15
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1438661
_
a
_
at
 A
rf2
 
A
D
P
-rib
o
sylatio
n
 facto
r 2
 
-
 
-
 
-
 
1
.11
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1451526
_
at
 
A
rhg
ap12
 
Rh
o
 G
TP
ase
 activ
ating
 p
rotein
 12
 
-
 
-
 
-
 
-
 
-1
.15
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1427522
_
at
 
A
rhg
ap2
-
 
Rh
o
 G
TP
ase
 activ
ating
 p
rotein
 2
-
 
-
 
-
 
-
 
1
.02
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1419296
_
at
 
A
rhg
ap4
 
Rh
o
 G
TP
ase
 activ
ating
 p
rotein
 4
 
-
 
-
 
-
 
-
 
1
.38
 
-
 
-
 
-
 
-
 
-
 
-
 
-
 
1423194
_
at
 
A
rhg
ap5
 
Rh
o
 G
TP
ase
 activ
ating
 p
rotein
 5
 
-
 
-
 
-
 
1
.09
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